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I	 hypothesise	 that	 cancer	 cells	 with	 high	 aldehyde	 dehydrogenase	 (ALDHhigh)	 activity	
present	 a	 new	 therapeutic	 target	 and	 will	 be	 selectively	 sensitive	 to	 5-nitrofuran											
pro-drugs.		
	
Cancers	 are	 heterogeneous	 and	 contain	 subpopulations	 of	 ALDHhigh	 cells	 with	 tumour	
initiating	potential.	ALDH	enzymes	metabolize	toxic	aldehydes,	and	are	highly	expressed	
in	 somatic	 and	 cancer	 stem	 cells	 (CSCs),	 although	 their	 function	 in	 CSCs	 is	 not	 fully	
understood.	In	a	small	molecule	screen	coupled	with	target	ID,	Zhou	et	al.	(2012)	recently	




nifurtimox,	 has	 anti-cancer	 properties	 and	 it	 is	 currently	 in	 Phase	 2	 clinical	 trials	 for	
neuroblastoma	 and	 medulloblastoma	 (ClinicalTrials.gov	 Identifier:	 NCT00601003),	
however	the	mechanism	underlying	this	anti-cancer	activity	is	unknown.		
	
In	melanoma	 and	 other	 cancers,	 ALDH1A1	 and	 ALDH1A3	 are	 highly	 expressed	 in	 CSCs.																
I	demonstrate	the	anti-cancer	activity	of	5-NFNs	in	cancer	cell	 lines,	where	they	express	
high	sensitivity	to	5-NFNs	in	cell	viability	assays	(A375	melanoma	cells	EC50	=	867nM).	To	
test	 if	ALDH1	enzymes	 are	 substrates	of	 5-NFNs,	 I	 performed	 in	 vitro	 activity	 assays	by	
monitoring	 NADH	 production	 (λ	 =	 340nm).	 I	 found	 that	 the	 clinically	 available	 5-NFNs,	
nifuroxazide	 and	 nifurtimox,	 in	 addition	 to	 our	 own	 newly	 synthesised	 5-NFNs,	 are	
competitive	 substrates	 for	 human	 ALDH1A3	 activity	 in	 vitro	 (P	 <	 0.05).	 Notably,	
nifuroxazide	 is	 not	 a	 substrate	 for	 ALDH2,	 suggesting	 that	 nifuroxazide	 may	 show	
selectivity	 toward	 ALDH1.	 Enzymatic	 assays	 with	 purified	 human	 ALDH2,	 demonstrate	
that	 ALDH2	 requires	 NAD+	 for	 bio-activation	 of	 5-NFNs.	 Consistent	 with	 these	 assays,																	
I	 found	 that	 5-NFNs	 are	 competitive	 substrates	 for	 ALDH	 activity	 in	melanoma	 cells	 by	
Aldefluor™,	with	 5-NFNs	displaying	 a	 prolonged	 competitive	 inhibition	of	ALDH	activity	
compared	 with	 the	 known	 inhibitor,	 DEAB.	 Importantly,	 no-nitro	 control	 compounds	







are	 protected	 from	 5-NFN	 toxicity	 (P	 >	 0.05)	 and	 cell	 death	 (DRAQ7™:	 P	 <	 0.0001),	
demonstrating	a	functional	role	for	ALDH1A3	in	mediating	5-NFN	activity	in	cancer	cells.	
In	 contrast,	 A375	 cells	 overexpressing	 ALDH1A3	 by	 cDNA	 transient	 transfection	 were	
hypersensitive	to	5-NFNs	(P	<	0.001),	determined	by	Muse™	cell	viability.	Computational	
docking	 studies	 reveal	 that	 5-NFNs	 have	 the	 potential	 to	 fit	 within	 the	 interior	 of	 the	
ALDH	 enzymatic	 cavity	 and	 interact	 with	 the	 catalytic	 cysteine,	 thereby	 offering	 a	
potential	mechanism	for	5-NFN	bio-activation.	Finally,	in	collaboration,	we	show	a	unique	
interaction	 between	 5-NFNs	 and	 ALDH	 using	 mass	 spectrometry	 and	 have	 initiated	
protein	crystallography	trials.	
	
My	 work	 demonstrates	 a	 novel	 and	 biologically	 relevant	 5-NFN-ALDH	 interaction	 in	
cancer	cells.	I	propose	5-NFNs	have	the	potential	to	target	ALDHhigh	CSCs	within	a	tumour	









5-nitrofurans	 (5-NFNs)	 are	 a	 class	 of	 antibiotic	 drugs	 used	 in	 the	 treatment	 of	 both	








and	diet,	which	can	otherwise	 lead	 to	DNA	damage.	 Like	 in	normal	 tissues,	 cancers	are	
heterogeneous,	 where	 there	 exists	 a	 subpopulation	 of	 cells	 that	 exhibit	 stem-cell	 like	
characteristics.	These	cells,	dubbed	cancer	stem	cells	(CSCs),	are	typically	more	resistant	




In	 melanoma,	 high	 levels	 of	 ALDH	 (ALDHhigh)	 also	 mark	 CSCs.	 Here	 I	 demonstrate	 the				
anti-cancer	 activity	 of	 5-NFNs	 in	 cancers,	 including	 melanoma,	 where	 5-NFNs	 can	
promote	 cancer	 cell	 death.	 I	 report	 that	 new	 5-NFNs	 compounds,	 as	 well	 as	 current	
clinical	5-NFNs,	can	target	ALDH	enzymes,	where	the	clinical	5-NFN,	nifuroxazide,	shows	
some	 specificity	 towards	 the	ALDH1	 isoform	 -	 the	ALDH	enzymes	most	 associated	with	
cancer.	As	well	as	being	able	to	target	 these	ALDHhigh	cells,	 I	 show	that	5-NFNs	can	also	
inhibit	 the	 activity	 of	 ALDH1	 enzymes	 in	melanoma	 cell	 cultures,	where	 ablating	 ALDH	
activity	 has	 been	 shown	 to	 make	 cancers	 more	 sensitive	 to	 chemotherapies.	 By	
decreasing	the	expression	of	ALDH1	enzymes	in	melanoma	cells,	we	show	that	melanoma	
becomes	more	 resistant	 to	5-NFNs,	where	 there	was	 significantly	 less	 cancer	 cell	 death	
upon	treatment.	In	parallel,	by	overexpressing	ALDH1	enzymes	in	these	melanoma	cells,	I	








collaboration	 at	 The	 University	 of	 Edinburgh,	 we	 discover	 that	 5-NFNs	 can	 irreversibly	
inhibit	ALDH	activity,	offering	a	dual	function	for	these	5-NFN	compounds.	
	
We	 demonstrate	 a	 novel	 mechanism	 that	 can	 both	 selectively	 target	 and	 kill	 ALDHhigh	
cancer	 cells	 coupled	 with	 irreversible	 inhibition	 of	 ALDH	 enzymes,	 where	 the	 clinical									
5-NFN,	nifuroxazide,	may	exhibit	specificity	towards	the	ALDH	enzymes	most	expressed	in	
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The	 aldehyde	 dehydrogenase	 (ALDH)	 superfamily	 is	 a	 group	 of	 enzymes	 responsible	 for	
metabolising	 toxic	 aldehydes.	 Aldehydes	 are	 continually	 produced	 in	 our	 bodies	 through	
metabolism	of	 amino	 acids,	 lipids,	 carbohydrates,	 vitamins	 and	 steroids,	 as	well	 as	 being	
accumulated	 through	 growth	 and	 diet.1	 One	 common	 example	 is	 the	 production	 of	
acetaldehyde	in	the	liver	as	result	of	drinking	alcohol	(ethanol),	which	is	then	broken	down	
by	 hepatic	 ALDH2.2	 Aldehydes	 are	 highly	 reactive	 electrophilic	 species,	 which,	 when	 left	
unchecked,	can	form	adducts	with	organic	macromolecules	such	as	DNA,	lipid	membranes	
and	proteins,	in	turn	promoting	DNA	damage,	cancer	development	and	stem	cell	failure.3,4.	
ALDH	 enzymes	 catalyse	 the	metabolism	 of	 these	 toxic	 aldehydes	 from	 the	 body	 through	
NAD(P)+-dependant	irreversible	oxidation	into	their	carboxylic	acid	conjugates	(Figure	1.1),	
which	 are	 less	 harmful	 to	 the	 body	 and	 can	 be	 excreted	 safely.	 Although	 ALDH	 plays	 a	
crucial	 role	 in	 detoxifying	 aldehydes	 from	 the	 body,	 some	 of	 the	 carboxylic	 acid	
intermediates	 produced,	 such	 as	 retinoic	 acid	 (RA)	 or	 γ-aminobutyric	 acid	 (GABA),	 are	
essential	 for	normal	physiology	and	embryonic	development.1	For	 instance,	conversion	of	
retinal	 to	 retinoic	 acid	 by	 ALDH1A	 enzymes	 is	 important	 for	 the	 regulation	 of	 gene	
expression	needed	for	growth	and	development,5	or	synthesis	of	GABA	by	ALDH9A1	in	the	
regulation	 of	 the	 dopaminergic	 pathway.2,6	 Many	 ALDH	 enzymes	 also	 have	 essential,							
non-catalytic	functions,	such	as	in	the	formation	of	crystallins	in	the	eye	or	acting	as	binding	



















The	 ALDH	 superfamily	 is	 evolutionarily	 conserved,	 with	 isoforms	 represented	 in	 all	 3	
factions	 of	 the	 taxonomic	 tree.8	 In	 the	 eukaryotic	 genome,	 ALDH	 expression	 is	 highly	
diverse	across	species	with	24	ALDH	families	currently	characterised.	In	humans,	there	are	
19	 distinct	 ALDH	 isoforms,	 all	 with	 different	 substrate	 specificities	 and	 physiological	
functions	 (Table	 1.1).2	 ALDH	 enzymes	 contain	 3	 domains,	 a	 NAD(P)+	 co-factor	 binding	
domain,	a	catalytic	binding	domain	and	a	 linker	region,	 important	for	oligomer	formation.	
ALDH	enzymes	are	non-functional	as	single	monomers,	and	as	such,	the	formation	of	dimer,	
tetramer	 or	 hexamer	 complexes	 from	 homo-ALDH	 subunits	 are	 important	 for	 enzyme	
functionality.9	This	is	paramount	in	the	ALDH2*2	mutation,	present	in	approximately	8%	of	
the	human	population.	Primarily	 localised	 in	persons	of	Eastern	Asian	descent,	 this	 single	
point	mutation	 (GA)	substitutes	 lysine	 in	place	of	glutamic	acid	 (E487K).	Although	both	
the	 catalytic	 and	 co-factor	 binding	 domains	 remain	 unaltered,	 the	 resultant	 mutation	
promotes	 the	 formation	 of	 a	 disordered	 α-helix,	 integral	 for	 ALDH	 dimer	 formation							
(Figure	 1.2).10	 The	 consequent	 incorporation	 of	 mutant	 ALDH2*2	 subunits	 into	 ALDH2	
tetramer	 complexes,	 ablates	 normal	 ALDH2	 activity,	 and	 individuals	 with	 this	 mutation	
exhibit	 alcohol	 intolerance	 and	have	 increased	 risk	 of	 cancer,	 stroke,	 cardiac	 disease	 and	
neurodegenerative	 diseases,	 such	 as	 Parkinson’s.10	 Although	 the	 latter	 is	most	 likely	 as	 a	




activity	 relies	 on	 a	 highly	 conserved	 catalytic	 cysteine	 (Cys302	 in	 ALDH1	 and	 ALDH2)	 to	



























ALDH2	 Acetaldehyde	 Ester	 hydrolysis;	 nitroglycerin	 bio-activation,	 oxidizes	LPO-derived	aldehydes;	binds	acetaminophen	
ALDH3A1	 Aromatic,	aliphatic	aldehydes	
Ester	 hydrolysis;	 scavenges	 ROS;	 UV-filter;	 corneal	







ALDH6A1	 Malonate	semialdehyde	 Esterase	 activity;	 only	 known	 human	 CoA-dependent	ALDH	
ALDH7A1	 α-Aminoadipic	semialdehyde	


















point	 mutation	 involving	 substitution	 of	 guanine	 (G)	 to	 adenine	 (A),	 in	 turn,	 resulting	 in	 the	
substitution	 of	 glutamic	 acid	 (E)	 to	 a	 lysine	 (K)	 residue.	 This	 amino	 acid	 substitution	 causes	 the	
disruption	 of	 the	 α-helix	 structure	 in	 the	 domain	 important	 for	 dimerization.	 Incorporation	 of	
ALDH2*2	monomers	 in	 ALDH	 tetramer	 complexes	 ablates	 activity,	 where	 ALDH	 activity	 decreases	








































ALDH	enzymes,	 although	having	 a	well-described	 role	 in	normal	physiology,	 are	 also	well	
established	stem	cell	markers.	Being	 first	described	 in	blood,	ALDHhigh	umbilical	blood	cell	
populations	were	shown	to	be	enriched	in	hematopoietic	progenitor	cells,	or	hematopoietic	
stem	 cells	 (HSCs).13	 ALDHhigh	 cells	 were	 determined	 by	 Storms	 et	 al.	 (1999)	 in	 the	 first	
described	 use	 of	 the	 Aldefluor™	 assay,	 a	 flow	 cytometry	 assay	 relying	 on	 the	 specific	
conversation	of	the	fluorescent	marker,	BODIPY-aminoacetaldhyde	(BAAA),	to	its	negatively	
charged	 BODIPY-aminoacetate	 conjugate	 by	 ALDH,	 leading	 to	 fluorescent	 accumulation.	
Using	 this	 method,	 they	 demonstrated	 that	 these	 ALDHhigh	 umbilical	 blood	 cells	 were	
depleted	 of	 differentiated	 cell	 populations	 (e.g.	 mature	 T-cells,	 natural	 killer	 cells	 and	
markers	 for	 myeloid,	 erythroid,	 and	 platelet	 populations)	 and	 enriched	 for	 another	 HSC	
marker,	 CD34.13	 ALDH	 as	 a	 marker	 for	 HSCs	 and	 neural	 stem	 cells	 has	 now	 been	 well	
established,14	so	it	is	expected	other	cell	types	will	also	share	this	characteristic	marker.	The	
work	 from	 Ginister	 et	 al.	 (2007)	 has	 highlighted	 this,	 where	 they	 reported	 an	 ALDHhigh	




shown	 to	 be	 a	marker	 for	 several	 stem	 and	 progenitor	 cell	 populations	 including,	 neural	




retinoic	 acid	 signalling	 is	 an	 important	 factor,	 considering	 the	 consistency	 of	 ALDH1	
enzymes	specifically	being	highlighted	as	stem	cell	markers.	Retinoic	acid	is	essential	in	the	
differentiation	 of	 cells,	 where	 binding	 of	 all-trans-retinoic	 acid,	 a	 product	 of	 ALDH1	
biosynthesis,	 to	retinoic	acid	receptors	 (RAR)	and	retinoid	X	receptors	 (RXR)	expressed	on	
target	 cellular	 nuclei,	 causes	 haematopoiesis,	 tissue	 patterning	 and	 cellular	
development.18,19	 ALDH	 inhibition	 in	 HSCs	 resulted	 in	 decrease	 retinoic	 acid	 activity	 and	
delayed	differentiation.20	It	has	also	been	suggested	that	ALDH1	and	retinoic	acid	signalling	
play	an	important	role	in	regulation	of	self-renewal	in	HSCs,	especially	as	ALDH1	inhibition	






HSC	 self-renewal.14,20	 Perhaps	 the	 role	 ALDH	 enzymes	 play	 in	 cellular	 detoxification	 and	
their	ability	 to	protect	cells	against	oxidative	stress	may	also	provide	an	 important	role	 in	
promoting	 stem	cell	 longevity,14	where	 loss	of	ALDH	expression	or	 function	 can	 lead	 to	a	
wide	spectrum	of	disease	severities.2,10	Similarly,	an	 interesting	report	 found	that	 isolated	
ALDHhigh	 bone	 marrow	 cells	 injected	 into	 patients	 with	 ischemic	 heart	 failure	 exhibited	
beneficial	 cardiac	 functionality	 6-months	 after	 treatment,	 highlighting	 the	 use	 of	 ALDH-
determined	stem	cells	as	a	future	therapeutic	option.21		
	
Aldehyde	detoxification	by	ALDH	enzymes	plays	 an	 important	 role	 in	 Fanconi	 anaemia.	 It	
has	 been	 reported	 that	 the	 Fanconi	 anaemia	 gene,	 Fancd2,	 has	 a	 functional	 role	 in	
protecting	 cells	 from	aldehyde	 toxicity,22	 and	 indeed,	 chicken	DT40	B	Fancd2-/-	 cells	were	
hypersensitive	to	formaldehyde	and	acetaldehyde	treatment.	Critically,	Patel	and	his	team	
discovered	 that	 Aldh2-/-Fancd2-/-	 murine	 pups	 had	 disrupted	 haematopoiesis	 upon	
continued	ethanol	exposure,	leading	to	bone	marrow	failure,	and	consequently	leukaemia;	
likely	 through	 the	 lack	of	ALDH2	 in	HSCs	offering	vital	 aldehyde	detoxification.22	A	 recent	
study	 by	 Garaycoechea	 et	 al.	 (2012)	 reported	 an	 important	 synergy	 between	 ALDH2	
expression	and	the	Fanconi	anaemia	DNA-repair	pathway	in	protecting	HSCs	from	aldehyde	
toxicity,	where	Fancomi	anaemia	driven	bone	marrow	failure	 is	 likely	caused	by	aldehyde	
accumulation.4	 They	 highlighted	 the	 importance	 of	 Fancd2	 in	 mediating	 sensitivity	 to	
aldehydes,	 where	 DNA	 repair	 pathways	 are	 likely	 to	 be	 important	 in	 HSC	 survival.	 They	
describe	 synthetic	 lethality	 of	 double	 knock-out	 (Aldh2-/-Fancd2-/-)	 HSCs	 upon	 aldehyde	
exposure,	where	aldehyde	metabolism	is	quintessential	 in	maintaining	the	HSC	pool.4	This	
is	validated	by	the	fact	that	the	HSC	pool	is	significantly	diminished	upon	double	knock-out	
of	Aldh2	 and	Fancd2;	where	 knock-out	 of	Aldh2	 only	 significantly	 inhibited	bone-marrow	
repopulation,	 and	 a	 likely	 cause	 of	 the	 haematological	 cancers	 associated	 with	 Fanconi	
anaemia.4	A	further	synergy	between	ALDH2	and	FANCD2	has	been	reported	in	embryonic	
development,	 where	 double	 Aldh2-/-Fancd-/-	 embryos	 were	 not	 viable	 unless	 maternal	
ALDH2	was	present	for	catabolism	of	aldehydes	and	oxidative	agents	in	order	to	protect	the	
foetuses.23	 This	 highlights	 the	 functional	 importance	 for	 ALDH2	 being	 required	 (both	
internally	 or	 maternally)	 in	 embryogenesis,	 particularly	 when	 DNA	 crosslink	 repair	










Many	 cancers	 have	 now	 been	 described	 to	 display	 certain	 heterogeneity	 and	 hierarchy,	
where	 there	 exists	 a	 sub-population	 within	 the	 cancer	 cell	 bulk	 that	 exhibits	 stem-like	
behaviours,	 these	 are	 coined	 cancer	 stem	 cells.24	 Cancer	 stem	 cells	 (CSCs)	 are	 a	 small							
sub-population	of	 cancer	 cells	 that	possess	 the	 tumorigenic	potential	 to	give	 rise	 to	both	
tumorigenic	 and	 non-tumorigenic	 progeny.25	 The	 proposed	 CSC	model	 describes	 CSCs	 as	
tumour	 initiating	 cells,	 where	 they	 propagate	 the	 differentiation	 of	 heterogeneous	 non-
tumorigenic	cancer	cells	that	constitutes	the	bulk	of	the	tumour	through	establishment	of	
progenitor	 cells	 that	 can	 further	 differentiate	 (Figure	 1.3).24,26	 However,	 unlike	 in	 normal	
tissue,	 it	 is	 the	 CSCs	 only	 that	 have	 the	 capacity	 to	 self-renew,	making	 them	essential	 in	
both	the	initiation	and	maintenance	of	a	tumour.27	CSCs	are	often	described	as	resistant	to	
conventional	 chemo-therapeutics;	whether	 that	 is	 through	upregulation	of	 such	 genes	 as	
the	multi-drug	resistant	gene	(MRP),28	 increased	expression	of	mechanisms	to	evade	drug	
toxicity,	 including	 increase	of	ATP-binding	cassette	 (ABC)	transporters	to	essentially	pump	
the	drugs	out	of	 the	cell.29	Another	 likely	source	of	CSC	chemo-resistance	may	 lie	 in	 their	
low-proliferative	potential,	where	therapeutics	targeting	rapidly	diving	cell	populations	will	
leave	 CSC	 subpopulations	 essentially	 unaffected.27	 It	 is	 hypothesised	 that	 where	 cancers	
have	 relapsed	 after	 conventional	 chemo-therapeutic	 treatment,	 it	 is	 the	 chemo-resistant	
CSCs	that	repopulate	the	regressed	tumour,	in	many	cases	presenting	resistance	to	original	
course	of	 therapy.26,27	 This	 tumorigenic	potential	of	CSCs	 coupled	with	 their	 resistance	 to	
conventional	therapies	makes	treatment	of	relapsing	tumours	increasingly	difficult,	on	top	
of	 any	 somatic	mutations	 that	may	occur	 during	 therapy	 to	 help	 drive	 repopulation.	 The	
‘gold-standard’	 assay	 for	 detection	 of	 CSCs	 is	 through	 serial	 in	 vivo	 transplantation	 into	
immunodeficient	mice,	where	only	the	tumorigenic	potential	of	CSCs	will	give	rise	to	cancer	
populations.27	CSCs	 currently	have	no	universal	marker,	with	many	 cancer	 types	 (or	even	

















ALDH	 activity	 has	 recently	 become	 a	 focus	 in	 cancer	 due	 to	 its	 prevalence	 in	 many	
cancers,32,33	 including	 melanoma,34,35	 colorectal,36	 pancreatic,37	 lung,38	 breast,15	 ovarian,39	
glioblastoma40	and	neuroblastoma.41,42	The	ALDHhigh	subpopulation	of	cells	within	a	tumour	
have	been	shown	to	exhibit	CSC-like	properties	such	as	chemo-resistance43,44	and	increased	
tumorigenicity.34	 ALDH	 is	 now	 on	 the	 verge	 of	 being	 labelled	 a	 universal	 functional	 CSC	
marker,44,45	 and	 in	 colorectal	 cancer	 especially,	 the	 ALDHhigh	 subpopulation	 overlapped	
sufficiently	 enough	 with	 CD44,	 a	 well-established	 CSC	 marker	 in	 this	 cancer,	 that	 the	
ALDHhigh	 subpopulation	 presented	 as	 a	 niche	within	 CD44	 cell	 subpopulation	 themselves,	
suggesting	 ALDH	 may	 serve	 as	 a	 more	 accurate	 marker	 for	 CSCs	 in	 colorectal	 cancer.36	
ALDHhigh	subpopulations	are	thought	to	be	involved	in	mediating	metastasis	in	a	number	of	
cancers.46	 In	 breast	 cancer,	 the	 transplantation	 of	 ALDHhighCD44+CD24−	 cells	 into	
NOD/SCID/IL2γnull	mice	matched	 the	metastatic	behaviour	observed	 in	patients.47	Cancers	
that	 have	 higher	 level	 of	 ALDH	 expression	 correlate	 with	 poor	 clinical	 outcome,	 and	 a	
number	of	studies	 reveal	 the	success	of	using	ALDH	expression	as	a	prognostic	marker	 to	
predict	 the	 response	 to	 treatment	 and	 clinical	 progression,39,48,49	 primarily	 dependant	 on	







markers	 also,	 dependant	 on	 specific	 cancer	 type.45	 For	 instance,	 in	 neuroblastoma,	 it	 is	
reported	 that	 ALDH1A2	 is	 the	 key	 driver	 of	 CSC-potential,42	 and	 ALDH3A1	 mediates	
tumorigenesis	in	prostate	cancer.50		
	
Summarised	 in	Table	 1.2,	 it	 is	 clear	 that	ALDH	as	 a	 CSC	marker	 is	 dynamic	 and	 complex,	





well	 established,	 in	particular	 regarding	BRCA2	mutations	and	breast	 cancer,52	 suggesting	




ALDH	 Cancer	type	 Source	 Cancer-related	function	
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Table	 1.2:	 Specific	 ALDH	 enzymes	 in	 their	 roles	 as	 cancer	 stem	 cell	 markers.	 The	 ALDH	 isoform	
associated	as	a	cancer	stem	cell	marker	varies	depending	on	cancer	type.	While	ALDH1A1	remains	









resistance,45	 	but	 the	exact	mechanism	 in	which	 this	occurs	 is	 still	not	 fully	understood	 in	
many	 cases.	 The	 correlation	 between	 ALDH	 expression	 and	 drug	 resistance	 has	 been	
observed	 in	 the	majority	 of	 tumour	 types	 and	 in	 patients	 with	 resistant	 tumours	 also,44	
linking	 ALDH	 expression	 to	 poor	 clinical	 prognosis	 as	 a	 consequence.	 The	 association	
between	ALDH	and	drug	resistance	has	 long	been	described,53	where	Moreb	et	al.	 (2000)	
initially	 described	 the	 functional	 role	 for	 ALDH1A1	 in	 mediating																																																	
4-hydroperoxycyclophosphamine	 (4-HC)	 resistance	 in	 tumours,	 by	 sensitising	 K562	
leukemic	and	A549	lung	cancer	cells	to	4-HC	upon	ALDH1A1	knock-down.54	ALDHhigh	cancer	
cells,	 isolated	 through	 Aldefluor™	 driven	 FACS,	 were	 consistently	 highly	 resistant	 to	 the	
conventional	chemotherapeutics,	where	it	was	demonstrated	that	sensitivity	to	treatment	
was	 restored	upon	ALDH	 inhibition	or	 knock-down	 in	 lung,	breast,	melanoma	and	gastric	
carcinoma	 tumours.43,55-57	 Meng	 et	 al.	 (2013)	 further	 showed	 the	 expression	 of	 ALDH1	
increased	in	A2780	ovarian	cells	upon	synthetic	induction	of	cisplatin	resistance,39	where	a	
distinct	 ALDH1high	 subpopulation	 was	 established.	 This	 was	 also	 reported	 in	 pancreatic	
xenographs,	 where	 treatment	 with	 gemcitabine,	 an	 anticancer	 nucleoside	 pro-drug,	
enriched	the	tumour	population	for	ALDH	expression,	as	well	as	other	CSC	markers.58		
	
Although	 the	 exact	 functional	 role	 and	 mechanism	 ALDH1	 enzymes	 play	 in	 CSC												
chemo-resistance	remains	unclear,	Raha	et	al.	 (2014)	demonstrated	that	the	ALDHhigh	CSC	
subpopulation	of	MET-amplified	 gastric	 carcinoma	 cells	were	 resistant	 to	 the	MET	 kinase	
inhibitor,	 crizotinib,	 in	 an	 otherwise	 highly	 sensitive	 cancer	 cell	 line.43	 In	 these	 resistant	
ALDHhigh	 cells,	 they	 reported	having	higher	 levels	of	oxidative	 stress	upon	 treatment	with	
crizotinib,	and	cell	death	was	induced	as	a	result	of	ROS	overexposure,	when	coupled	with	
inhibition	 of	 ALDH.43	 This	 highlights	 ALDH	 providing	 a	 protective	 role	 in	 chemo-resistant	
CSCs,	where	ALDH1	 specifically	 contributes	 to	protection	against	DNA	damage	within	 the	















ALDH	 enzymes	 have	 also	 been	 shown	 to	 have	 a	 functional	 role	 in	 facilitating																							
chemo-resistance	 by	 directly	 metabolising	 drugs	 or	 their	 active	 intermediates.60,61	 ALDH	
enzymes	have	been	reported	in	the	catabolism	of	an	important	class	of	chemotherapeutic						
pro-drugs,	 the	oxazaphosphorines,	 rendering	 them	 inert.62	Cyclophosphamide,	one	of	 the	
most	 widely	 used	 oxazaphosphorines,	 is	 bio-activated	 by	 hepatic	 cytochrome	 P450	 to	
produce	 the	 4-HC	metabolite,	which	 releases	 the	 alkylating	 agent	 that	 drives	 anti-cancer	
activity.63	The	role	of	ALDH	in	cyclophosphamide	resistance	was	reported	by	Hilton	(1984)	
who	 described	 a	 uniquely	 high	 expression	 of	 ALDH	 in	 cyclophosphamide-resistant	 L1210	
leukaemia	cells	in	vitro	and	in	vivo.53	And	as	such,	the	ability	for	ALDH1A1	and	ALDH3A1	to	
metabolise	 this	 cytotoxic	 4-HC	 metabolite	 into	 a	 non-toxic	 carboxyl	 derivative	 in	 breast	
carcinomas,61	 presents	 a	 functional	 role	 for	 ALDH	 in	 specifically	 mediating																										
chemo-resistance	to	this	class	of	pro-drugs.	Further,	when	cells	transfected	to	overexpress	
ALDH3A1	were	exposed	 to	 cyclophosphamide,	 it	was	 found	 they	were	highly	 resistant	 to	
treatment.63,64	 This	 presents	 a	 functional	 role	 for	 ALDH	 enzymes	 in	 directly	metabolising	




Retinoic	 acid	 pathways	 are	 also	 likely	 to	 play	 an	 important	 role	 in	 mediating	 CSC	 drug	




It	 is	 likely	 that	 interplay	 between	 ALDH1	 expression	 and	 retinoic	 acid	 levels	 are	 at	 the	
foundation,	where	 only	 the	 ALDHhigh	 breast	 cancer	 cells,	 and	 not	 ALDHlow	 cells,	 displayed	
increased	 sensitivity	 to	 paclitaxel	 after	 retinoic	 acid	 pre-treatment.56	 It	 is	 suggested	 that	
due	 to	 the	 function	 of	 retinoic	 acid	 as	 a	 cellular	 differentiation	 agent,	 chemo-sensitivity	
could	 be	 driven	 by	 reduction	 of	 CSC-like	 properties	 in	 the	 chemo-resistant	 population.44	












It	 is	 now	 understood	 that	 there	 is	 a	 stem-like	 sub-population	 of	 cells	 expressed	 in	
melanoma,	which	 are	 highly	 tumorigenic,67,68	 chemo-resistant,57	 and	 can	 implement	 self-
renewal	as	well	as	differentiation	to	give	rise	to	heterogeneous	progeny.69	Fang	et	al.	(2005)	
first	 described	 a	 stem-like	 subpopulation	 within	 primary	 metastatic	 melanoma	 cultures,	
possibly	 due	 to	 spheroid	 formation,	 self-renewal	 and	 melanocytic	 differentiation,	 where	
transplantation	 into	 immunosuppressed	 mice	 drove	 tumour	 formation.67	 Isolation	 of	 a	





that	 can	be	 identified	by	ABCB5	expression,	 a	marker	which	 in	 turn	 can	mediate	 chemo-
resistance.30	 They	 reported	 that	 ABCB5	 expression	 overlapped	 with	 expression	 of	
melanotransferrin,	 a	 factor	 important	 for	 melanoma	 growth,	 and	 monoclonal	 antibody	
driven	 ablation	 of	 ABCB5	 significantly	 inhibited	 tumour	 growth	 in	 vivo,30	 suggesting	 an	
important	 functional	 role	 for	 melanoma	 CSCs	 in	 initiation,	 growth	 and	 maintenance	 of	




be	 involved	 in	 both	 foetal	 development	 and	 retinoic	 acid	 synthesis,2	 but	 somewhat	
unsurprisingly	is	shown	to	have	a	key	role	in	certain	chemo-resistance	pathways	in	a	variety	
of	 cancers.73-75	Melanoma	 is	no	exception	 to	 this	 trend	of	ALDH	as	 a	biomarker	 for	CSCs,	
where	Aldefluor™	flow-sorted	ALDH+	primary	melanoma	cells	xenographed	into	NOD/SCID	
mice	 were	 found	 to	 have	 significantly	 more	 rapid	 and	 efficacious	 tumour	 formation,	








whereas	 ALDH-	 xenographs	 were	 not	 able	 to	 replenish	 an	 ALDH+	 population.35,76	 ALDH+	
melanoma	 flow-sorted	 cells	 were	 able	 to	 give	 rise	 to	 a	 heterogeneous	 cancer	 cell	
population	 and	 had	 increased	 sphere	 formation,	 which	 again	 was	 not	 seen	 in	 ALDH-	
cells.34,35	ALDHhigh	 subpopulations	have	 shown	 localisation	 to	 the	 tumour/host	 interface,34	
suggesting	a	functional	role	for	ALDH	in	both	tumour	proliferation	and	invasion.	Although,	
another	 study	 found	 no	 difference	 in	 tumorigenic	 potential	 between	 ALDH+	 and	 ALDH-	
melanoma	 cells	 when	 transplanted	 into	 NSG	 mice.77	 However,	 this	 study	 suffered	 from	
discrepancies	 in	 comparison	 to	 previous	 studies,	 in	 both	 cellular	 samples	 and										
methodology	i.e.	the	‘gold	standard’	of	serial	transplantation	in	order	to	reveal	the	capacity	
of	 both	 these	 populations	 to	 self-renew	 and	 drive	 continued	 tumorigenicity,	 was	 not	
investigated.78	
	
Microarray	 analysis	 of	 human	 melanoma	 cells,	 subcutaneously	 xenographed	 into	
immunosuppressed	mice,	found	>15	fold	increase	in	the	ALDH1A1	and	ALDH1A3	isoforms,	
while	 siRNA	 induced	 knock-down	 of	 ALDH1A3	 inhibited	 xenograph	 tumour	 formation	 in	
mice,	promoted	cell	cycle	arrest,	and	reduced	cell	viability	and	sphere	formation.35,76	They	
concluded	 that	 ALDH1A1	 and	 ALDH1A3	 specifically	 are	 the	 key	 ALDH	 markers	 for	 CSC		
‘stem-like’	potential	 in	melanoma.	Aldefluor™	flow	sorting	of	cancer	cells	has	been	shown	
to	correlate	with	cellular	expression	of	ALDH1A1	and	1A3.46,79,80	 In	melanoma,	Aldefluor™	
flow-sorted	 cells	 showed	 increased	 resistance	 to	 the	 chemotherapeutics;	 temozolomide,	
paclitaxel	 and	doxorubicin	 as	well	 as	being	 the	driver	of	melanoma	 cancer	 cell	 growth	 in	
xenographed	mice.35	This	highlights	the	requirement	of	ALDH1A1	and	1A3	in	melanoma	to	
maintain	 cancer	 cell	 ‘stemness’.	 Further,	 microarray	 data	 showed	 upregulation	 of	
downstream	 retinoic	 acid	 associated	 genes,	 many	 associated	 with	 stem	 cell	 behaviour,				
anti-apoptosis	 or	 cell	 cycle	 arrest.31	 ALDH1A1	 specifically	 is	 required	 to	 modulate	 CSC	
behaviour,	 with	 specific	 knock-down	 in	 melanoma	 cells	 reducing	 cell	 migration,	 but	
interestingly	 did	 not	 inhibit	 tumorigenesis	 in	 this	 study.81	 The	overlap	of	ALDH1A1high	 cell	
populations	 with	 other	 melanoma	 CSC	 markers	 (CD133+/CD29+/CD44+),	 also	 decreased	
upon	 ALDH1A1	 knock-down,	 highlighting	 the	 role	 of	 ALDH1A1	 in	 maintaining	melanoma	
CSC	potential.81	
	
Questions	 have	 been	 raised	 regarding	 the	 frequency	 of	 ALDH	 driven	 CSCs	 present	 in	






makes	 it	 incredibly	difficult	 to	establish	and	describe	a	distinct	CSC	niche	with	 conflicting	
data,	however	it	has	been	suggested	these	discrepancies	may	arise	from	factors	such	as	the	
set	ALDH	expression	limitation,	the	model	and	assay	in	which	these	cells	are	subjected	to,		
as	 well	 as	 heterogeneity	 within	 the	 cancer	 cell	 populations	 themselves.82	 This	 may	 also	





The	 role	 of	 ALDH	 in	 melanoma	 CSCs	 is	 largely	 unknown,	 however,	 considering	 the	
involvement	of	ALDH1A	enzymes	in	melanoma	CSCs,	it	seems	logical	to	conclude	their	role	
in	 retinoic	 acid	 signalling.	 Luo	 et	 al.	 (2012)	 did	 show	 that	 the	 stem	 cell	 gene,	 CDC42,	









essential	 for	 functionality	 in	 normal	 cells.	 STAT3	 is	 thought	 to	 be	 involved	 in	 progression	
and	 regulation	 in	 several	 cancers,87	 where	 STAT3	 upregulation	 is	 associated	 with	 poor	
prognosis	 in	melanoma	patients.88	 STAT3	activation,	 and	 consequent	 signalling	pathways,	
are	associated	with	senescence	of	CSC-like	cells	in	melanoma,	where	this	STAT3	expression	
is	also	coupled	with	an	increase	in	ALDH1A3	expression.85	As	ALDH1A3	has	been	highlighted	
as	 a	melanoma	 stem	 cell	marker,79	 this	 suggests	 interplay	 between	 ALDH1A3	 expression	
and	STAT3	activation	in	mediating	and	regulating	CSC	potential	in	melanoma.	
	
Hedgehog-GLI	 (HH)	signalling	has	also	been	 linked	to	cancer	cell	 ‘stemness’	 in	melanoma.	
HH	 expression	 is	 elevated	 in	 melanoma,	 compared	 to	 normal	 melanocytes,	 where	
pharmacological	 inhibition	 as	 well	 as	 genetic	 knock-down	 of	 the	 HH-pathway	 reduced	






tumorigenic	 capability	 of	 CSCs.89,90	 Knock-down	 of	 the	 HH-pathway	 also	 significantly	







DNA	 damage	 and	 apoptosis	 upon	 knock-down.91	 Similarly	 to	 HH,	 Sox2	 expression	 was	
significantly	higher	in	ALDHhigh	melanoma	cells,	compared	to	ALDHlow,	and	Sox2	knock-down	
decreased	the	tumorigenic	capacity	of	ALDHhigh	cells,	as	well	as	the	total	number	of	ALDHhigh	
cells	within	 the	melanoma	 population.	 Interestingly,	 Sox2	 expression	 has	 been	 shown	 to	
directly	 affect	 ALDH1A1	 expression	 in	 melanoma81	 in	 a	 study	 where	 the	 dioxin	 receptor	





AhR	 can	 mediate	 ALDH1A1/Sox2	 expression	 to	 induce	 differentiation	 potential.81	 This	
suggests	 a	possible	mechanism	 for	 the	expression	and	 function	of	ALDH	 in	maintaining	 a	






Although	 the	 correlation	 between	 folate	 levels	 and	 cancer	 risk	 is	 currently	 unclear,93-97	 a	
recent	study	 looking	at	frequency	of	circulating	melanoma	cells	 in	xenographed	NSG	mice	











and	 the	 efficiency	 at	 which	 they	 can	 cause	metastasis	 is	 even	 lower,100	 these	 circulating	
melanoma	cells	essentially	fail	to	survive	long	enough	in	the	blood	to	cause	metastases	due	
to	 oxidative	 stress.98	 This	 suggests	 an	 important	 role	 for	 ALDH1L2	 in	metastasis	 through	
regulation	 of	 pathways	 to	 suppress	 oxidative	 stress	 in	 these	 circulating	 melanoma	 cells.	
Although	 there	 is	 some	 evidence	 that	 suggests	 ALDH1L2	 may	 contribute	 to	 Aldefluor™	
activity	in	rhabdomyosarcoma	cells,101	where	these	ALDHhigh	cells	(by	Aldefluor™)	were	also	









Considering	 the	 CSC	 model,	 it	 is	 reasonable	 to	 assume	 that	 tumour	 growth	 and	 cancer	
development	 is	 driven	 by	 CSCs.24,26,102	 Normal	 chemotherapeutics	 (for	 instance	 platinum	
compounds	 that	 cause	 DNA	 damage	 in	 rapidly	 diving	 cells)	 will	 only	 target	 the															
highly-proliferative,	 non-tumorigenic	 cell	 majority.	 However	 the	 dormant	 CSC	 population	
remain	unscathed.26,102	This	is	supported	by	reports	that	subpopulations	of	cancer	cells,	i.e.	
CSCs,	 have	 much	 greater	 potential	 for	 chemo-resistance	 through	 various	 defence	
mechanisms.26-29	 As	 such,	 these	 dormant	 CSCs	 are	 regarded	 as	 the	 primary	 culprit	 in	
mediating	 cancer	 relapse,	 considering	 their	 characteristically	 high	 tumorigenicity.26										
Chen	 et	 al.	 (2012)	 showed	 in	 glioblastoma	 that	 a	 subset	 of	 dormant	 cells	 in	 the	 cell	
population	 remained	 after	 treatment	 with	 temozolomide	 (TMZ),	 where	 TMZ	 was	 only	
shown	 to	 target	 the	 highly	 proliferative	 glioblastoma	 cell	 bulk.	 Genetic	 ablation	 of	 these	
dormant	 cells	was	performed	using	a	nestin-Cre	 system	 in	mouse,	where	 tumour	 relapse	
was	 consequently	 delayed	 following	 treatment	 of	 the	 glioblastoma	 xenographs	 with	
TMZ.103	Resistance	in	CSCs	can	also	include	increased	DNA	damage	repair	agents,	protective	








The	 use	 of	 retinoic	 acid	 in	 the	 treatment	 of	 cancer	 is	 widely	 used	 against	 some	 blood	
cancers,	where	 the	promotion	of	differentiation	 through	 retinoic	acid	 signalling	pathways	
plays	an	apparent	role	in	reducing	the	‘stem-like’	potential	and	resistance	in	CSCs,	providing	
an	 effective	 and	 lasting	 anti-cancer	 treatment.44	 The	 use	 of	 retinoic	 acid	 to	 sensitise	
tumours	 to	 conventional	 chemotherapeutics	 is	 now	becoming	more	 favourable	 in	 a	wide	
range	 of	 cancers.44,65	 Although	 this	 treatment	 does	 prove	 effective,	 it	 is	 one	 of	 very	 few	
examples	that	are	seeking	to	affect	the	CSCs	specifically	within	the	tumour	bulk	in	order	to	




Most	 oncological	 drug	 discovery	 is	 focused	 towards	 compounds	 that	 exhibit	 potent	
cytotoxicity	 against	 whole	 cancer	 cell	 populations.27,104	While	most	 treatments,	 including	
targeted	therapies,	now	common	place	in	melanoma	treatment,	will	only	target	the	tumour	
bulk	unambiguously,	 it	 is	becoming	 increasingly	clear	that	designing	therapeutics	that	can	
target	 these	 CSC	 subpopulations	 will	 be	 highly	 desirable,	 especially	 in	 developing	
treatments	 that	 will	 deliver	 long	 lasting	 cancer	 remission.44,45,104	 In	 melanoma	 there	 has	
been	a	lot	of	progress	in	developing	new	compounds	with	potent	anti-cancer	activity,	with	
the	 new	 class	 of	 BRAF	 inhibitors	 now	 being	 in	 the	 front	 line	 treatment	 for	 malignant	
melanoma.106,107	However,	 resistance	 is	a	hard	 fought	battle	 in	melanoma	drug	discovery,	





Tirosh	 et	 al.	 (2016)	 discovered	 a	 subpopulation	 of	 cells,	 through	 single	 cell	 sequencing,	
within	 malignant	 melanomas	 that	 have	 an	 altered	 cell	 state	 and	 are	 key	 to	 mediating	
resistance	 of	 these	 tumours	 to	 MAPK	 inhibitors.108	 This	 subpopulation	 of	 AXLhighMITFlow	
melanoma	cells,	within	the	tumour	bulk,	had	significant	alterations	in	cellular	state,	which	
increased	 upon	 treatment	 with	 debrafenib	 and	 trametinib.108	 This	 highlights	 the	 cellular	
heterogeneity	 that	 exists	 within	 malignant	 melanoma,	 and	 how	 changes	 to	 the	 cellular	
ecosystem	can	alter	cell	 state,	 	mediate	 resistance	and	ultimately,	provides	evidence	of	a	







an	 efflux	 pump	 highly	 expressed	 in	 melanoma	 CSCs	 that	 directly	 contributes	 to												
chemo-resistance.30	 They	 found	 that	 the	 ABCB5+	 subpopulation	 is	 highly	 tumorigenic	
through	in	vivo	xenotransplantation	in	mice,	confirming	their	use	as	a	functional	melanoma	
CSC	 selection	 marker.	 Treatment	 of	 xenographed	 mice	 with	 anti-ABCB5	 monoclonal	
antibodies	 inhibited	 tumour	 growth,	 where	 antibody	 mediated	 cell	 toxicity	 specifically	
targeted	the	ABCB5+	tumorigenic	CSC	population.30	Yue	et	al.	(2015)	put	forward	ALDH1	as	
a	potential	target	against	melanoma,	where	they	found	that	inhibition	of	ALDH1	with	DEAB	







ABCB5,	 CD271	 and	 ALDH	 expression	 are	 associated	 markers	 for	 melanoma	 CSCs.	 Conventional	
chemotherapy	will	target	and	reduce	the	cancer	cell	population	unequivocally,	however	CSCs,	which	
are	 typically	 resistant	 to	 these	 therapies,	 will	 drive	 cancer	 repopulation	 upon	 chemo-failure	 or	
relapse.	Designing	therapies	that	can	specifically	target,	kill	and	ablate	these	CSC	subpopulations	will	















one	 is	 available	 clinically.60	 The	 ALDH2	 inhibitor,	 daidzin	 (Figure	 1.5A),	 derived	 from	 the	
Chinese	vine,	Puearia	 lobata,	 is	a	potent	competitive	 inhibitor	for	ALDH2	(IC50	=	80nM).109	
The	mechanism	of	daidzin	mediated	ALDH	inhibition	works	through	a	strong	van	der	waals	
contribution	within	the	catalytic	pocket,	forming	interactions	with	the	catalytic	Cys302	and	
Glu268	 residues,	 essential	 for	 activity.	 Disulfiram	 (Figure	 1.5B)	 in	 currently	 the	 only	





of	 its	 metabolites	 promoting	 the	 carbamylation	 of	 the	 catalytic	 Cys302	 residue.	 Upon	
treatment	 with	 disulfiram,	 the	 active	 metabolites	 are	 produced	 biologically	 through	 the	
cleavage	 of	 the	 disulphide	 bond	 via	 sulphide	 exchange	 with	 Cys302	 on	 ALDH2.60																																											
N,N-diethylaminobenzaldehyde	 (DEAB)	 (Figure	 1.5C),	 although	 labelled	 as	 an	 ALDH	
inhibitor,	 is	 more	 accurately	 described	 as	 a	 competitive	 substrate	 for	 ALDH,	 where	 the	
catalytic	 conversion	 of	 the	 tightly	 bound	 benzaldehyde	 derivative	 to	 its	 benzoic	 acid	
conjugate	 by	 ALDH	 occurs	 so	 exceptionally	 slowly	 that	 ALDH	 activity	 is	 essentially	
inhibited.110	DEAB	is	commonly	used	as	a	negative	control	in	the	Aldefluor™	assay,13	where	
the	 inhibition	 of	 Aldelfuor™	 expression	 is	 through	 its	 specificity	 as	 a	 substrate	 for	 both	
ALDH1A1	 and	 1A3.110	 Although	 ALDH	 activity	will	 begin	 to	 recover	 over	 time	 after	 DEAB	
treatment,	 as	 the	DEAB	 carboxylate	 is	 produced,	 it	 is	 interesting	 to	 note	 that	 a	 covalent	





























Figure	 1.5:	 Molecular	 structures	 of	 ALDH	 inhibitors.	A)	 Molecular	 structure	 of	 daidzin.	 The	 triple	
aromatic	ring	structure	is	critical	for	ALDH	inhibition,	where	the	phenol	hydroxyl	plays	a	key	role	in	
Cys302	 interaction	 and	 the	 glycosyl	 has	 a	 strong	 interaction	 with	 the	 hydrophobic	 cleft	 opposite	
NAD+	binding	pocket.	B)	Molecular	structure	of	disulfiram.	Cleavage	of	the	disulphide	bond	by	ALDH	
Cys302	 sulphide	 exchange	mediates	 inhibitory	 activity,	 where	 the	metabolites	 of	 disulfiram	 upon	
cleavage	 become	 highly	 electrophilic	 to	 promote	 carbamylation	 of	 the	 catalytic	 ALDH	 cysteine.																










to	 chemo-therapeutics	 in	 breast	 and	 lung	 cancers43,55,56	 Classically,	 disulfiram	 has	 been	
described	 as	 an	 inhibitor	 for	 ALDH2,	 however,	 it	 is	 a	 much	 more	 potent	 inhibitor	 of	
ALDH1A1.113	 Its	 anti-cancer	 effectiveness	 as	 an	 ALDH1	 inhibitor	 was	 reported	 by														
Raha	 et	 al.	 (2014),	 who	 demonstrated	 that	 treatment	 with	 disulfiram	 promotes											
A	












drove	 the	 differentiation	 of	 ALDHhigh	 breast	 CSCs,	 through	 disruption	 of	 retinoic	 acid	
signalling,56	but	also	reduced	melanoma	tumour	growth	in	xenographed	mice,	and	reduced	
melanoma	CSC	 tumorigenic	potential.106	As	ALDH	plays	a	 vital	 role	 in	 the	metabolising	of	
cyclophosphamide	 chemotherapeutics	 to	 invoke	 resistance	 in	 cancers,61	 inhibiting	 ALDH	
therefore	 presents	 itself	 as	 a	 favourable	 target	 to	 promote	 chemo-sensitivity.	 Novel	
ketone-based	covalent	ALDH	inhibitors	have	recently	been	synthesised	by	Mochley-Rosen,	
Hurley	 and	 their	 team,117	 in	 a	bid	 to	 combat	 this.	 These	ALDH1A1	and	3A1	 inhibitors	 are	
reported	 as	 non-toxic	 yet	 increased	 sensitivity	 of	 cancer	 cell	 lines	 to	 cyclophosphamide-
based	 therapeutics,	 paving	 the	 way	 for	 a	 new	 series	 of	 ALDH	 inhibitors	 as	 potential	
therapeutic	 option	 for	 chemo-resistant	 cancers.	 Last	 year	 (April	 2016),	 a	 clinical	 trial	was	
initiated	looking	at	the	effect	the	ALDH	inhibitor,	dimethylampalthiolester	(DIMATE)	has	on	
both	leukaemia	and	normal	haematopoietic	stem	cells,	and	whether	DIMATE	treatment	can	





Designing	 therapeutics	 targeting	 ALDH	 has	 previously	 been	 offered	 up	 as	 a	 favourable	
target	 to	 hit	 CSCs	 in	 tumour	 cell	 populations.35,45,118	 The	 association	 between	 ALDH	
expression	and	chemo-resistance	in	melanoma	presents	a	favourable	therapeutic	target	to	
combat	highly	aggressive,	 chemo-resistant	melanoma	and	development	of	drugs	 that	can	
inhibit	 ALDH	 enzymes	 to	 sensitise	 cells	 to	 therapy,	 or	 better	 yet,	 to	 selectively	 target	
ALDHhigh	cancer	cell	populations,	are	increasingly	desirable.	
	
During	 a	 small	 molecule	 screen,	 5-nitrofurans	 (5-NFNs)	 (Figure	 1.6A)	 were	 shown	 to	 be	
substrates	for	ALDH2	 in	vitro	and	 in	vivo.115	Zhou	et	al.	(2012)	reported	that	bio-activation	






functional	 group	 to	 generate	 free	 radical	 oxygen	 species,	 that	 can	 cause	 melanocyte	
specific	 cell	death	 in	 zebrafish.	Bio-activation	of	5-NFNs	by	ALDH2	 is	 seen	across	multiple	
species,	 where	 pre-treatment	 with	 the	 ALDH2	 inhibitor,	 daidzin,	 offers	 protection	 from							
5-NFN	 toxicity,	 however	 loss	 of	 the	 5-NO2	 moiety	 (Figure	 1.6B)	 confers	 the	 compounds	
inactive.	This	suggests	5-NFN	toxicity	 is	mediated	by	reduction	of	the	NO2	moiety	to	drive	
ROS	 production;	 in	 similarity	 to	 the	 action	 of	 5-NFNs	 at	 NTRs.119	 Patton	 and	 her	 team	
discovered	 their	 synthetic	 5-NFNs,	 and	 the	 clinical	 5-NFN	nifurtimox	 (NFX	–	 Figure	 1.6C),	
were	substrates	for	human	ALDH2	in	vitro,	and	were	cytotoxic	in	human	melanoma	cells.115	









Figure	 1.6:	5-nitrofuran	moiety.	A)	Generic	molecular	 structure	of	5-NFNs,	where	 the	5-nitrofuran	
moiety	 is	 highlighted	 in	 red.	 The	5-NO2	 is	 important	 in	 activity	of	 5-NFNs,	where	 the	R-group	will	
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and	 veterinary	 medicine.	 NFX	 is	 one	 of	 the	 most	 widely	 used	 5-nitrofuran	 drugs	 as	 a							
front-line	 treatment	 for	 Chagas	 Disease	 (Trypanosoma	 cruzi),	 endemic	 in	 Latin	 America	
affecting	 around	16-18million	people	worldwide.120	 The	mode	of	 5-NFN	action	 is	 through	
reduction	 of	 the	NO2-moiety	 by	 nitroreductases	 (NTRs),	 not	 common	 to	 eukaryotic	 cells,	
thereby	 inducing	cytotoxicity	 (Figure	1.7).119	Although	NFX	 is	on	the	WHO	list	of	essential	
medicines,121	 treatment	 often	 leads	 to	 many	 undesirable	 side	 effects	 including	




the	primary	use	of	 5-NFNs	was	originally	 as	 an	antibiotic	 additive	 to	 animal	 feeds.123	 The	
practise	of	bulk	treating	livestock	with	5-NFNs	was	consequentially	banned	in	1993	by	the	




in	 the	 USA.	 5-NFNs	 are	 also	 plagued	 by	 their	 poor	 pharmacokinetics.	 5-NFNs	 are	 orally	
bioavailable	and	almost	completely	absorbed,	however	the	total	serum	concentrations	are	
relatively	low.126-128	Upon	treatment	with	NFT,	nearly	70%	of	the	total	dose	was	lost	almost	
immediately,	 presumably	 through	 high	 first-pass	metabolism	 in	 the	 liver;127	where	 it	was	
reported	 to	 be	 greater	 than	 90%	 for	 NFX.126,129	 Sholler	 et	 al.	 (2011)	 reported	 better	
bioavailability	 in	 patients	 under	 21,	with	 a	mean	of	 4.80µg/mL	max	 serum	 concentration												
6-hours	 after	 a	 single	 30mg/kg	 dose,	 compared	 to	 a	 mean	 of	 0.751µg/mL	 serum	
concentration	2.2-hours	after	a	single	15mg/kg	dose	 in	healthy	human	males.126	Although	
the	minimum	 inhibitory	 IC50	 for	NFX	 in	 the	 treatment	of	 Chagas	disease	 is	 relatively	 low,	










NTR II NTR I 
	
Figure	 1.7:	 Mechanism	 of	 action	 of	 5-NFNs	 against	 NTRs.	 5-NFNs	 are	 one	 electron	 reduced	 to	 a									
5-NFN	 radical	 species	 in	 an	 initial	 reaction	 by	 NTR	 II.	 The	 consequent	 5-NFN	 radical	 can	 reduce	
oxygen	to	a	radical	species,	which	in	turn,	can	cascade	through	super	oxide	dismutase	redox-cycling,	








girl	 with	 chemo-resistant	 neuroblastoma	 who	 also	 contracted	 Chagas	 disease,														
Sholler	et	al.	 (2006)	reported	that	treatment	with	NFX	 induced	tumour	regression.131	This	
finding	 led	 Sholler	 and	 her	 team	 to	 discover	 the	 anticancer	 potential	 of	 NFX	 in	
neuroblastoma.132	 They	 reported	 NFX	 treatment	 induced	 apoptosis	 in	 childhood	
neuroblastoma	 cell	 lines	 and	 was	 paralleled	 with	 inhibition	 of	 tumour	 growth	 in	
xenographed	 mice.	 Further,	 they	 suggested	 that	NFX	 interferes	 with	 the	 TrkB	 signalling	
pathways,	 another	 mediator	 of	 chemo-resistance	 in	 neuroblastoma,	 where	 downstream	
phosphorylation	 of	 Akt,	 vital	 for	 cell	 survival,	 is	 ablated	 upon	NFX	 treatment.132	 Similar	
findings	 have	 also	 been	 reported	 in	 the	 NFX	 treatment	 of	 meduloblastoma,112	 and	 a	
successful	 phase	 I	 clinical	 trial	 in	 the	 treatment	 of	 relapsed,	 chemo-resistant	






described	 in	 other	 neuronal	 tumour	 cell	 lines,	 such	 as	 glioblastoma,	where	 the	 synthetic	
lethal	action	of	buthionine	sulfoximine	(BOS),	a	γ-glutamylcysteine	synthetase	 inhibitor,	 is	
also	described.133	γ-Glutamylcysteine	synthetase	regulates	glutathione	(GSH)	production,	an	
intercellular	 tri-peptide	 with	 crucial	 antioxidant	 action,	 further	 alluding	 to	 direct	 ROS	
production	via	NFX	and	explaining	the	observed	NFX-BOS	synergy.	As	Phase	2	clinical	trials	
for	 the	 treatment	of	neuroblastoma	and	medulloblastoma	with	NFX	 in	patients	under	21	
continue	 (ClinicalTrials.gov,	 Identifier:	 NCT00601003),	 the	 underlying	 mechanism	 for	 this	
anticancer	 activity	 remains	 unknown.	 NFX	 treatment	 of	 neuroblastoma	 cells	 reduced	
viability	 and	 promoted	 cell	 cycle	 arrest	 through	 the	 formation	 of	 ROS.132,134	 Further,	 the	
levels	 of	N-Myc,	 a	proto-oncogene	amplified	 in	malignant	 and	 chemo-resistant	 childhood	











been	 published,	 where	 inhibition	 of	 cell	 proliferation,	 promotion	 of	 apoptosis	 and	
accumulation	 of	 intercellular	 ROS	 in	 melanoma	 cells,	 coupled	 with	 the	 suppression	 of	
metastasis	 in	 melanoma	 xenographs	 have	 been	 observed	 post-NAZ	 treatment.137	
Interestingly,	NFT	 (Figure	 1.8B)	 has	 been	 demonstrated	 to	 be	 effective	 at	 killing	 bladder	


























The	 anti-cancer	 potential	 of	 NFX	 has	 been	 described	 in	 neuroblastoma	 and	
medulloblastoma,	 however	 the	 mechanism	 of	 this	 anti-cancer	 activity	 is	 unknown.	
Considering	the	findings	that	5-NFNs,	including	NFX,	are	competitive	substrates	for	ALDH2	
in	 vitro	 and	 in	 vivo,	 coupled	with	 Sholler	et	 al.	 (2011)	 reporting	 that	 treatment	with	NFX	
increased	intercellular	ROS	in	cancer	cells,	 it	 is	 likely	that	NFX	driven	cancer	cell	toxicity	 is	
mediated	 by	 ALDH-driven	 bio-activation.	 Zhou	 et	 al.	 (2012)	 showed	 that	 the	 toxicity	 of							
5-NFN	pro-drugs	is	initiated	by	an	ALDH-dependent	reduction	of	the	5-NO2	functional	group	
to	 generate	 free	 radical	 oxygen	 species,	 that	 then	 causes	 cell	 death	 in	 zebrafish	
melanocytes	 and	 in	 melanoma	 cells,115	 which	 would	 explain	 why	 NFX	 was	 so	 active	 in	
neuroblastoma,	 considering	 dopaminergic	 rich	 neuroblastoma	 need	 increased	 levels	 of	
ALDH	 for	 dopamine	 metabolism.	 Further,	 Stanchi	 et	 al.	 (2015)	 reported	 NFX	 treatment	






also	 help	 to	 explain	 the	 severe	 side	 effects	 associated	 with	 5-NFN	 treatment,	 such	 as	
gastrointestinal	 distress,	 neuronal	 problems	 and	 alcohol	 intolerance,122	 where																				
bio-activation	of	5-NFNs	by	ALDH	enzymes	offers	a	 likely	 source.	This	 is	not	 the	 first	case	
where	 antibiotics	 have	 been	 known	 to	 have	 ALDH	 enzymes	 side	 targeting,	 where	
cephalosporin	 antibiotics	 have	 been	 shown	 to	 covalently	 inhibit	 ALDH1A1	 enzymes,	 in	 a	
similar	mechanism	to	that	of	disulfiram.139		
	
I	 hypothesise	 that	 5-NFNs	 can	be	bio-activated	by	ALDH	enzymes	 to	promote	 cancer	 cell	
death.	Similar	to	the	mechanism	between	5-NFNs	and	NTRs	in	anti-microbial	action,	ALDH	
enzymes	 can	 bio-activate	 5-NFNs,	 through	 5-NO2	 reduction/cleavage,	 promoting	 ROS	
formation	 and	 driving	 cancer	 cell	 death	 (Figure	 1.9).	 ALDHhigh	 subpopulations,	 especially	
ALDH1,	are	thought	to	be	associated	with	 increased	tumorigenicity,	promoting	metastasis	
and	 driving	 chemo-resistance,	 now	 commonly	 described	 as	 CSCs.	 If	 5-NFNs	 can	 be													







that	 can	 reduce	 tumorigenesis,	 inhibit	metastasis	 and	ultimately,	 prevent	 cancer	 relapse.	
This	 new	 approach	 to	 ALDH	 targeting	 offers	 a	 pro-drug	 that	 can	 selective	 target	 and	 kill	








Figure	 1.9:	 Hypothesised	 mechanism	 of	 5-NFN	 bio-activation	 by	 ALDH	 enzymes.	 Cleavage	 of	 the								



























5-Nitrofurans	 (5-NFNs)	are	pro-drugs	commonly	used	 for	parasitic	and	bacterial	 infection.	
We	have	 recently	 shown	 that	ALDH2	enzymes	can	bio-activate	5-NFNs	 in	yeast,	 zebrafish	
and	 in	 vitro.	 This	 is	 significant	 for	 cancer	 because	 ALDH	 enzymes	 are	 enriched	 in	 cancer	
stem	 cells	 in	 many	 cancer	 types.	My	 hypothesis	 is	 that	 5-Nitrofuran	 pro-drugs	 have	 the	






The	 overall	 Aim	 of	 my	 work	 is	 to	 understand	 the	 molecular	 mechanism	 of	 5-NFN-ALDH	









markers,	 ALDH1A1	 and	 ALDH1A3.	 Through	 genetic	 knock-down	 and	






There	 are	 around	 a	 dozen	 5-NFNs	 used	 clinically	 for	 infection.	 Importantly,	
nifurtimox	 is	 in	 clinical	 trial	 for	 treating	 neuroblastoma	 and	 medulloblastoma	
(ClinicalTrials.gov	 Identifier:	 NCT00601003),131	 but	 the	 mechanism	 of	 action	











Aim	4. Determine	 the	 mechanism	 and	 structure	 of	 ALDH	 enzymes	 with	 5-NFNs.	
Working	 in	collaboration	with	Dr	Alex	von	Kriegsheim	at	 the	Edinburgh	Cancer	
Research	UK	Centre	 (University	 of	 Edinburgh),	Dr	Martin	Weir	 and	Dr	Douglas	
Houston	 at	 the	 Institute	 of	 Structural	 and	 Molecular	 Biology	 (University	 of	
Edinburgh).	 This	 is	 important	 because	 it	 will	 enable	 us	 determine	 the	 how											
5-NFNs	 engage	 with	 ALDH	 enzymes,	 provide	 a	 platform	 for	 how	 to	 develop	









































































OriGene	 ALDH1A3	 Human	 cDNA	 Clone	 pCMV6-XL4	 vector	
(NM_000693)	
























































































































Plasmids	 for	 His-tagged	 human	 ALDH2	 and	 ALDH2*2	 in	 the	 pTrcHis-TOPO®	 vector	 were	
kindly	 provided	 by	 Dr	 Che-Hong	 Chen	 and	 Professor	 Daria	 Mochley-Rosen	 (Stanford	
University,	 CA,	 USA).140	 Expression	 trials	 were	 conducted	 by	 transformation	 into	 E.coli	
strains	 BL21,	 BL21*	 and	 C41.	 Target	 plasmids	 (1µL)	 were	 incubated	 with	 50mL	 E.coli	
cultures	 on	 ice	 (20mins),	 heat	 shocked	 (42oC,	 2mins)	 and	 put	 back	 on	 ice	 (3mins).	 Super	
optimal	broth	(250µL)	was	added	and	resultant	cultures	placed	in	shaking	incubator	(37oC,	






plates	 and	 incubated	 (37oC)	 overnight.	 Single	 colonies	 picked	 and	 inoculated	 in	 5mL	 LB	
broth	 and	 carbenicillin	 (100μg/mL).	 Cultures	 were	 incubated	 (37oC,	 250rpm)	 until	
Absorbance	=	0.6,	measured	by	Ultrospec®	10	Cell	Density	Meter	against	blank	LB,	where	
expression	 induced	 with	 1mM	 isopropyl	 β-D-1-thiogalactopyranoside	 (IPTG)	 and	 grown	
overnight	 (37oC	or	30oC,	250rpm).	Samples	 (1mL)	were	 taken	pre-inoculation,	 centrifuged	
(5500g,	5mins,	4oC)	and	frozen	(-20oC)	for	non-induction	controls.	Overnight	cultures	(1mL)	
were	centrifuged	 (5500g,	5mins,	4oC)	 suspended	 in	2M	NaCl	 solution	 (333.3µL)	and	 lysed	
via	sonication	(Amplitude	4.2,	10secs)	on	SoniPrep	150	prep	sonicator.	Whole	cell	samples	
and	 aqueous	 samples	 -	 taken	 from	 supernatant	 after	 centrifuging	 (14,000g,	 5mins,	 4oC),	
were	mixed	with	sample	buffer	(5:1)	and	assessed	for	ALDH2	or	ALDH2*2	expression	using	
gel	 chromatography.	 Non-induction	 controls	 were	 also	 resuspended	 in	 2M	 NaCl	 (100µL)	
and	sonicated,	where	only	whole	cell	samples	were	used	as	non-expressing	controls.	
	
Gel	 chromatography	was	 performed	 by	 the	 following	 protocol	 throughout:	 Sample	 (5µL)	
was	added	to	sample	buffer	(1µL)	and	boiled	(100oC,	3mins).	The	samples	were	loaded	onto	
Mini-PROTEAN®	 TGX™	 Precast	 Gel	 or	 Stain	 Free	 Gel	 and	 proteins	 separated	 by	
electrophoresis	 (240V,	 26mins)	 in	 running	 buffer.	 The	 gel	 was	 either	 stained	 with	
InstaBlue™	 (50mL,	 30mins)	 or	 activated	 by	 Gel	 Doc™	 EZ	 Gel	 Documentation	 System					










From	 previous	 cultured	 plates,	 single	 colonies	 picked	 from	 BL21*	 streaked	 plates	 for	
ALDH2-His	 or	 ALDH2*2-His	 and	 inoculated	 in	 5mL	 LB	 broth	 and	 carbenicillin	 (100μg/mL),	
and	 grown	 overnight	 (37oC,	 250rpm).	 Inoculation	 cultures	 added	 to	 LB	 broth	 (500mL	 +	
100μg/mL	 carbenicillin)	 and	 cultured	 (37oC,	 250rpm)	 until	 Absorbance	 =	 0.5,	 and	 further	






cultured	 overnight	 (30oC,	 250rpm).	 ALDH2-His	 or	 ALDH2*2-His	 expression	 was	 assessed,	
against	 non-induction,	 using	 gel	 electrophoresis	 as	 before.	 Cultures	 were	 centrifuged	
(5000g,	30mins,	4oC)	and	resuspended	in	HEPES	buffer.	Suspension	were	homogenised	and	













containing	 His-tagged	 ALDH,	 was	 run	 over	 charged	 HiTrap	 IMAC	 FF	 1mL	 column	 on	
ÄKTApurifier™	UPC	100.	Column	washed	with	20mL	HEPES	buffer	 and	His-tagged	protein	
was	eluted	over	a	gradient	of	1M	NaCl	HEPES	buffer	(0%-100%	over	30mL	buffer).	Fractions	
collected	 (500μL)	 were	 assessed	 for	 ALDH	 expression	 by	 gel	 chromatography.	 Fractions	
with	 high	 ALDH	 expression	 were	 pooled	 and	 concentrated	 to	 <5mL	 using	 Vivaspin	 20	
concentrator	spin	column	(4000g,	10+mins,	4oC)	
	
HiLoad™	 16/600	 Superdex™	 200	 pg	 size	 exclusion	 column	 was	 equilibrated	 on	
ÄKTApurifier™	 UPC	 100	 with	 HEPES	 buffer	 (180mL).	 Pooled	 ALDH-His	 fractions	 were	
injected	onto	 the	 size	 exclusion	 column	and	eluted	with	HEPES	Buffer	 (180mL).	 Fractions	
collected	 (1mL)	 were	 assessed	 for	 ALDH	 expression	 by	 gel	 chromatography	 and	 purified	
ALDH	fractions	pooled.		
	
ALDH	 was	 equilibrated	 into	 phosphate	 buffer	 using	 HiPrep™	 26/10	 Desalting	 column	
equilibrated	 on	 ÄKTApurifier™	 UPC	 100	 with	 phosphate	 buffer	 (50mL).	 Fractions	 pooled	
and	 protein	 concentrated	 using	 VivaSpin20	 centrifugal	 concentrator	 (4000rpm,	 4oC,	











His-tagged	 ALDH2	 and	 ALDH2*2	 were	 characterised	 using	 thermal	 denaturation.	 Serial	
dilutions	of	ALDH2	or	ALDH2*2	(8μM,	4μM,	2μM	…	)	were	mixed	with	SYPRO	orange	(25μL,	





ALDH	 in	 vitro	 activity	 was	 determined	 based	 on	 previous	 method.115	 Purified	 His-tagged	
ALDH2,	ALDH2*2	ALDH1A1	or	ALDH1A3	(5μg)	was	pre-incubated	at	25oC	in	50mM	sodium	
phosphate	buffer	(pH7.4)	and	2.5mM	NAD+	for	10mins.	The	assay	was	initiated	with	2.5mM	
NAD+	 acetaldehyde,	 totalling	 a	 reaction	 volume	 of	 100μL.	 NADH	 turnover	was	measured	
using	 Spectramax	M5	 plate	 reader	 at	 340nm	 (ε	 =	 6.22mM/cm)	 for	 a	 total	 of	 30mins	 to	
determine	 ALDH	 activity.	 The	 enzymatic	 rate	 (V)	 was	 determined	 using	 the	 initial	 linear	
change	of	 absorbance	between	60	 –	 300secs.	 This	was	 repeated	over	 a	 series	 of	 protein	
concentrations	(10μg	–	1.25μg).	
	
Purified	His-tagged	 ALDH	 enzymes	were	 subject	 to	 characterisation	 by	Michaelis-Menten	
kinetics.	 To	 determine	 Km	 values	 for	 NAD+,	 the	 assay	was	 conducted	 as	 before	 against	 a	
serial	dilution	of	NAD+	(10μM,	5μM	…	).	Similarly,	the	same	was	repeated	to	determine	Km	

























The	 in	 vitro	 activity	 assay	 to	 assess	 for	 RC-NFN5	 ALDH2	 activity	 was	 conducted	 using	
commercially	 bought	 ALDH2	 (BioVision)	 rather	 than	 synthesised	 His-tagged	 protein	 as	
before.	ALDH2	(5μg)	was	pre-incubated	at	25oC	in	50mM	sodium	phosphate	buffer	(pH7.4),	
0.4mM	NAD+	 and	1μM	RC-NFN5,	 or	 vehicle	 (1%	DMSO),	 for	 10mins.	Daidzin	 (10μM)	was	
used	as	a	positive	control.	The	assay	was	initiated	by	the	addition	of	0.4mM	acetaldehyde,	
totalling	a	reaction	volume	of	100μL.	NADH	turnover	was	measured	using	NanoDrop™	2000	






ALDH1A3,	 rather	 than	 synthesised	 His-tagged	 protein	 as	 before.	 ALDH1A3	 (5ug)	 was								
pre-incubated	at	25oC	 in	50mM	sodium	phosphate	buffer	 (pH7.4),	0.4mM	NAD+	and	drug	
(1μM	NFN1,	RC-NFN5,	NFN1.1;	 10μM	NAZ)	 or	 vehicle	 (1%	DMSO)	 for	 10mins.	Disulfiram	
(10μM)	when	was	 used	 as	 a	 positive	 control.	 The	 assay	was	 initiated	 by	 the	 addition	 of	
0.4mM	acetaldehyde,	totalling	a	reaction	volume	of	100μL.	NADH	turnover	was	measured	
using	 NanoDrop™	 2000	 UV-Vis	 spectrophotometer	 at	 340nm	 (ε	 =	 6.22mM/cm)	 after	
















The	 cell	 lines	 below	 were	 kindly	 gifted	 from	 colleagues	 within	 the	 Edinburgh	 Cancer	
Research	UK	Centre,	 IGMM	(University	of	Edinburgh,	UK).	A375	 is	a	malignant	melanoma	




Cell	 lines	 in	 the	melanoma	 cell	 panel	 kindly	 provided	 by	Dr	Marco	 Ranzani	 and	Dr	David	
Adams	(Wellcome	Trust	Sanger	Institute,	Cambridge,	UK).	 Information	for	cell	growth,	cell	






Cell	 cultures	 were	 split	 at	 60%-80%	 confluence.	 Adhered	 cells	 were	 washed	 with															
PBS	(T25	–	5mL;	T75-	10mL)	and	trypsonised	(Trypsin:	T25	–	500µL;	T75	-	1mL,	5mins,	37oC).	
Trypsin	was	 inactivated	with	DMEM	growth	media	 (9mL)	and	centrifuged	 (1000g,	5mins).	
Cell	 pellets	 were	 resuspended	 in	 DMEM	 growth	 media,	 seeded	 at	 dilution	 factor	 1:10,	
unless	 otherwise	 stated,	 in	 same	 media	 (T25	 –	 6mL;	 T75	 -	 15mL)	 and	 incubated	 until							






















were	 seeded	 (A375,	 A2780	 and	 HCT116	 on	 a	 96-well	 plate	 under	 a	 serial	 cell	 density	
dilution	(10,000cell/well,	5,000cell/well	…	625cells/well)	 in	DMEM	growth	media,	totalling	
100µL	per	well.	Cells	were	grown	for	7days,	and	cell	growth	was	assessed	by	the	addition	





Cells	were	 seeded	on	 a	 96-well	 plate	 and	 incubated	 48hrs	 prior	 to	 treatment.	 A375	 cells	
were	 seeded	 at	 1000cells/well,	 A2780	 cells	 were	 seeded	 at	 1000cells/well,	 HCT116	 cells	
were	seeded	at	1000cells/well.141	Cells	were	treated	at	48hrs	with	a	0.1%	logarithmic	drug	
dose	(10µM,	3µM	…	1nM,	vehicle	only)	in	DMSO	and	incubated	for	96hrs.	Cell	viability	was	
assessed	by	 the	addition	10µL	PrestoBlue™	and	 incubated	 for	1hr.	 Fluorescence	emission	






















of	 1	 x	 105	 cells/mL.	 Cells	 were	 put	 through	 the	 Aldefluor™	 assay,	 followed	 according	
manufacturer	 instructions.	 Cell	 suspensions	 were	 washed	 with	 PBS	 (2x	 2mL)	 and	
resuspended	 in	 Aldefluor	 Buffer	 (1mL).	 Cell	 suspensions	were	 incubated	with	 Aldefluor™	







24hrs.	The	subsequent	cultures	were	 treated	with	drug	 (1µM	NFN1,	NFN1.1,	 RC-NFN5	or	
10µM	NAZ,	NFX)	against	vehicle	(1%	DMSO)	and	incubated	a	further	24hrs.	Cells	were	put	
through	 the	Aldefluor™	assay,	 followed	according	manufacturer	 instructions.	Cell	 cultures	
were	trypsonised	(500µL),	washed	with	PBS	(2x	2mL)	and	resuspended	in	Aldefluor	Buffer	
(1mL).	 Cell	 suspensions	 were	 incubated	 with	 Aldefluor™	 Reagent	 (5µL/mL)	 for	 45mins.	
DEAB	(10µL/mL)	was	used	as	a	negative	control.	Fluorescence	analysed	on	the	BD	LSR	II™	or	





A375	melanoma	 cells	were	 seeded	 on	 a	 6-well	 plate	 at	 5	 x	 104	 cells/well	 and	 incubated.	
2hrs,	24hrs,	48hrs,	72hrs	and	96hrs	prior	to	Aldefluor™	analysis,	cell	cultures	were	treated	
with	 NFN1	 (1µM)	 or	 vehicle	 (1%	 DMSO)	 and	 incubated.	 Cells	 were	 put	 through	 the	






trypsonised	 (500µL),	 washed	 with	 PBS	 (2x	 2mL)	 and	 resuspended	 in	 Aldefluor™	 Buffer	
















(1%	DMSO)	 and	 incubated	 a	 further	 24hrs.	 Cells	were	 put	 through	 the	Aldefluor™	 assay,	
followed	 according	 manufacturer	 instructions.	 Cell	 cultures	 were	 trypsonised	 (500μL),	
washed	 with	 PBS	 (2x	 2mL)	 and	 resuspended	 in	 Aldefluor	 Buffer	 (1mL).	 Cell	 suspensions	
were	incubated	with	Aldefluor™	Reagent	(5μL/mL)	for	45mins.	DEAB	(10μL/mL)	was	used	as	
a	negative	control.	Cell	suspensions	(500µL)	were	placed	on	a	glass	slide	and	imaged	using	























The	 subsequent	 cultures	 were	 treated	 with	 5pmol	 siRNA	 (ALDH1A1	 (QIAGEN),	 ALDH1A3	
(LifeTechnologies)	 or	 ALDH2	 (LifeTechnologies)	 vs	 scrambled	 control	 (Sigma))	 in															
Opti-MEM™	media	with	Lipofectamine	RNAiMAX	(1.5µL/well)	and	incubated	for	96hrs.	Cell	
growth	was	monitored	using	an	 IncuCyte	ZOOM®	(10x	magnification,	4	photos/well	every	




repeated	 as	 previous	 however,	 cultures	 were	 treated	 with	 3µM	 NFN1	 or	 vehicle	 (1%	
DMSO),	 24hrs	 after	 siRNA	 transfection	 and	 incubated	 for	 a	 further	 72hrs.	 Apoptosis	was	






ALDH	 activity	 of	 siRNA	 treated	 A375	melanoma	 cells	 was	 analysed	 using	 Aldefluor™	 kit.	
A375	cells	were	seeded	on	a	6-well	plate	at	5	x	104	cells/well	and	incubated	for	24hrs.	The	
subsequent	 cultures	were	 treated	with	 30pmol	 siRNA	 (ALDH1A3	 vs	 scrambled	 control)	 in	
OptiMEM	media	 with	 Lipofectamine	 RNAiMAX	 (9µL/well)	 and	 incubated	 for	 96hrs.	 Cells	
were	put	through	the	Aldefluor™	assay,	followed	according	manufacturer	instructions.	Cell	
cultures	were	trypsinised	(500μL),	washed	with	PBS	(2x	2mL)	and	resuspended	in	Aldefluor	
Buffer	 (1mL).	 Cell	 suspensions	 were	 incubated	 with	 Aldefluor™	 Reagent	 (5μL/mL)	 for	












Lipofectamine	 RNAiMAX	 (9µL/well)	 and	 incubated	 for	 24hrs.	 Cultures	 were	 treated	 with	
1mM	NFN1	or	vehicle	(1%	DMSO)	and	incubated	for	a	further	72hrs.	Consequent	cultures	
were	 trypsonised	 centrifuged	 (1000g,	 5mins)	 and	 washed	 2x	 with	 PBS.	 Resuspended	














added	 and	 resultant	 culture	 placed	 in	 shaking	 incubator	 (37oC,	 1hr,	 250rpm).	 	 Cultured	
suspensions	 (15μL)	were	 streaked	onto	 ampicillin	 lased	 agar	plates.	 Plates	 and	 incubated	
(37oC)	overnight.	From	the	resultant	plate	cultures,	single	colonies	were	picked	to	inoculate	
LB	Broth	 (10mL	with	1μL/mL	Ampicillin)	and	 incubated	overnight	 (37oC,	250rpm).	The	cell	
cultures	 were	 centrifuged	 (4000g,	 4oC,	 15mins)	 and	 cDNA	 extracted	 from	 pellet	 using	














was	 added	 to	 PCR	Master	Mix	 (49µL)	 and	 PCR	 performed	 on	G-Storm	GS2	 Thermocycler	
PCR	 system.	 PCR	 conditions	 as	 table	 below.	 cDNA	 purity	 was	 analysed	 using	 gel	
electrophoresis.	 PCR	 samples	 (1µL)	 were	 combined	 with	 sample	 buffer	 (5µL)	 and	 gel	

















subsequent	 cultures	were	 treated	with	0.1µg	 cDNA	 (ALDH1A3/pCMV6-XL4	 vs	pCMV6-XL4	
empty	 vector	 control)	 in	 Opti-MEM™	 media	 with	 Lipofectamine	 3000	 (0.3µL/well)	 and	
P3000™	Reagent	(0.2µL/well),	and	incubated	for	72hrs.	IncuCyte™	NucLight™	Red	BacMam	
3.0	 Reagent	 was	 also	 added	 to	 detect	 cellular	 proliferation.	 Cell	 growth	 was	 monitored	
using	 an	 IncuCyte	 ZOOM®	 (10x	 magnification,	 4	 photos/well	 every	 30-60mins).	 Cellular	
proliferation	 was	 analysed	 using	 IncuCyte	 ZOOM®	 in-built	 artificial	 intelligence	 software.	



















subsequent	 cultures	were	 treated	with	2.5µg	 cDNA	 (ALDH1A3/pCMV6-XL4	 vs	pCMV6-XL4	
empty	 vector	 control)	 in	 OptiMEM	 media	 with	 Lipofectamine	 3000	 (7.5µL/well)	 and	






ALDH	 activity	 of	 transient	 ALDH1A3	 overexpressing	 A375	 melanoma	 cells	 was	 analysed	
using	 Aldefluor	 kit.	 A375	 cells	 were	 seeded	 on	 a	 6-well	 plate	 at	 5	 x	 104	 cells/well	 and	
incubated	 for	 24hrs.	 The	 subsequent	 cultures	 were	 treated	 with	 2.5µg	 cDNA	
(ALDH1A3/pCMV6-XL4	 vs	 pCMV6-XL4	 empty	 vector	 control)	 in	 OptiMEM	 media	 with	
Lipofectamine	3000	(7.5µL/well)	and	P3000™	Reagent	(5µL/well),	and	incubated	for	48hrs.	
Cells	were	put	through	the	Aldefluor™	assay,	followed	according	manufacturer	instructions.	
Cell	 cultures	 were	 trypsonised	 (500μL),	 washed	 with	 PBS	 (2x	 2mL)	 and	 resuspended	 in	
Aldefluor™	 Buffer	 (1mL).	 Cell	 suspensions	 were	 incubated	 with	 Aldefluor™	 Reagent	








Cell	 cultures	 on	 6-well	 plates	 were	 washed	 with	 cold	 PBS	 (2x	 2mL)	 and	 lysed	 with	 lysis	
buffer	 (100μL).	 Cell	 cultured	 were	 scraped	 and	 incubated	 on	 ice	 for	 20mins	 prior	 to	
centrifuging	 (10mins,	 4oC,	 13,000g).	 Protein	 concentrations	 were	 analysed	 using	








in	 running	 buffer.	 The	 resultant	 gel	 was	 placed	 in	 a	 transfer	 dock	 with	 nitrocullulose	
blotting	membrane	 and	 transferred	 (400mA,	 1hr)	 in	 transfer	 buffer.	 The	membrane	was	
blocked	 in	 5%	milk	 in	 PBS/T	 solution	 (1hr)	 and	 treated	 with	 primary	 antibody	 overnight	
(ALDH1A1	1:10,000;	ALDH1A3	1:10,000;	ALDH2	1:2000;	GAPDH	1:10,000	in	5%	milk/PBS/T	
solution,	4oC).	Membrane	washed	(3x	PBS/T,	5mins	each)	and	LI-COR	fluorescent	secondary	
antibodies	 added	 (1:10,000	 in	 5%	 milk/PBS/T	 solution,	 1hr).	 Membrane	 washed	 again								



















treated	 with	 drug	 (1µM	 NFN1,	 3µM	 RC-NFN-WP1,	 10µM	 NAZ)	 vs	 vehicle	 (1%	 DMSO)	
control,	for	48hrs.	Drug	was	washed	out	with	fresh	E3	media	(1mL),	zebrafish	decoreonated	
and	grown	 for	 72hrs.	At	 5dpf,	 zebrafish	embryos	were	 culled	with	MS222	 (1:10,000)	 and	
imaged	 using	 Nikon	 COOLPIX	 MxA	 5400	 digital	 camera	 under	 the	 Nikon	 SMZ1500	
Stereomicroscope.	 Melanocyte	 cell	 number	 on	 the	 head	 and	 tail	 of	 each	 embryo	 was	











All	 experiments	 were	 conducted	 under	 an	 inert	 N2	 atmosphere	 throughout	 using	
commercially	 available	 anhydrous	 solvents.	 Unless	 stated	 otherwise,	 all	 reagents	 were	
purchased	from	Sigma-Aldrich,	UK	or	Fisher	Scientific,	UK	and	used	without	purification.		
	
1H-nuclear	magnetic	 resonance	 (NMR)	 spectra	 of	 all	 synthesised	 compounds	 dissolved	 in	
deuterated	DMSO	were	obtained	on	a	500MHz	Bruker	Avance	 III	 spectrometer.	Chemical	
shifts	 are	 reported	 in	 parts	 per	 million	 (ppm)	 and	 multiplicity	 denoted	 as:	 	 s	 =	 singlet,												
d	=	doublet,	t	=	triplet,	q=	quartet,	m	=	multiplet.	
	






Synthesis	 of	 RC-NFN-WP1	 was	 produced	 following	 Scheme	 1,	 originally	 designed	 to	
produce	RC-NFN5.	N,N'-diisopropylcarbodiimide	(DIC	–	554mg,	4.4mmol,	2.2eq)	was	added	
to	 5-nitro-2-furoic	 acid	 (690mg,	 4.4mmol,	 2.2eq)	 and	 1,4-phenylene	 diamide	 (216mg,	
2mmol,	 1eq)	 in	 DCM	 (10mL)	 under	 reflux	 (12hrs,	 60oC).	 DCM	was	 used	 as	 it	 has	 a	 low-
dielectric	 constant,	 and	 therefore	 should	 promote	 amide	 formation.	 The	 reaction	 was	
confirmed	using	thin	 layer	chromatography	(TLC).	Reaction	solution	was	washed	(3x	dH2O	
brine),	 dried	 with	 MgSO4	 and	 filtered.	 Side-product,	 RC-NFN-WP1	 was	 purified	 by	 flash	








+ve)	 -	Mass	 found:	 [M+Na+]	=	306.12Da.	No	RC-NFN5,	or	 indeed	any	5-NFN	 including	 the	
benzene	linker,	was	synthesised	through	this	mechanism.		
	
Scheme	 2.1:	 Synthesis	 of	 RC-NFN-WP1.	 Single	 step	 reaction	 using	 carbodiimide,																																		
N,N'-diisopropylcarbodiimide	(DIC)	to	promote	peptide	bond	formation	between	diamide	and	furoic	
acid.	 Dual	 peptide	 bond	 formation	 to	 create	 bis-5-NFN	 expected	 end	 product.	 The	 reaction	 was	
carried	out	in	DCM,	at	60oC	over	12hrs.	RC-NFN-WP1	was	created	as	an	unavoidable	side	product	to	
















Synthesis	 of	 RC-NFN5	 was	 produced	 following	 Scheme	 2.	 i:	 The	 reaction	 between																			
5-nitro-2-furoic	acid	(690mg,	4.4mmol)	in	thionyl	chloride	(5mL,	xs)	was	initiated	with	DMF	
(0.1mL)	added	dropwise	and	refluxed	(75oC,	24hrs).	The	reaction	was	confirmed	using	TLC.	
Thionyl	 chloride	 was	 removed	 via	 rotary	 evaporation	 and	 washed	 with	 diethyl	 ether											
(2x	10mL),	forming	an	oil.	ii:	Trethylamine	(0.5mL,	xs)	was	added	dropwise	to	the	reaction	
oil	and	1,4-phenylene	diamide	(216mg,	2mmol)	in	DCM	(10mL)	and	stirred	(48hrs,	rt).	The	
reaction	 was	 confirmed	 using	 TLC.	 Reaction	 solution	 was	 washed	 (3x	 dH2O	 brine),	 dried	
with	 MgSO4	 and	 filtered.	 Product,	 RC-NFN5	 was	 purified	 by	 flash	 chromatography	








The	same	synthetic	mechanism	 for	RC-NFN5	 (Scheme	2)	was	 followed	using	2-furoic	acid	





















Scheme	 2.2:	 Synthesis	of	RC-NFN5	 –	bis-nitrofuran	molecule	with	 a	1,4-phenylene	diamide	bridge	







All	 experiments	 were	 replicated	 at	 least	 in	 triplicate,	 unless	 stated	 otherwise.	 All	 graphs	
were	 created	using	GraphPad	Prism	6.0.	 All	 cell	 viability	 EC50	 data	was	 extrapolated	by	 a	
fitted	sigmoidal	variable	slope	curve,	where	the	data	was	normalized	to	the	untreated	cells	
(100%)	 and	 no	 cell	 (0%).	 All	 enzyme	 kinetic	 data	was	 extrapolated	 by	 a	 fitted	Michaelis-
Menten	kinetics,	drug	IC50	values	were	extrapolated	by	fitted	Log(inhibitor)	curves	against	
DMSO.	All	statistics	were	extrapolated	computationally	by	GraphPad	Prism	6.0	also.	Unless	
















xylene.	 Immunostaining	 against	 ALDH1	 was	 achieved	 using	 the	 Abcam	 anti-ALDH1A1	
antibody	 (ab23375).	 Slides	 were	 bleached	 from	 pigment	 with	 3%	 H2O2	 (15mins)	 and	
subjected	to	antigen	retrieval	in	pressure	cooker	and	microwave	(1.8mM	citric	acid,	8.2mM	
sodium	citrate,	distilled	water,	pH	6	–	7mins).	 Sections	were	 incubating	 in	3%	hydrogen	
peroxidase	 (10min)	 and	 washed	 with	 TBS.	 Sections	 were	 then	 treated	 with	 serum-free	
protein	 blocking	 solution	 (DAKO	 –	 30mins)	 and	washed.	 Sections	were	 further	 incubated	
with	 primary	 anti-ALDH1A1	 antibody	 diluted	 in	 DAKO	 (1:1000,	 overnight,	 4oC).	 Sections	
washed	with	TBS	and	 treated	with	HRP	anti-rabbit	 secondary	antibody	 (30mins).	Washed	
sections	were	then	treated	with	1:50	DAB	chromogen:DAB	substrate	(30mins)	and	counter	








on	 Autodock	 4.2.3	 and	 Autodock	 Viva.	 Water	 molecules	 and	 other	 hetero	 atoms	 were	
removed	 from	 the	 structures	 of	 ALDH1A1	 (PDB	 4XL4)145	 and	 the	 program	 PDB2PQR	 1.8	
used	 to	 assigned	 position-optimised	 hydrogen	 atoms,146	 utilising	 the	 additional	 PropKa	
algorithm	 with	 a	 pH	 of	 7.4	 to	 predict	 protonation	 states.147	 The	 MGLTools	 1.5.4	 utility	
prepare_receptor4.py	 was	 used	 to	 assign	 Gasteiger	 charges	 to	 atoms.	 Hydrogen	 atoms	
were	assigned	to	compound	structures	using	OpenBabel	2.3.2,148	utilising	the	-p	option	to	





















Thomas	D.	Hurley.	 ALDH	 samples	were	 set	 up	 using	 10µM	ALDH	 isoenzyme	with	 100µM	
drug	(NFN1,	NFX,	NAZ,	NFN1.1	or	vehicle	–	2%	final	DMSO	concentration)	±NAD+	(500µM)	
and	incubated	(1hr,	rt)	in	HEPES	buffer	(10mM,	pH	7.5).	Samples	(2µL)	were	injected	using	
an	 Agilent	 1200SL	 HPLC	 with	 a	 low	 rate	 of	 0.3	 mL/min	 consisting	 of	 70%	 H2O	 and	 30%	








Purified	 ALDH2-His	 and	 ALDH2*2-His	 from	 earlier	 enzymatic	 experiments	 were	 used	
throughout.	 ALDH	 samples	 were	 set	 up	 using	 5µg	 ALDH	 isoenzyme	 with	 100µM	 drug	
(NFN1,	 NAZ,	 NFN1.1	 or	 vehicle	 –	 1%	 final	 DMSO	 concentration)	 ±NAD+	 (500µM)	 and	
incubated	 (1hr,	 rt)	 in	 HEPES	 buffer.	 Samples	 were	 trypsin	 digested,	 cysteine	 alkylated	
(iodoacetamide)	and	subjected	 to	 reverse	phase	HPLC.	Fragmented	protein	samples	were	
injected	 onto	 Q	 Exactive™	 Plus	 Hybrid	 Quadrupole-Orbitrap™	 mass	 spectrometer	 the	













































and	 5-NFNs	 have	 been	 demonstrated	 to	 be	 competitive	 substrates	 for	 human	 ALDH2	 in	
vitro.115	Interestingly,	8%	of	the	human	population	have	a	non-active	ALDH2*2	mutation,10	
and	it	would	be	also	interesting	to	explore	how	5-NFNs	may	interact	with	this	mutant	ALDH	
enzyme	 in	 vitro.	 Many	 cancers,	 including	 melanoma,79,151	 have	 a	 subpopulation	 of					
tumour-initiating,	 chemo-resistant	 cells	 with	 characteristically	 high	 ALDH	 expression.	
ALDH1A1	 and	 ALDH1A3	 are	 highly	 expressed	 in	 melanoma	 (specifically	 ALDH1A3	 in	 the	
A375	 melanoma	 cell	 line),79	 where	 their	 role	 is	 associated	 with	 cancer	 stem	 cell-like	
behaviour	 and	are	 considered	 functional	 CSC	markers.	Recently,	ALDH1	has	been	offered	
up	 as	 a	 favourable	 target	 in	 the	 treatment	 of	many	 cancers,	 including	melanoma.35,45,118	
Inhibition	 of	 ALDH	 enzymes	 has	 been	 reported	 as	 a	 new	 approach	 in	 treating	 and										
chemo-sensitising	cancers,43,55,56,116	and	development	of	novel	ALDH	inhibitors	is	beginning	
to	cultivate	interest.60,117,152	Development	of	compounds	that	can	both	inhibit	ALDH	as	well	
as	 drive	 cytotoxicity,	 will	 therefore	 offer	 a	 novel	 approach	 in	 exploiting	 high	 ALDH	
expression	in	melanoma.	I	hypothesize	that	5-NFNs	can	be	bio-activated	by	ALDH	enzymes,	
where	 5-NFNs	 are	 competitive	 substrates	 for	 ALDH1	 in	 vitro.	 Through	 in	 vitro	 enzymatic	
activity	 assays	 of	 ALDH1	 and	 ALDH2	 enzymes	 coupled	with	 utility	 of	 the	 flow	 cytometry	




Here	 I	demonstrate	that	5-NFNs	are	substrates	 for	human	ALDH2	 in	vitro,	which	 is	 lost	 in	
the	human	ALDH2*2	mutation.	I	also	demonstrate	that	5-NFNs	are	competitive	substrates	
for	 the	 A375	 functional	 CSC	marker,	 ALDH1A3,	 highly	 expressed	 in	 this	 cell	 line.79	 I	 also	
describe	 5-NFNs	 as	 competitive	 substrates	 for	 ALDH	 activity	 in	 A375	 cells,	 where	 5-NFN	
treatment	 also	 gave	 rise	 to	 a	 prolonged	 reduction	 in	 ALDH	 activity	 assessed	 through	












As	 5-NFNs	 are	 competitive	 substrates	 for	 Aldh2b	 in	 zebrafish,115	 and	 are	 toxic	 in	 human	
cancer	cells,115,132,153	I	hypothesise	that	human	ALDH	enzymes	are	bio-activating	5-NFNs,	in	
these	cancer	cell	 lines,	to	drive	toxicity.	ALDH2	was	the	obvious	candidate	to	explore	first,	
to	 further	characterise	 the	effect	of	NFN1	on	human	ALDH2,	and	whether	 the	non-active	
ALDH2*2	mutant,	present	in	8%	of	the	human	population,10	can	still	bio-activate	5-NFNs	in	
vitro	also.	ALDH1	enzymes	are	highly	expressed	 in	melanoma,79	and	other	cancers,2,14,44,80	






























Figure	3.1:	Gels	 for	His-tagged	ALDH2	 (left)	and	ALDH2*2	 (right)	expression	 (55kDa,	 red	box)	 trials	
stained	 with	 InstaBlue.	 Expression	 trials	 were	 performed	 at	 30oC	 and	 37oC	 in	 E.clo	 strains:	 BL21,	
BL21*	and	C43.	Expression	of	ALDH2-His	was	much	stronger	in	BL21*	at	30oC	(blue	box).	Expression	




Growth	 of	 induced	 E.coli	 was	 consequently	 scaled	 up	 to	 produce	 higher	 quantities	 of	
protein.	 Bacterial	 cells	 from	 these	 large	 scale	 cultures	were	 lysed,	 protein	 extracted	 and	
assessed	for	ALDH-His	expression.	Purification	of	ALDH-His	proteins	occurred	over	2	steps,	
firstly	through	His-trapping	with	the	HiTrap	IMAC	FF	1mL	column	and	then	gel	filtration	size	
exclusion	 column,	 using	 a	 Superdex	 200	 column.	 The	 His-tagged	 protein	 can	 be	 purified	
using	 a	His-trap,	 by	 running	 sample	over	 the	 column	and	eluting	over	 a	 gradient	 of	NaCl	
buffer	 to	 cleave	 the	 His-Tag	 interaction	 in	 the	 column.	 This	 provided	 a	 quick	method	 to	
effectively	remove	the	majority	of	the	E.coli	proteins	against	an	increasing	salt	gradient	to	
allow	 distinction	 between	 non-specific	 binding	 proteins	 and	 his-tagged	 ALDH	 (Figure	
3.2A,B).	As	ALDH2	exists	as	a	tetramer	(212kDa),9,10	the	his-tagged	protein	can	be	purified	






























Figure	 3.2:	 Purification	of	ALDH2-His	by	His-trap	and	 size	exclusion	 columns.	A)	UV	 trace	of	 crude	
ALDH2-His	protein	samples	after	 loading	onto	HiTrap	column	from	ÄKTAPurifier	100.	1M	imidazole	
buffer	was	used	to	elute	over	30-step	gradient	 (green	 line).	ALDH2-His	 likely	 found	 is	 later	protein	
peak	as	His-tag	is	eluted	off	the	column	(red	box).	B)	Gel	to	check	purity	of	His-trap	elution	fractions.	
ALDH2-His	expression	is	much	higher	and	cleaner	in	later	wells	corresponding	with	red	box	fractions.	
C)	 UV	 trace	 of	 crude	 ALDH2-His	 protein	 samples	 after	 loading	 onto	 Superdex	 200	 size	 exclusion	
column	from	ÄKTAPurifier	100.	ALDH2-His	 likely	 found	 is	 later	protein	peak	as	His-tag	 is	eluted	off	






His-tagged	 ALDH2	 and	 ALDH2*2	 were	 assessed	 for	 thermal	 denaturation	 using	 SYPRO	
orange	over	 increasing	temperature	(1oC	 increments,	20oC-90oC)	and	analysed	using	 iQ™5	
Multicolor	 Real-Time	 iCycler.	 ALDH2-His	 had	 a	 denaturation	 temperature	 of	 51.57oC	
(Figures	3.3A)	and	ALDH2*2	has	a	denaturation	temperature	of	54.89oC	(Figure	3.3B).	The	
increased	 denaturation	 temperature	 for	 ALDH2*2-His	 suggests	 that	 the	 mutant																										
A	 	 	 	 	 	 C	

























ALDH2*2-His	 tetramer	 is	 bound	more	 strongly	 than	 the	 native	 ALDH2-His	 tetramer.	 This	
may	be	indicative	of	the	structural	alteration	inferred	by	the	single	amino	acid	substitution	
of	ALDH2*2,	where	disorder	of	 the	alpha-helix	 important	 in	dimer	 formation,	will	 lead	 to	
much	tighter	binding,	and	as	such,	lose	the	plasticity	needed	for	native	ALDH	activity.	
		









To	determine	 the	enzymatic	activity	of	ALDH2-His,	 an	 in	 vitro	 assay	was	 set	up	 similar	 as	
previously	 described.115	 ALDH2-His	 and	 ALDH2*2-His	 were	 pre-incubated	 with	 NAD+	 and	
enzymatic	 activity	 initiated	 with	 acetaldehyde	 addition.	 ALDH	 activity	 was	 monitored	
through	 NADH	 production	 at	 λ	 =	 340nm	 (ε	 =	 6220M-1cm-1).	 ALDH2*2-His	 activity	 was								
200-fold	 lower	 than	 ALDH2-His	 activity	 (Figure	 3.4A),	 reflecting	 previous	 reports.154					
ALDH2-His	 was	 further	 subjected	 to	 Michaelis-Menten	 kinetic	 studies	 against	 NAD+	 and	
acetaldehyde	(AcAld),	the	natural	substrates	for	ALDH2.	Systematic	concentrations	of	NAD+	
were	measured	against	constant	acetaldehyde	concentration	to	determine	KmNAD+,	and	the	
reverse	 was	 done	 to	 determine	 KmAcAld.	 ALDH2-His	 kinetics155	 were	 determined															
































To	 determine	 the	 potency	 of	 5-NFNs	 in	 vitro,	 His-tagged	 ALDH2	was	 subjected	 to	 the	 in	
vitro	 activity	 assay	 as	 described	 above,	 where	 ALDH2-His	 was	 pre-incubated	 with	 NAD+	
against	 a	 varying	 doses	 of	NFN1	 prior	 to	 acetaldehyde	 initiation.	 Present	 controls	 were	
vehicle	(1%	DMSO),	no-nitro	control	NFN1.1	and	ALDH2	inhibitor,	daidzin.	DEAB	could	not	
be	used	as	a	control,	as	emission	of	DEAB	at	360nm	bleeds	into	the	band	at	340nm	at	which	
NADH	production	 is	monitored.110	NFN1	 exhibited	potent	 reduction	 in	ALDH2-His	 activity	
(Figure	 3.5A);	 IC50	 =	 69.3nM,	 where	 ALDH2-His	 activity	 was	 significantly	 reduced	 at	
concentrations	 >100nM	 (P	 <	 0.0001).	 As	 expected,	 the	 ALDH2	 inhibitor,	 daidzin,	 had	
significant	 reduction	 of	 ALDH2-His	 activity	 in	 vitro	 (P	 <	 0.0001)	 and	 the	 no-nitro	 control,	
NFN1.1,	 showed	no	 reduction	 in	ALDH2-His	activity,	 further	evidence	 for	 the	need	of	 the	
NO2	moiety	for	5-NFN	activity	towards	ALDH	enzymes.	
	
The	ALDH2*2	mutation	 is	present	 in	8%	of	 the	human	population,	primarily	 in	persons	of	
Eastern	Asian	descent.10	As	the	mutant	ALDH2*2-His	still	has	some	 in	vitro	activity,	 it	was	
expected	 that	 5-NFNs	 could	 also	 be	 competitive	 substrates	 for	ALDH2*2-His	 in	 vitro.	 The	
same	experiment	was	set	up	as	described	above,	where	ALDH2*2-His	activity	was	assessed.	
Although	reduction	in	ALDH2*2-His	activity	is	seen	(Figure	3.5B)	with	significant	reduction	
in	 activity	 at	much	 higher	NFN1	 doses	 (P	 =	 0.023,	 IC50	 =	 8.31µM),	 the	 accuracy	 of	 these	
findings	were	limited	to	the	sensitivity	of	the	SpectraMax®	M5	Multimode	Plate	Reader.	As	
ALDH2*2-His	 activity	 is	 200-fold	 less	 than	 ALDH2-His	 and,	 as	 previously	 mentioned,			
ALDH2-His	 activity	 is	 slower	 than	 expected,	 the	 degree	 of	 accuracy	 of	 measuring	 the	
changes	 in	the	rate	of	ALDH2*2-His	upon	NFN1	 treatment	had	a	standard	error	±1.47µM,	
compared	 to	 ALDH2-His	 at	 ±5.2nM.	 Although	 there	 was	 a	 significant	 reduction	 in						
ALDH2*2-His	 activity,	 the	 actual	 interpretation	of	 behaviour	 is	 therefore	 limited.	 It	 is	 still	
expected	 that	 ALDH2*2-His	 activity	 will	 be	 attenuated,	 as	 shown,	 however,	 it	 will	 be	 a	
reduction	in	activity	which	was	otherwise	negligible	to	begin	with.	The	ALDH2*2	mutation	
results	in	ablation	ALDH2	activity	in	vivo,10	and	although	it	exhibited	some	affinity	for	NFN1,	








ALDH1	 is	 the	predominant	marker	 for	CSCs,44	where	ALDH1A3	 is	 the	stem	cell	marker	 for	
A375	 melanoma	 cells.79,151	 If	 5-NFNs	 are	 competitive	 substrates	 for	 ALDH2	 in	 vitro,	 I	
hypothesised	 that	5-NFNs	will	also	be	competitive	substrates	 for	ALDH1	 isoforms.	To	 test	
for	this,	I	set	up	an	ALDH1A3	in	vitro	assay	along	the	same	lines	as	with	ALDH2	and	previous	
work.157	ALDH1A3	was	pre-incubated	with	NAD+	and	NFN1,	prior	to	acetaldehyde	initiation.	
Activity	was	monitored	 against	 vehicle	 (1%	DMSO)	 control,	 no-nitro	 control,	NFN1.1	 and	
ALDH1	 inhibitor,	 disulfiram.	 NFN1	 treatment	 significantly	 reduced	 ALDH1A3	 activity												
(P	=	0.03,	Figure	3.5C)	where	NADH	turnover	was	reduced	by	78%.	As	expected,	the	ALDH1	
inhibitor,	disulfiram,	had	significant	reduction	of	ALDH1	activity	 in	vitro	 (P	=	0.017)	and	 in	





a	 similar	 set	 up	 as	 for	 ALDH2-His.	 His-tagged	 ALDH1A1	 and	 1A3	 had	 been	 produced,	
through	 plasmids	 kindly	 created	 by	 a	 senior	 research	 assistant	 in	 our	 group,	 Dr	 Zhiqiang	























Figure	 3.5:	NFN1	 is	 a	 competitive	 inhibitor	 for	ALDH	enzymes.	A)	ALDH2-His	activity	against	NFN1	
(orange)	 treated	over	a	 logarithmic	dose	 range,	against	NFN1.1	 (purple),	DMSO	 (blue)	and	daidzin	
(green).	Enzymatic	rate	determined	using	initial	linear	rate	of	NAD+	to	NADH	turnover	at	λ	=	340nm	
(ε	=	6220M-1cm-1),	upon	acetaldehyde	initiation.	ALDH2-His	activity	significantly	reduced	(P	<	0.0001)	
upon	 NFN1	 treatment	 higher	 than	 100nM.	 NFN1	 IC50	 =	 63.9nM.	 The	 ALDH2	 inhibitor,	 daidzin	
(10µM),	had	significant	reduction	 in	ALDH2-His	activity	 (87%,	P	<	0.0001:	ANOVA)	and	NFN1.1	had	
no	significant	effect	of	ALDH2-His	activity	(n=3).	B)	ALDH2*2-His	activity	NFN1	(orange)	treated	over	
a	 logarithmic	 dose	 range,	 against	NFN1.1	 (purple),	 and	 DMSO	 (blue).	 Enzymatic	 rate	 determined	
using	 initial	 linear	 rate	 of	 NAD+	 to	 NADH	 turnover	 at	 λ	 =	 340nm	 (ε	 =	 6220M-1cm-1),	 upon	
acetaldehyde	 initiation.	 ALDH2*2-His	 activity	 significantly	 reduced	 (P	 <	 0.05:	 ANOVA)	 upon	NFN1	
treatment	 only	 at	 10µM.	NFN1	 IC50	 =	 8.31µM.	NFN1.1	 had	 no	 significant	 effect	 of	 ALDH2*2-His	
activity.	 ALDH2*2-His	 activity	 remained	 200-fold	 less	 active	 than	 ALDH2-His	 (n=2).	C)	 ALDH1A3	 in	
vitro	 enzymatic	 activity	 upon	 NFN1	 (1µM,	 orange),	 NFN1.1	 (10µM,	 purple),	 DMSO	 (blue)	 and	
disulfiram	 (10µM,	 green)	 treatment	 was	 determined	 using	 NADH	 turnover	 at	 λ	 =	 340nm																									
(ε	=	6220M-1cm-1)	after	10mins.	ALDH1A3	activity	represented	at	%DMSO	activity.	ALDH1A3	activity	

























































in	 the	 Aldefluor™	 kit,	 is	 used	 as	 a	 positive	 control,	 preventing	 the	 ALDH-driven	 cellular	
oxidation	of	Aldefluor™,	so	passes	through	the	cell	 leading	to	no	accumulation	and	a	non-	
fluorescing	cell.	 It	has	been	reported	that	Aldefluor™	is	only	active	in	ALDH1	specifically,32	
and	this	 report	 is	also	shared	by	 the	manufacturers	description,	however,	 there	has	been	
some	evidence	that	other	ALDH	enzymes,	such	as	ALDH2,	can	also	have	a	major	impact	on	
Aldefluor™	activity	also,4,32,45	so	the	exact	ALDH	isoforms	contributing	to	Aldefluor™	activity	
in	 the	 cell	 lines	 tested	 is	 largely	 unknown.	 Cells	were	 incubated	with	Aldefluor™	 reagent	
and	subjected	to	cell	counting	by	flow	cytometry.	Alive	cells	were	gated,	and	assessed	for	
Aldefluor™	 activity	 (represented	 by	 FITC).	 DEAB	 was	 used	 a	 positive	 control,	 where	
Aldefluor™	activity	is	downshifted	upon	DEAB	treatment.	The	overall	Aldefluor™	activity	is	
represented	 as	 a	 histogram,	 where	 the	 mean	 fluorescence	 is	 taken	 throughout													
(Figures	 3.6B-E).	 FITC	parameters	were	used	 (and	 consequently	 axis-labelled)	 as	 they	 are	





If	 5-NFNs	 are	 competitive	 substrates	 for	 ALDH	 in	 vitro,	 it	 was	 expected	 that	 a	 shift	 in	




approximately	 80%	 reduced	 in	 the	NFN1	 treated	 cells,	 compared	 to	 vehicle	 (1%	 DMSO)	
control	(Figure	3.6F).	After	the	reagents	are	left	on	for	24hrs,	DEAB	treated	cells	began	to	
recover	their	ALDH	activity,	as	DEAB	is	a	reversible	inhibitor	of	ALDH,110	however	this	is	not	







after	 2hrs.	 This	 unexpected	 result	 gave	 some	 clue	 into	 the	mechanism	 in	 which	 5-NFNs	
interact	 with	 ALDH,	 and	 there	 may	 be	 some	 form	 of	 potent	 inhibition,	 irreversible	 or	
otherwise,	of	the	ALDH	enzymes	coupled	with	the	bio-activation	of	5-NFNs.	This	correlates	
with	previous	work,	where	other	synthetic	irreversible	ALDH1	&	3	inhibitors	also	sustained	








5-NFN	 treatment.	 A375	 melanoma	 cells	 were	 treated	 with	 NFN1	 at	 systematic	 time	




likely	 due	 to	5-NFN	driven	 cell	 death	 (Figure	 3.7B,C).	 This	 is	 a	 good	 indication	 that	ALDH	
activity	 is	 being	 directly	 inhibited	 by	 5-NFN	 treatment	 and	 its	 lasting	 affect	 (upwards	 of	
48hrs)	hinting	as	an	irreversible	mechanism	in	doing	so.	A	possible	explanation	for	why	the	
ALDH	activity	recovers	after	72hrs	may	be	due	to	the	cells	replenishing	their	ALDH	activity	
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Figure	 3.6:	NFN1	 treatment	 leads	 to	a	prolonged	 reduction	 in	A375	melanoma	Aldefluor™	activity	
(n=3).	 Aldefluor™	 activity	 (FITC)	 represented	 as	 histogram	 counts	 of	 A375	melanoma	 cells	 treated	
with	NFN1	and	NFN1.1	(1µM	and	10µM	respectively).	DMSO	and	DEAB	treated	A375	cells	after	2hrs	
assumed	100%	and	0%	Aldefluor™	activity	respectively.	A)	Mechanism	of	Aldefluor™	activity	in	cells.	
Fluorescent	 BAAA	Aldefluor™	 reagent	 is	 negatively	 charged	 by	 cellular	 ALDH	 enzymes,	 is	 retained	









































BAAA	Aldefluor™	 reagent	 activation,	 and	will	 pass	 through	 the	 cell,	 resulting	 in	 a	 non-fluorescent	
cell.	 Figure	 adapted	 from	 Luo,	 Y.	 et	 al.	 (2012).79	B)	 Flow	 cytometry	 plot	 of	 A375	melanoma	 cells	
plotted	 as	 forward	 scatter	 (FSC)	 against	 side	 scatter	 (SSC),	 gated	 around	 the	 Alive	 cell	 population	
(88.4%).	C)	Flow	cytometry	plot	of	488/525nm	(FITC)	expression	in	A375	melanoma	cells	against	FSC.	
FITC	parameters	were	used	 (and	consequently	axis-labelled)	as	 they	are	 identical	 to	 those	needed	
for	 Aldefluor™	 activity.	 Thus,	 FITC	 intensity	 correlates	 to	 Aldefluor™	 activity.	 A375	 cells	 have	 high	
expression	 on	 Aldefluor™,	 with	 the	 majority	 cell	 population	 with	 an	 intensity	 >104.	 D)	 Flow	
cytometry	 plot	 of	 FITC	 intensity	 in	 A375	melanoma	 cells	 only	 against	 FSC	 (red)	 and	DEAB	 treated	
A375	 melanoma	 cell	 (green).	 DEAB	 has	 a	 clear	 downshift	 in	 FITC	 intensity.	 E)	 Histogram	
representation	 of	 FITC	 intensity	 count	 of	 A375	 melanoma	 cells	 only	 (red)	 vs	 DEAB	 treated	 A375	
melanoma	 cells	 (green).	 DEAB	 treatment	 noticeably	 downshifts	 A375	 melanoma	 FITC	 intensity.									
F)	 Aldefluor™	 activity	 of	 A375	 cells	 after	 2hrs	NFN1	 (orange)	 treatment.	 DMSO	 (blue)	 vehicle	 and	
DEAB	(green)	negative	controls	treated	for	2hrs	also.	NFN1	reduces	Aldefluor™	activity	in	A375	cells	
by	72.2%	after	2hour	of	treatment	(Mean	intensity:	1.94	x	104	DMSO	vs	5.40	x	103	NFN1).	Ablation	of	
















Figure	 3.7:	 NFN1	 mediated	 inhibition	 of	 Aldefluor™	 activity	 is	 sustained	 up	 to	 48hrs	 post	 NFN1	
treatment	 (1µM,	 n=2).	 A)	 Aldefluor™	 activity	 (FITC)	 of	 A375	 melanoma	 cells	 treated	 with	 NFN1	
(orange)	over	96	hours	compared	to	vehicle	(1%	DMSO,	blue)	control.	NFN1	mediated	reduction	in	
Aldefluor™	 activity	 is	 seen	 at	 both	 24hrs	 and	 48hrs	 post	NFN1	 treatment.	 After	 72hrs	 post	NFN1	
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activity	 peak,	 likely	 due	 debris	 from	NFN1	 mediated	 A375	 cell	 death.	 Full	 recovery	 of	 Aldefluor™	
activity	is	seen	after	96hours,	again	with	debris	peak	from	NFN1	driven	cell	death.	B)	Pseudocolour	
flow	cytometry	plot	of	A375	melanoma	cells,	upon	DMSO	treatment,	plotted	as	forward	scatter	(FSC)	
against	 side	 scatter	 (SSC),	 gated	 around	 the	 Alive	 cell	 population	 (92.5%).	 C)	 Pseudocolour	 flow	
cytometry	plot	of	A375	melanoma	cells,	72hours	post-NFN1	 treatment,	plotted	as	 forward	 scatter	







the	 Aldefluor™	 assay,	 I	 also	 validate	 that	 5-NFNs	 are	 inhibitors	 for	 ALDH	 enzymes	 in	
melanoma	cells.	Further,	 I	 report	 that	5-NFNs	can	also	potently	 inhibit	ALDH	enzymes	 for	
up	 to	 72hrs,	 suggesting	 a	 new	mechanism	 for	 5-NFN-ALDH	 activity	 (Figure	 3.8).	 Finally,	 I	
demonstrate	that	the	human	ALDH2*2	mutation	has	limited	normal	functionality,	to	which,	




































ALDH1A1	 and	 ALDH1A3	 have	 been	 reported	 as	 CSC	 markers	 for	 melanoma,79,151	 where	
ALDH1A3	appears	to	be	the	major	ALDH	enzyme	for	marking	CSCs	 in	the	A375	melanoma	
line.79	 These	 ALDHhigh	 melanoma	 cells	 are	 highly	 tumorigenic67,68	 and	 exhibit	 increased	
resistance	 to	 conventional	 chemo-therapeutics,57	 that	 in	many	 cases,	 will	 lead	 to	 cancer	
relapse,	 usually	more	 aggressive	 and	 chemo-resistant	 than	 the	 original	 tumour.	 As	 such,	
being	able	to	target	these	ALDHhigh	cells	 in	melanoma	could	be	therapeutically	favourable.	
From	 the	 previous	 chapter,	 I	 have	 demonstrated	 that	 5-NFNs	 are	 inhibitors	 of	 ALDH1A3,	
and	following	previous	work	reporting	ALDH	mediated-toxicity	in	zebrafish,115	I	hypothesise	
that	 5-NFNs	 should	 present	 potent	 toxicity	 in	 the	 A375	 melanoma	 cell	 lines.	 If	 ALDH1	
enzymes	 play	 a	 key	 role	 in	 mediating	 5-NFN	 toxicity	 in	 A375	 cells,	 then	 knock-down	 of	
ALDH1	 should	 invoke	 cellular	 resistance	 to	 5-NFNs,	 and	 in	 a	 mirror	 experiment,	
overexpressing	 ALDH1	 enzymes	 should	 also	 hypersensitise	 these	 cells	 to	 5-NFNs.	
Considering	 current	 literature,45,79,80,151	 siRNA	 knock-down	of	ALDH	enzymes	 in	A375	 cells	
should	 be	 able	 to	 provide	 some	 insight	 into	 whether	 ALDH1	 enzymes	 contribute	 to	
Aldefluor™	activity	 in	this	cell	 line,	and	to	what	extent	do	the	levels	of	 individual	 isoforms	
correlate	 with	 Aldefluor™.	 Further,	 it	 would	 be	 interesting	 to	 explore	 how	 all	 19-ALDH	





NFN1	 did	 not	 correlate	 to	 ALDH1A3	 expression,	 I	 hypothesise	 that	 ALDH1A3	 activity	
contributes	 to	 sensitivity	 for	 a	 small	 subpopulation	 of	 cells,	 where	 I	 display	 that	 A375	
melanoma	 cells	 and	 human	 melanoma	 sections	 are	 heterogeneous	 for	 ALDH+	
subpopulations,	 in	 keeping	 with	 literature	 reports79,151	 I	 describe	 a	 functional	 role	 for	
ALDH1A3	 in	 driving	 5-NFN	 mediated	 toxicity	 in	 A375	 melanoma	 cells.	 Knock-down	 of	
ALDH1A3	by	siRNA	renders	A375	cells	resistant	to	NFN1,	and	overexpression	of	the	enzyme	
induces	 in	 A375	 hypersensitivity.	 Further,	 I	 show	 that	 ALDH1A3	 is	 the	 key	 ALDH	 isoform	
responsible	for	Aldefluor™	activity	in	A375	cells,	where	there	is	some	indication	of	a	small	







ALDH-driven	 5-NFN	mediated	 cell	 toxicity,	 especially	 in	my	 findings	 that	 there	was	 not	 a	






High	 ALDH	 expression	 is	 a	 marker	 CSCs	 in	 melanoma,79,151	 and	 other	 cancers.7,14,44	 As												
5-NFNs	are	competitive	substrates	for	Aldh2b	in	zebrafish,115	and	with	Aldefluor™	in	A375	





To	 test	 the	 potential	 for	 5-NFNs	 to	 target	 cancer	 cells,	 the	 cytotoxicity	 of	 four	 5-NFN	
compounds,	identified	through	a	previous	small	molecule	screen,115	were	tested	against	the	
A375	melanoma	cell	 line.	A375	 is	a	malignant	melanoma	cancer	 cell	 line	with	a	BRAFv600E	
mutation	 established	 from	a	 54-year-old	 female.	 A375	 cells	were	 incubated	with	NFN1-4	
(Figure	4.1A-D)	over	a	logarithmic	concentration	range,	where	cell	viability	was	determined	
by	PrestoBlue™	treatment	and	EC50	concentrations	were	obtained	(Figure	4.1E).	All	5-NFNs	
tested	 exhibited	 toxicity	 in	 the	 A375	melanoma	 cell	 line,	 EC50	 =	 1.77µM	 (NFN1);	 7.52µM	
(NFN2);	4.50µM	(NFN3);	8.77µM	(NFN4).	NFN1	was	the	most	potent	5-NFN	tested	 in	 this	
cell	 line,	however	all	four	compounds	exhibited	A375	cell	toxicity	with	EC50	values	ranging	
from	 1-10µM.	 This	 provides	 evidence	 that	 5-NFNs	 are	 cytotoxic	 against	melanoma	 cells.	











Figure	 4.1:	 5-NFN	 activity	 on	 A375	 melanoma	 cells.	 A-D)	 Molecular	 structures	 of	 NFN1-4	
respectively.	The	5-nitrofuran	moiety	is	highlighted	in	red.	E)	Cell	viability	assay	of	A375	melanoma	
cell	treated	with	NFN1	(red),	NFN2	(blue),	NFN3	(green),	and	NFN4	(purple)	over	96hrs.	EC50	values	







have	 CSC	 ALDH	 expression:	 A2780	 (ovarian)	 and	HCT116	 (colorectal);36,79,159	 compared	 to	
A375	melanoma	cells.	A2780	 is	 a	human	ovarian	 carcinoma	cell	 line,	established	 from	an	




doses	of	NFN1.	 The	no-nitro	 compound,	NFN1.1,	was	used	as	a	 control	 to	 see	 if	 the	NO2	





in	 A2780	 ovarian	 cells	 could	 reflect	 a	 much	 higher	 ALDH	 activity	 status.	 The	 no-nitro	








































the	 cells	were	 subjected	 to	 the	 flow	 cytometry	 based	Aldefluor™	 assay.	 A375	melanoma	
cells,	A2780	ovarian	cells	and	HCT116	colorectal	cells	cells	were	subjected	to	the	Aldefluor™	
assay,	where	Aldefluor™	activity	was	measured	using	BD	LSR	II	Flow	Cytometer.	DEAB	was	
used	 as	 a	 negative	 control,	 and	 represented	 mean	 shown	 as	 green	 dashed	 line.	 A375	
melanoma	cells	had	high	Aldefluor™	activity,	with	HCT116	colorectal	cells	having	more	of	a	
broad,	 heterogeneous	 expression	 (Figure	 4.3).	 It	 was	 unusual	 to	 see	 that	 A2780	 ovarian	
cells	had	 low	Aldefluor™	activity,	considering	their	high	sensitivity	 to	NFN1,	however,	 this	











































sensitivity,	 EC50	 values	 were	 obtained	 for	NFN1	 on	 a	 panel	 of	 melanoma	 cell	 lines	 with	
previously	characterised	ALDH	RNA	expression	 levels.	 It	was	expected	that	melanoma	cell	
lines	 with	 high	 expression	 of	 ALDH1A3	 should	 be	 more	 sensitive	 to	NFN1.	 Cell	 viability	
assays	were	set	up	as	before	and	in	accordance	to	Appendix	I,	treated	with	NFN1.	Cell	lines	
were	also	treated	with	NFN1.1	as	a	control.	Sensitivity	to	NFN1	(EC50	value)	was	correlated	
against	the	RNAseq	expression	for	ALDH1A3	 in	each	 individual	cell	 line.	Of	the	21	cell	 lines	
provided,	 after	 only	 half	 were	 recorded,	 it	 was	 clear	 to	 see	 there	 was	 no	 correlation	
between	ALDH1A3	expression	and	5-NFN	sensitivity	(Figure	4.4).	Although	a	trend	towards	
lower	EC50	values	 is	matched	with	higher	ALDH1A3	sensitivity,	 there	 is	a	weak	correlation	
(R2	=	0.0246)	and	it	is	visually	obvious	when	examining	the	raw	points	themselves.	This	lack	
of	correlation	was	surprising	considering	work	from	Chapter	3,	demonstrating	5-NFNs	can	
inhibit	 ALDH1A3	 activity	 in	 vitro.	 As	 ALDH1A3	 is	 a	 previously	 described	 functional	 CSC	
marker	 for	 A375	melanoma	 cells,	 it	 is	 likely	 that	 only	 a	 subpopulation	 of	 cells	 are	more	
highly	sensitive	to	5-NFNs,	and	this	is	why	no	correlation	is	observed	when	probing	whole	
cell	 populations.	 As	 such,	 knock-down	 of	 ALDH1A3	 should	 invoke	 resistance	 in	 this	




a	 single	 ALDH	 isoform	 from	 a	 family	 of	 19	 may	 not	 be	 representative	 of	 which	 ALDH	
isoforms	 are	 driving	 5-NFN	 toxicity	 in	 each	 individual	 cell	 line.	 Most	 likely,	 it	 will	 be	 a	
differing	series	of	ALDH	expression	in	each	cell	line	that	contributes	to	5-NFN	toxicity,	and	
will	 not	 be	mediated	 by	 just	 one	 isoform.	 It	would	 be	 interesting	 to	 discover	 the	 affinity	






sensitivity	over	a	series	of	expression	patterns.	There	 is	 likely	valuable	 information	within	
this	 dataset,	 however,	 it	 almost	 becomes	 obsolete	 when	 trying	 to	 consider	 single	 ALDH	
isoforms	only	rather	than	digging	for	statistical	correlations	for	the	whole	ALDH	expression	
pattern	 and	protein	 levels.	 Ideally,	 the	ALDH	expression	would	 be	 characterised	 for	 each	
cell	line	after	every	cell	viability	assay,	to	give	a	true	representation	of	ALDH	expression	at	
that	specific	time,	for	that	particular	EC50.	Further,	it	would	also	be	possible	to	explore	how	
fluctuations	 in	 both	 EC50	 and	 ALDH	 expression	 in	 the	 same	 cell	 line	 over	 time/serial	





Figure	 4.4:	 Scatter	 plot	 correlating	 NFN1	 sensitivity	 to	 ALDH1A3	 expression	 in	 a	 panel	 of	 11	
melanoma	cells.	NFN1	 sensitivity	 is	 represented	by	EC50	 values	determined	by	 cell	 viability,	where	
the	lower	the	EC50	the	more	sensitive	the	cell	line	is	to	NFN1.	ALDH1A3	is	determined	through	RNAseq	
and	directly	proportional	to	expression.	Although	some	correlation	that	NFN1	sensitivity	increases	as	
ALDH1A3	expression	 is	higher,	 this	 is	very	weak	 (R2	=	0.0246).	Looking	at	 the	raw	data	points,	 it	 is	
clear	that	most	melanoma	cells	have	low	ALDH1A3	and	those	with	much	higher	levels	were	not	more	

















melanoma	 cells	 treated	 with	 Aldefluor™	 reagent	 were	 imaged	 using	 Nikon	 SMZ1500	
stereomicroscope	 (Ex:	 488nm,	 Em:	 525nm).	 The	 A375	 cells	 appear	 have	 a	 clear	
heterogeneous	 expression	 of	 Aldefluor™	 activity	 seen	 visually	 (Figure	 4.5A).	 This	 is	 in	
keeping	with	literature	reports	that	there	is	a	heterogeneous	population	in	regards	to	ALDH	




To	 visualise	 ALDH	 heterogeneity	 seen	 in	 A375	 melanoma	 cells	 reported	 previously,79,151	
malignant	 melanoma	 and	 healthy	 skin	 sections	 were	 purchased	 from	 US	 Biomax	 and	
stained	 for	ALDH1	through	3,3’-diaminobenzidine	 (DAB)	 immunohistochemistry	 (IHC)	by	a	
Ph.D.	 student	 in	 our	 group,	 Sonia	Wojciechowska	 (University	 of	 Edinburgh,	 UK).	 The	 IHC	
staining	 reveals	 that	 melanoma	 sections	 have	 clear	 subpopulations	 with	 high	 ALDH1	
expression	and	other	cells	 that	have	no	detectable	ALDH1	expression	at	all	 (Figure	4.5B).	
This	mirrors	the	characteristics	seen	in	the	Aldefluor™	treated	A375	melanoma	cells	and	in	
previous	 literature.79,151	 The	 healthy	 skin	 showed	 almost	 no	 ALDH1	 activity	 (Figure	 4.5C)	
suggesting	 that	high	ALDH1	cellular	 subpopulations	are	unique	 to	 cancer	of	 the	 skin,	 and	
not	 healthy	 skin	 tissue,	 in	 agreement	with	 a	 previous	 study90	 and	work	 from	 the	Human	
Atlas	Project,	where	only	very	low	expression	of	ALDH1	is	seen	in	skin	tissue.160	It	is	notable	
that	ALDH1	expression	in	the	melanoma	sections	was	surprisingly	higher	than	expected	for	
the	CSC	population	percentage,30	 although	 this	may	be	explained	by	 reports	 stating	CSCs	
may	 have	 a	 higher	 incidence	 in	 melanoma	 than	 previously	 reported.68,71	 One	 other	
explanation	could	be	down	to	specificity	of	the	antibody	staining,	where	low	ALDH1	activity	
may	be	detected	by	IHC,	but	is	not	detected	by	Aldefluor™.	Thus,	while	the	IHC	may	not	be	
quantitative	 compared	 with	 Aldefluor™,	 this	 staining	 has	 shown	 a	 clear	 heterogeneous	












between	 5-NFN	 sensitivity	 and	 ALDH	 expression	 was	 reported,	 however	 further	
quantitative	 analysis	would	 be	 needed	 to	 verify	 this	 hypothesis.	While	 treatment	 of	 cells	
with	5-NFNs	through	cell	viability	explores	the	sensitivity	of	the	whole	cell	population,	the	
expression	of	ALDH1,	specifically	ALDH1A3	in	this	instance,	may	only	correlate	to	sensitivity	
of	 the	 subpopulation	 of	melanoma	 cells.	 As	 such,	 considering	 the	 likely	 heterogeneity	 of	
ALDH1A3	 expression	 in	 the	 A375	 melanoma	 cells,	 knock-down	 of	 ALDH1A3	 expression	
should	 invoke	resistance	 in	 the	sensitivity	of	 this	cell	 line	 to	5-NFN	treatment.	This	would	
provide	 an	 explanation	 for	why	whole	 cell	 ALDH1A3	expression	did	 not	 correlate	with	 5-













Figure	 4.5:	 Visual	 images	 showing	 ALDH	 heterogeneity	 in	 melanoma	 cells.	 A)	 Adhered	 A375	
melanoma	 cells	 stained	 with	 Aldefluor™	 imaged	 10x	 magnification	 (Ex:	 488nm,	 Em:	 525nm).	
Heterogeneity	within	the	A375	cell	population	is	seen,	both	high	Aldefluor™	expressing	cells	(white	
arrows)	and	 low	Aldefluor™	expressing	cells	appear	are	present	 in	the	whole	A375	cell	population.	
Cells	with	high	Aldefluor™	activity	appear	more	 rounded,	whereas	 low	Aldefluor™	expressing	 cells	
show	elongation.	B)	Section	of	a	human	malignant	melanoma	from	the	right	thumb	of	a	62-year	old	
patient.	 The	 section	was	DAB-stained	 for	 ALDH1	 and	 counter	 stained	with	 hematoxylin	 and	 eosin	
(H&E).	A	heterogeneous	ALDH1+	subpopulation	of	cells	 (brown)	 is	present	 in	 the	whole	melanoma	
cell	 population,	 where	 ALDH1-	 cells	 (purple)	 are	 readily	 abundant	 also.	 C)	 Section	 of	 healthy	 skin	
tissue	 adjacent	 to	melanoma	 from	 a	 50-year	 old	 female	 patient.	 The	 section	was	DAB-stained	 for	

















CSC	markers	 in	melanoma,	 with	 ALDH1A1	 being	 largely	 found	 as	 the	 key	 CSC	marker	 in	
primary	melanoma	tissue	and	ALDH1A3	as	the	major	ALDH	CSC	marker	in	A375	melanoma	
cells.79	 Although	 there	 was	 no	 correlation	 between	 ALDH1	 expression	 in	 melanoma	 and						
5-NFN	 sensitivity,	 it	 is	 likely	 that	 it	 is	 only	 a	 subpopulation	 of	 the	 whole	 cell	 population	
which	 is	highly	 sensitivity	 to	5-NFNs.	As	 such,	 if	5-NFN	 toxicity	 is	driven	by	ALDH	 in	A375	
cells,	 knock-down	 of	 ALDH	 expression	 through	 siRNA	 treatment	 should	 offer	 some	







in	 a	 73.1%	 and	 87.4%	 reduction	 in	 protein	 expression	 respectively,	 against	 GAPDH	





(Figure	 4.6D),	 suggesting	 that	 any	 phenotypes	 observed	 will	 likely	 be	 attributable	 to	 a	
reduction	ALDH1A3	activity.	Loss	of	ALDH	activity	was	also	confirmed	by	Aldefluor™	activity	
(Figure	 4.6E).	 The	 Aldefluor™	 assay	 analyses	 ALDH	 activity	 in	 live-cell	 population,	 where	
ALDH	activity	will	negatively	charge	a	fluorescent	marker	which	is	then	retained	within	the	
cell	 and	 it	 will	 fluoresce	 green.	 DEAB	 is	 an	 ALDH	 inhibitor	 provided	 in	 the	 kit,	 used	 as	 a	
negative	ALDH	activity	control,	where	ALDH	activity	 is	 inhibited,	not	allowing	the	negative	
charging	 of	 the	 fluorescent	 molecule,	 so	 will	 pass	 through	 the	 cell	 and	 not	 fluoresce.	
Histogram	plots	rendered	from	flow	cytometric	analysis	of	Aldefluor™	expression	indicates	








a	 partial	 reduction	 of	 Aldefluor™	 activity	 is	 seen	 with	 ALDH1A1	 knock-down.	 ALDH2								
knock-down	 appeared	 to	 have	 no	 effect	 of	 Aldefluor™	 activity	 in	 these	 cells.	 This	 shows	
that	ALDH1A3	activity	is	the	key	ALDH	isoform	that	drives	Aldefluor™	activity	in	A375	cells.	
Although	 some	 loss	 of	 Aldefluor™	 activity	 is	 seen	 with	 ALDH1A1	 knock-down,	 this	 is	 in	
keeping	 with	 the	 reduction	 of	 ALDH1A3	 expression	 observed	 by	 western	 blot	 upon	
treatment	 with	 siALDH1A1.	 Knock-down	 of	 ALDH1A1,	 1A3	 and	 ALDH2	 by	 siRNA	 in	 A375	
melanoma	 cells	 did	 not	 have	 any	 effect	 of	 cell	 behaviour	 or	 growth.	 Visually,	 ALDH							
knock-down	 of	 A375	 cells	 appeared	 normal	 in	 morphology	 and	 behaviour	 (Figure	 4.7),	
compared	 to	 control	 siRNA	 treated	 and	WT	 A375	 cells.	 Luo	 et	 al.	 (2012)	 reported	 siRNA	
knock-down	of	ALDH1A3	in	ALDH+	A375	cells	induced	apoptosis	and	led	to	a	55%	reduction	
in	 cell	 viability,79	 however,	 this	was	only	 reported	 in	 the	ALDHhigh	 subpopulation,	 and	not	






































A,B)	Western	 blot	 of	 ALDH1A3	 and	 ALDH2	 knock-down	 A375	 cells	 respectively	 against	 scrambled	
siRNA	control	 and	WT	A375	cells.	GAPDH	expression	was	used	as	a	 loading	 control.	ALDH1A3	and	
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Treatment	 with	 scrambled	 control	 led	 to	 no	 alteration	 in	 ALDH	 expression.	 C)	 Western	 blot	 of	
ALDH1A1	 knock-down	 A375	 cells	 against	 scrambled	 siRNA	 control,	 WT	 A375	 cells	 and	 positive	
controls:	 HepG2	 cells	 and	 recombinant	 ALDH1A1	 protein.	 There	 is	 no	 detectable	 ALDH1A1	
expression	in	A375	cells	upon	western	blotting	with	ALDH1A1	antibody.	D)	Western	blot	of	ALDH1A1	
and	 ALDH1A3	 knock-down	 A375	 cells	 against	 WT	 A375	 cells	 stained	 with	 ALDH1A3	 antibody.	
ALDH1A1	knock-down	cells	displayed	a	52%	reduction	in	ALDH1A3	expression	(86%	upon	siALDH1A3	
treatment	 as	 control)	 E)	 Aldefluor™	 activity	 of	 ALDH1A1	 (purple),	 1A3	 (yellow)	 and	 ALDH2	 (pink)	
knock-down	A375	cells	against	scrambled	siRNA	control	(red)	and	WT	(blue)	A375	cells.	DEAB	(green)	
was	used	as	a	negative	control.	ALDH1A1	knock-down	led	to	a	reduction	in	Aldefluor™	activity,	with	














Figure	 4.7:	 IncuCyte	 ZOOM®	 images	 of	 ALDH1A1,	 1A3	 and	 ALDH2	 knock-down	 A375	 cells	 against	





ALDH1A1	siRNA	A375				 	 							 ALDH1A3	siRNA	A375	







4.4.2	 A375	 melanoma	 cells	 are	 resistant	 to	 5-nitrofurans	 upon	 ALDH1A3	 knock-
down		
	
Aldh2b	 drives	 5-NFN	 activity	 in	 zebrafish	 melanocytes,115	 so	 ALDH2	 was	 the	 obvious	
candidate	to	explore	first	when	looking	at	ALDH-driven	bio-activation	of	5-NFNs	in	human	
melanoma	cells.	ALDH2	was	knocked-down	 in	A375	melanoma	cells	by	siRNA	and	treated	
with	 NFN1	 or	 vehicle	 (1%	 DMSO),	 compared	 to	 a	 scrambled	 siRNA	 control.	 ALDH2								
knock-down	 A375	 melanoma	 cells	 grew	 to	 100%	 confluence,	 as	 monitored	 by	 IncuCyte	
ZOOM®,	when	treated	with	vehicle	(1%	DMSO)	control	(Figure	4.8A).	The	growth	was	also	
shown	 to	be	 consistent	with	 control	 siRNA	 treated	A375	melanoma	 cells.	 Knock-down	of	
ALDH2	 in	 A375	 melanoma	 cells	 did	 offer	 some	 protection	 against	 5-NFN	 activity	 upon	
treatment	 with	 NFN1	 (Figure	 4.8B),	 however,	 this	 protection	 was	 not	 significant																			
(P	 =	 0.2672).	 This	 indicates	 that,	 unlike	 in	 zebrafish	melanocytes,	 ALDH2	may	 not	 be	 the	
primary	 ALDH	 isoform	 responsible	 for	 5-NFN	 toxicity	 in	 A375	 cells.	 ALDH1	 isoforms	 have	
markedly	increased	expression	in	melanoma	cells	due	to	their	function	as	CSC	markers,79,151	
so	it	is	likely	that	knock-down	of	these	isoforms	would	provide	more	significant	protection	
against	 5-NFNs.	 Luo	 et	 al.	 (2012)	 reported	 that	 expression	 of	 ALDH1A	 enzymes	 were									
>15-fold	 greater	 in	 the	ALDH+	population	 compared	 to	ALDH-	 cells,	where	ALDH1A3	 copy	
number	 was	 200-fold	 more	 abundant	 on	 average	 in	 ALDH+	 melanoma	 cell	 lines	 than	
ALDH1A1,	 leading	 them	 to	 conclude	 that	ALDH1A3	expression	 specifically	 is	 a	marker	 for	
CSC	 activity	 in	 A375	 melanoma	 cells,	 so	 it	 is	 likely	 ALDH1A3	 will	 have	 a	 much	 greater	
contribution	to	5-NFN	toxicity	than	ALDH1A1	in	this	cell	line.79	
	
To	 query	 whether	 5-NFN	 toxicity	 is	 driven	 by	 ALDH1	 isoforms	 in	 A375	 melanoma	 cells,	
ALDH1A1	and	ALDH1A3	expression	was	silenced	through	siRNA	and	treated	with	the	same	
dose	of	NFN1	or	vehicle	(1%	DMSO),	compared	to	a	scrambled	siRNA	control.	ALDH1A1	and	




NFN1	 treatment	 against	 the	 scrambled	 control	 (Figure	 4.8D),	 however	 ALDH1A1	 knock-
down	 did	 not	 share	 this	 characteristic	 (P	 =	 0.6302),	 showing	 that	 5-NFN	 toxicity	 can	 be	








eventually	 rupture,	 compared	 to	 ALDH1A3	 knocked-down	 A375	 cells.	 The	 abundance	 of	
these	rounded	up	cells	is	much	clearer	when	artificially	coloured	purple	(Figure	4.9B).	It	 is	




Figure	 4.8:	 Confluence	 graphs	of	 siRNA	A375	melanoma	 cells	 treated	with	NFN1	 (1µM)	or	 vehicle														
(1%	 DMSO).	 Confluence	 is	 normalised	 to	 0%	 prior	 to	 treatment	 with	 drug.	A)	 Growth	 of	 ALDH2	
knock-down	 A375	 cells	 (green)	 compared	 to	 scrambled	 control	 siRNA	 A375	 cells	 (red)	 after	































Figure	 4.9:	 IncuCyte	 ZOOM®	 stills	 of	 ALDH1A3	 knock-down	 A375	 melanoma	 cells	 compared	 to	




































the	 accuracy	 of	 the	 IncuCyte	 ZOOM®	 artificial	 intelligence	 (AI)	 to	 measure	 cellular	
confluence,	where	dying/dead	cells	and	cellular	debris	can	still	contribute	towards	cellular	
confluence	 by	 the	 in-built	 AI	 software	 (Figure	 4.10A,B).	 As	 such,	 I	 wanted	 to	 refine	 the	
assay,	and	the	way	 in	which	cellular	sensitivity	to	NFN1	was	measured.	 If	ALDH1A3	knock	
down	protected	A375	melanoma	cells	 from	5-NFN	activity,	 then	a	 reduction	 in	 cell	death	





Figure	 4.10:	 Confluence	 masks	 do	 not	 accurately	 discriminate	 A375	 melanoma	 cells.	 A)	 Cell	
confluence	on	WT	A375	melanoma	cells	during	normal	growth	as	recorded	by	the	IncuCyte	ZOOM®	
AI	software.	Confluence	mask	(yellow)	highlights	adhered	A375	cells	by	defining	the	cellular	boarder	












To	 more	 accurately	 investigate	 the	 protection	 against	 5-NFN	 toxicity	 seen	 in	 ALDH1A3	
knock-down	 A375	 melanoma	 cells,	 apoptosis	 was	 monitored	 fluorescently	 using						
NucView™	–	a	fluorescent	caspase-3/7	cellular	marker.	ALDH1A1	or	1A3	knock-down	A375	
cells	 were	NFN1	 treated	 in	 the	 presence	 of	 NucView™,	 compared	 to	 a	 scrambled	 siRNA	
control,	 and	 analysed	 using	 the	 IncyCyte	 ZOOM®.	 There	 was	 no	 detectable	 change	 in	
NucView™	expression	in	the	ALDH1A1	or	1A3	knock-down	cells	compared	to	the	scrambled	
siRNA	control	cells	 (Figure	4.11).	Although	there	was	an	 increase	 in	apoptosis	upon	NFN1	
treatment,	this	only	amounted	to	6%	of	the	confluent	population.	This	may	largely	be	due	
to	 the	 mechanism	 by	 which	 cell	 death	 is	 induced	 by	 5-NFNs.	 Ferroptosis	 is	 a	 newly	
discovered	 form	 of	 regulated	 cell	 death,	 distinct	 from	 previously	 described	 pathways	 of	
regulated	 cell	 death,	 such	 as	 apoptosis.161,162	 Ferroptosis	 is	 an	 iron-dependant	 process,	
which	results	in	mitochondrial	membrane	rupture	that	drives	cell	death	and	can	be	induced	
by	an	accumulation	of	intercellular	ROS.161	5-NFN	toxicity	is	driven	by	the	formation	of	ROS	
within	 the	 cell	 to	 promote	 cell	 death,115	 and	 as	 such,	 it	 is	 likely	 that	 cell	 death	 could	 be	
driven	 by	 ferroptosis	 in	 5-NFN	 treated	 cells,	 where	 it	 has	 been	 previously	 reported	 that	


















Figure	 4.11:	 NucView™	 expression	 in	 ALDH1A1	 (purple)	 and	 1A3	 (orange)	 knock-down	 A375	 cells	
compared	 to	 scrambled	 control	 cells	 (red)	 upon	 treatment	 with	 NFN1	 (3µM).	 Apoptosis	 is	
represented	as	percentage	of	total	population	and	normalised	to	0%	prior	to	NFN1	treatment	(n=2).	
Although	apoptosis	increase	upon	NFN1	treatment	in	all	cells,	there	was	no	difference	in	the	amount	




4.4.4	 ALDH1A3	 knock-down	 protects	 A375	 melanoma	 cells	 from	 5-nitrofuran	
mediated	cell	death	
	
As	 it	 is	 likely	 that	5-NFN	mediated	 cell	 death	does	not	occur	 via	 apoptotic	pathways,	 cell	
death	was	monitored	more	broadly	using	Draq7	 (Ex:	 633nm,	 Em:	599nm)	–	 a	membrane	
impermeable	 fluorescent	dye	 that	only	 stains	 the	nuclei	 of	dead	and	permeabilized	 cells;	
which	is	useful	considering	nuclei	of	cells	that	have	undergone	ferroptosis	remain	intact.164	
ALDH1A3	 knock-down	A375	 cells	were	 treated	with	NFN1	 in	 the	 presence	 of	Draq7,	 and	
analysed	 using	 the	 IncyCyte	 ZOOM®,	 compared	 to	 a	 scrambled	 siRNA	 control.	 ALDH1A3	
knock-down	significantly	reduced	Draq7	labelling	of	 in	A375	cells	compared	to	the	control	
(Figure	 4.12A;	 P	 <	 0.0001)	 upon	NFN1	 treatment.	 The	 protection	 ALDH1A3	 knock-down	
provided	against	5-NFN	driven	cell	death	can	also	be	seen	visually	from	stills	taken	from	the	











dye	which	binds	membrane	 surface-expressing	phosphatidylserine	 in	early	apoptotic	 cells	
(Exitation:	495nm,	Emission:	519nm).	 	ALDH1A3	knock-down	A375	cells	were	treated	with	
NFN1	in	the	presence	of	AnnexinV,	and	analysed	using	the	BD	LSRFortessa™,	compared	to	a	
scrambled	 siRNA	 control	 (Figure	 4.6C;	 20%	 AnnexinV+	 ALDH1A3	 vs	 35.4%	 AnnexinV+	
control).	 This	 data	 shows	 that	 there	 is	 a	 distinct	 AnnexinV+	 population	 in	 the	 A375	 cells	
treated	with	NFN1,	which	 is	 lost	upon	ALDH1A3	knock-down.	This	population	 is	 indicative	




It	 is	 clear	 that	 ALDH1A3	 knock-down	 protects	 A375	melanoma	 cells	 from	 5-NFN	 induced	
cell	death,	however	it	was	unusual	to	find	that	this	behaviour	was	not	mirrored	in	apoptosis	
levels	 between	 the	 ALDH1A3	 knock-down	 and	 scrambled	 siRNA	 control	 populations.	
NucView™	 expression,	 although	 increasing	 upon	 5-NFN	 addition,	 was	 unexpectedly	 low,	
with	only	approximately	6%	of	the	confluent	population	expressing	the	apoptotic	markers,	
caspse-3/7,	 after	 drug	 treatment.	 The	 detection	 of	 phosphatidylserine,	 by	 utility	 of	 the	
AnnexinV	 assay,	 presented	 a	 substantial	 increase	 in	 expression	 upon	 5-NFN	 treatment.	
Phosphatidylserine	 is	 important	 in	 the	 phagocytic	 clearance	 of	 cells,	 upon	 regulated	 cell	
death,	where	 phosphatidylserine	 is	 expressed	 as	 soon	 as	 cellular	 functions	 shut	 down.166	
Phosphatidylserine	 is	 widely	 considered	 as	 a	 surface	 marker	 in	 the	 detection	 of	 early	
apoptotic	 cells,167	 so	 its	 increase	 upon	 5-NFN	 treatment	 appears	 counter-intuitive	
considering	 this	 was	 not	 reflected	 in	 the	 caspase-3/7	 assay.	 However,	 a	 recent	 review	
highlighting	 how	 the	 expression	 of	 phosphatidylserine	 could	 be	 important	 in	 phagocytic	
clearance	 of	 cells	 in	 other,	 non-apoptotic	 cell	 death	 pathways,168	 provides	 evidence	 that	












Figure	 4.12:	 Effect	 of	 ALDH1A3	 knock-down	 had	A375	melanoma	 cell	 death	 upon	 treatment	with	
NFN1	 (3µM).	A)	 Expression	of	 cell	 death	 stain,	Draq7	 (Ex:	 633nm,	 Em:	 599nm),	 of	ALDH1A3	A375	
melanoma	cells	(orange)	compared	to	scrambled	control	siRNA	A375	cells	upon	NFN1	treatment	or	
1%	 DMSO	 (vehicle).	 NFN1	 treatment	 results	 in	 sizable	 increase	 in	 cell	 death,	 however	 ALDH1A3	

















noticeably	 lower	 Draq7	 protection	 and	 less	 cell	 death	 after	NFN1	 treatment	 compared	 to	 control	
siRNA	 cells.	 Draq7	 and	 cell	 death	 prior	 to	 treatment	 was	 low	 and	 consistent	 in	 both	 cells.	 C)	
AnnexinV,	an	early	apoptotic	marker	stain,	expression	(Ex:	495nm,	Em:	519nm)	of	ALDH1A3	knock-
down	A375	cells	 compared	 to	control	 siRNA	cells	upon	NFN1	 treatment.	AnnexinV	expression	was	
recorded	by	flow	cytometry	and	analysed	using	FlowJo	software.	ALDH1A3	knock-down	had	reduced	












Overexpression	 of	 ALDH1A3	 in	 A375	 melanoma	 cells	 were	 produced	 through	 transient	
transfection	 of	 human	 cDNA	 clones.	 The	 empty	 vector	 (EV),	 pCMV6-XL4,	 was	 used	 in	
parallel	as	a	control	 throughout.	ALDH1A3	overexpression	 in	A375	cells	was	confirmed	by	
western	blot	(Figure	4.13A),	leading	to	a	42.4%	increase	in	ALDH1A3	expression.	ALDH1A3	
overexpression	 was	 also	 confirmed	 by	 the	 Aldefluor™	 assay	 (Figure	 4.13B)	 where	
Aldefluor™	intensity	increased	3-fold	from	empty	vector	control	and	WT	cells.	Visually,	both	
ALDH1A3	 overexpressing	 and	 empty	 vector	 control	 A375	 cells	 appeared	 normal	 in	 shape	
and	size,	compared	to	WT	A375	cells	(Figure	4.13C-E).	
	
ALDH1A3	 overexpression	 in	 A375	 cells	 did	 have	 an	 effect	 on	 cellular	 proliferation.	
Proliferation	 of	 transiently-transfected	 A375	 cells	 was	 monitored	 using	 IncuCyte™	
NucLight™	Green	BacMam	3.0	reagent,	which	enables	expression	of	nuclear-restricted	GFP	
(Excitation:	 400nm,	 Emission:	 509nm).	 Proliferation	 was	 recorded	 by	 nuclei	 count	 and	
analysed	 by	 IncuCyte	 ZOOM®.	 Proliferation	 was	 much	 slower	 in	 the	 ALDH1A3	
overexpressing	cells	compared	to	empty	vector	control	cells	(Figure	4.13F).	It	appeared	the	
process	of	transiently-transfecting	A375	cells	could	directly	affect	proliferation,	with	empty	


































































although	 did	 produce	 a	 broader	 Aldefluor™	 activity	 characteristic.	 C-E)	 IncuCyte	 ZOOM®	 stills	 of	
ALDH1A3	 overexpressing	 A375	 cells	 against	 empty	 vector	 control	 and	WT	 A375	 cells	 respectively	
during	normal	growth.	Stills	were	taken	12-hours	after	transfection.	Transfection	of	both	ALDH1A3	
and	 empty	 vector	 control	 appeared	 to	 have	 no	 effect	 of	 cellular	 visual	 appearance	 or	 behaviour	
compared	 to	WT	 A375	 cells.	 F)	 Cell	 proliferation	 of	 ALDH1A3	 overexpressing	 A375	 cells	 (orange)	
compared	 to	 empty	 vector	 control	 (red)	 and	 WT	 (yellow)	 A375	 cells	 during	 normal	 growth.	
Proliferation	 was	 determined	 by	 GFP-expressing	 nuclei	 count	 (Ex:	 400nm,	 Em:	 509nm).									









5-NFN	 sensitivity,	 ALDH1A3	 overexpression	 within	 the	 same	 cells	 should	 result	 in										
hyper-sensitivity	 to	 NFN1.	 Unlike	 siRNA	 treated	 cells,	 which	 grew	 at	 the	 same	 rate,	
ALDH1A3	overexpressing	A375	cells	grew	much	slower	compared	to	empty	vector	control	
cells.	 As	 such,	 cell	 viability	 (i.e.	 the	 ratio	 of	 live	 to	 dead	 cells)	 was	 assessed	 upon	NFN1	
treatment	 rather	 than	 looking	 at	 changes	 in	 cell	 growth	 as	 before.	 Cell	 viability	 was	
assessed	 using	 Muse™	 count	 and	 viability	 reagent,	 where	 live	 and	 dead	 cells	 are	
differentially	stained	based	on	their	permeability	 to	 the	DNA-binding	dyes	 in	 the	reagent.		
Cell	viability	of	transiently	transfected	A375	cells	was	analysed	using	Muse®	Cell	Analyser.	
Cells	were	 trypsinised	and	 treated	with	 the	Muse®	Cell	 viability	 Live/Dead	marker	before	
being	subjected	to	Muse®	Cell	Viability	Cell	Analysis.	ALDH1A3	overexpression	significantly	
hyper-sensitised	the	A375	cells	to	NFN1	toxicity,	compared	to	empty	vector	control	(Figure	
4.14A,	 P	 <	 0.001).	 ALDH1A3	 overexpression	 led	 to	 63.8%	 reduction	 in	 cell	 viability	 upon	
NFN1	treatment,	compared	to	20.3%	seen	in	the	empty	vector	control.	Empty	vector	cells	
also	 had	 reduced	 viability	 compared	 to	 WT	 cells	 (EV	 20.3%	 reduction	 vs	 WT	 10.0%	
reduction)	however	this	was	not	significant	 (P	=	0.147).	Cell	viability	remained	unchanged	







in	 cell	 death	 with	 ALDH1A3	 overexpression	 compared	 to	 empty	 vector	 control.	 The	
ALDH1A3	overexpressing	A375	cells	do	appear	slightly	altered	in	morphology	compared	to	
empty	vector	control	cells,	where	they’re	slightly	elongated,	possibly	an	indication	of	stress.	
It	 could	be	argued	 that	ALDH1A3	overexpressing	A375	cells	are	more	prone	 to	cell	death	
when	looking	at	cell	viability,	where	there	is	a	slight	decrease	in	vehicle	(1%	DMSO)	treated	





As	 the	 previous	 transient	 transfection	 protocol	 was	 showing	 signs	 of	 toxicity,	 through	




The	 sensitivity	 of	 A375	 cells	 transiently	 transfected	 to	 overexpress	 ALDH1A3	 was	
determined	 using	 cell	 viability	 against	 NFN1,	 in	 comparison	 to	 A375	 melanoma	 cells	
transiently	 transfected	 with	 pCMV6-XL4	 empty	 vector	 (Figure	 4.15B).	 ALDH1A3	
overexpression	 hypersensitised	 the	 A375	 cells	 to	 NFN1	 (EC50	 =	 584nM	 ttALDH1A3	 vs								
EC50	 =	 1.15µM	 EV	 Control).	 This	 correlated	 to	 results	 of	 the	 Muse®	 cell	 viability	 assay													













dose	 (500nM)	 of	 NFN1	 (n=2).	 A)	 Cell	 viability	 of	 ALDH1A3	 overexpressing	 A375	 cells	 (orange)	
compared	to	empty	vector	(EV)	control	(red)	and	WT	A375	cells	(yellow)	upon	treatment	with	NFN1	
or	 1%	 DMSO	 (vehicle).	 Cell	 viability	 is	 represented	 as	 percentage	 viable	 cells	 vs	 non-viable	 cells.	




























seen	 in	 the	ALDH1A3	overexpressing	 cells	 compared	 to	20.3%	 in	empty	vector	 cells.	 Empty	vector	
cells	 had	 reduced	 viability	 compared	 to	WT	 also	 (EV	 20.3%	 vs	 WT	 10.0%)	 however	 this	 was	 not	
significant	(P	=	0.147)	Cell	viability	remained	unchanged	between	all	3	cells	upon	DMSO	treatment.	
B)	 Photographs	 (10x	 magnification)	 of	 adhered	 ALDH1A3	 overexpressing	 A375	 melanoma	 cells	
compared	 to	 adhered	 empty	 vector	 control	 A375	 cells	 pre-	 and	 24-hours	 post	 NFN1	 treatment.	
ALDH1A3	overexpressing	 cells	 had	 drastically	 less	 adhered	 cells	 and	more	 cell	 death	 compared	 to	









Figure	 4.15:	 A375	 melanoma	 cells	 overexpressing	 ALDH1A3	 by	 transient	 transfection	 are	
hypersensitive	 to	 NFN1	 by	 cell	 viability.	 A)	 Western	 blot	 of	 ALDH1A3	 overexpression	 A375	 cells	
against	empty	vector	(EV)	control.	GAPDH	expression	was	used	as	a	loading	control.	ALDH1A3	cDNA	
transfection	 led	 to	 a	136%	 increase	 in	ALDH1A3	expression	 compared	 to	empty	 vector	 control.	B)	
Cell	 viability	 assays	 upon	 NFN1	 treatment	 over	 24hrs,	 EC50	 values	 determined	 by	 PrestoBlue™	
treatment	 and	 normalised	 to	 vehicle	 (1%	 DMSO)	 control.	 A375	 melanoma	 cells	 overexpressing	
ALDH1A3	by	transient	transfection	(ttALDH1A3	–	orange)	were	more	sensitive	to	NFN1	compared	to	


















the	 A375	 melanoma	 cell	 lines.	 The	 heterogeneity	 of	 ALDH1	 expression	 in	 melanoma,	
including	 A375	 cells,	 offered	 an	 explanation	 for	 why	 no	 correlation	 between	 5-NFN	
sensitivity	and	ALDH1	expression,	either	by	Aldefluor™	or	RNAseq,	was	observed.	ALDH1A3	
has	 previously	 been	 described	 as	 a	 CSC	 marker	 in	 the	 A375	 melanoma	 cell	 line,79	 so	 I	
hypothesised	that	ALDH1A3	was	driving	5-NFN	sensitivity	 in	a	subpopulation	of	A375	cells	
and	 consequently,	 the	 sensitivity	 of	 the	 ALDH1A3high	 A375	 melanoma	 subpopulation	 to						
5-NFNs	 was	 explored.	 Knock-down	 of	 ALDH1A3	 by	 siRNA	 invoked	 resistance	 of	 A375	
melanoma	 cells	 to	 5-NFN	 toxicity,	 and	 in	 contrast,	 ALDH1A3	 overexpression	 induced	
hypersensitivity	 to	5-NFNs.	Displayed	 in	Figure	4.16,	 I	highlight	ALDH1A3	 is	driving	5-NFN	




Figure	 4.16:	 Schematic	 describing	 the	 mechanism	 of	 5-NFN	 toxicity	 in	 the	 A375	 melanoma	 cells.	
A375	 cells	 are	 heterogeneous	 for	 ALDH1	 expression,	 as	 described	 by	 Aldefluor™.	 5-NFN	 are	
competitive	 substrates	 for	 ALDH1A3,	 determined	 in	 vitro	 and	 by	 Aldefluor™,	 where	 5-NFNs	 are						
bio-activated	in	a	subpopulation	of	cells	by	ALDH1A3	to	drive	melanoma	cell	death.	Manipulating	the	































The	 anti-cancer	 activity	 of	 clinical	 5-NFNs	 in	 patients	 has	 been	 previously	 reported,126,131	
with	nifurtimox	(NFX),	an	anti-parasitical	5-NFN	pro-drug,	currently	in	phase	2	clinical	trials	
for	 the	 treatment	 of	 neuroblastoma	 and	 medulablastoma	 (ClinicalTrials.gov	 Identifier:	
NCT00601003).	 Previous	 to	 this	 trial,	 Sholler	 and	 her	 team	 demonstrated	 that	 NFX	 can	
induce	apoptosis	 in	neuroblastoma	cells	and	 inhibit	growth	of	neuroblastoma	xenographs	
in	 vivo,	where	an	 increase	of	ROS	 formation	 is	 a	 likely	driver	of	 this	phenotype.132	 This	 is	
shared	 in	the	treatment	of	medulloblastoma	cells	with	NFX	also,	where	cells	 treated	with	
NFX	upregulated	HMOX1,	GCLM,	SLC7A11	and	SRXN1	-	all	genes	associated	with	oxidative	
stress,	where	 use	 of	 the	 anti-oxidant,	 N-acetyl-L-cysteine,	 rescued	medulloblastoma	 cells	
from	NFX	 induced	 apoptosis.112	 The	 exact	 target	 of	NFX	 in	 cancer,	 and	 consequently	 the	
mechanism	in	which	this	can	mediate	ROS	accumulation,	 is	currently	unclear.	Considering	





seen	 in	 patients	 with	 Parkinson’s	 disease.171,172	 ALDH1A1	 may	 also	 have	 a	 role	 in	
metabolising	 levels	of	 the	 toxic	dopaminergic	aldehyde,	3,4-dihydroxyphenylacetaldehyde	
(DOPAL).172	ALDH9A1	is	also	highly	expressed	in	the	brain,	likely	due	to	its	high	affinity	for	
DOPAL,	 but	 is	 also	 essential	 in	 the	 alternative	 biosynthesis	 of	 GABA,	 and	 as	 such	 has	 an	
important	 role	 in	 brain	 development.2	 ALDH	 also	 plays	 an	 important	 part	 in	 the	
pathogenesis	of	brain	tumours.40	ALDH2	is	essential	in	dopaminergic	neurons,	where	it	has	
been	 reported	 that	 cocaine-induced	 dopamine	 release	 can	 be	 suppressed	 in	 rats	 upon	
selective	 ALDH2	 inhibition,	 suggesting	 an	 important	 functional	 role	 for	 ALDH2	 in	 the	
synthesis	 of	 dopamine.173	 In	 neuroblastoma	 cells,	 ALDH1A2,	 ALDH1L1	 and	 ALDH3B2	 are	
highly	 upregulated,	 where	 ALDH1A2	 specifically	 is	 shown	 to	 be	 essential	 in	 sphere	 and	
colony	 formation,	 tumorigenesis,	 and	 triggering	 resistance	 to	 RA	 treatment.42	 This	
tumorigenic	potential	has	also	been	described	 in	 the	ALDH+	 subpopulation	 in	a	variety	of	
brain	 cancers,	 including	 medulloblastoma,40	 where	 ALDH	 expression	 has	 further	 been	







brain	 tissues,	 coupled	with	 the	 sensitivity	of	neuroblastoma,	medulloblastoma,	and	other	
neural	cancers	to	NFX,112,132,133	I	hypothesise	that	the	anti-cancer	activity	reported	with	NFX	
being	 is	mediated	 by	 ALDH-driven	 bio-activation.	 This	 is	 also	 supported	 by	 data	 showing	
that	dopamine-dependant	catecholaminergic	neurons	are	more	sensitive	to	NFX,132	which	
is	 likely	due	 to	 the	higher	expression	of	ALDH	needed	 in	 the	dopaminergic	pathway.	 It	 is	
thus	logical	to	assume	that	other	clinical	5-NFNs	may	also	be	substrates	for	ALDH	enzymes	






ALDH	 enzymes,	 and	 as	 such	 exhibit	 potent	 anti-cancer	 activity,	 and	 to	 develop	 new,	
synthetic	 5-NFN	molecules	 that	 are	 efficient	 ALDH	 substrates.	 	 Here,	 I	 compare	NFX	 and	
NAZ,	 and	 demonstrate	 that	 NAZ,	 a	 clinical	 compound	 used	 primarily	 as	 a	 livestock	
antibiotic,	displays	promising	anti-cancer	activity	and	some	selectivity	for	ALDH1	enzymes.	
Further,	 through	 the	development	 of	bis-5-NFN	derivatives,	 I	 describe	 novel	 5-NFNs	with	
two	 active	 moieties	 per	 molecule,	 increasing	 drug	 efficiency,	 i.e.	 a	 ‘double	 hit’.	 These	
benzene-linked	 para-bis-5-NFN	 compound	 have	 strong	 anti-cancer	 and	 ALDH-targeting	



























The	 anti-cancer	 activity	 of	 the	 clinical	 5-NFN,	 nifurtimox	 (NFX),	 has	 previously	 been	
described	 in	 neuroblastoma,126,131,132	 and	 phase	 2	 clinical	 trials	 for	 the	 treatment	 of	
neuroblastoma	and	medulablastoma	with	NFX	 in	 patients	under	21	 is	 showing	promising	
results	in	clinical	trials	(ClinicalTrials.gov	Identifier:	NCT00601003),	however	the	mechanism	
underlying	 this	 anti-cancer	 activity	 in	 unknown.	 I	 hypothesise	 that	 the	 anti-cancer	
properties	 seen	 in	 both	 neuroblastoma	 and	 medulloblastoma	 are	 derived	 from																				




was	 set	 up	 as	 before.	 A375	 cells	 were	 treated	 with	 NFX,	 NFN1,	 NFN1.1	 and	 vehicle															
(0.1%	DMSO).	Although	NFX	has	proven	effective	against	neuroblastoma	in	clinic,	this	was	
not	 represented	 in	A375	cells	 (Figure	 5.1A).	NFX	 did	not	 converge	 to	determine	an	exact	






treatment	 (Figure	5.1B).	This	 indicates	 that	ALDH	enzymes	are	a	 target	 for	NFX,	however	
the	 affinity	 is	 low.	 This	 was	 further	 shown	 by	 determining	 the	 affinity	 of	 NFX	 towards	
ALDH2-His.	ALDH2-His	in	vitro	activity	assay	was	set	up	as	before,	treated	with	a	logarithmic	
dose	 of	NFX.	 Daidzin	 and	 vehicle	 (1%	 DMSO)	were	 used	 as	 controls.	NFX	 treatment	 has	






dose	 (100µM)	 was	 any	 notable	 reduction	 of	 ALDH	 activity	 seen,	 although	 this	 was	 not	
significant	(P	=	0.0506).	The	PK	of	NFX	is	considerably	poor	(Cmax	=	4.8µg/ml	in	serum)	and	
as	 such	 it	 is	 administered	 in	 much	 higher	 doses	 for	 treatment	 of	 neuroblastoma	
(30mg/kg/day),126	which	may	also	help	overcome	its	low	affinity	towards	ALDH2.		
	
Although	NFX	 does	 present	 some	 anti-cancer	 activity,	 which	 is	 likely	 driven	 by	 its	 weak	
interaction	with	ALDH	enzymes	 in	the	A375	melanoma	cell	 line,	 it	 is	still	considerably	 less	
active	 than	 the	 tool	 compound,	NFN1.	 As	 the	 use	 of	 5-NFNs	 as	 anti-cancer	 therapeutics	
continues,	it	will	become	increasingly	important	to	discover	and	development	new	5-NFNs	
with	 improved	 anti-cancer	 activity,	 ALDH	 affinity	 and	 PK.	 As	 such,	 there	 is	 potential	 for	
other	 5-NFNs,	 both	 clinically	 available	 and	 newly	 synthetic,	 to	 be	 identified	 as	 potential	


















(n=2).	A)	A375	melanoma	cell	viability	assay	upon	NFX	 (yellow),	NFN1	 (orange)	or	NFN1.1	 (purple)	
treatment	 over	 96hours,	 EC50	 values	 determined	 by	 PrestoBlue™	 treatment	 and	 normalised	 to	
vehicle	 (1%	DMSO)	 control.	NFX	 did	not	 converge	past	50%,	 so	an	estimated	EC50	=	103.1µM	was	
determined.	NFN1	 EC50	 =	 1.01µM.	B)	 Aldefluor™	 activity	 of	 A375	 cells	 treated	with	NFX	 (red)	 for	
24hours.	Vehicle	(1%	DMSO,	blue)	and	2hrs	DEAB	(green)	was	used	as	positive	and	negative	controls.	
NFX	 treatment	 led	 to	 a	 18.3%	 reduction	 in	 Aldefluor	 activity	 in	 A375	 cells.	 C)	 ALDH2-His	 activity	
against	NFX	(orange)	treated	over	a	logarithmic	dose	range	against	DMSO	(blue)	and	daidzin	(green).	






























5.2.2	 Nifuoxazide	 highlighted	 for	 promising	 anti-cancer	 activity	 from	 a	 screen	 of	
clinical	5-nitrofurans	
	
As	 5-NFNs	 are	 not	 novel	 compounds,	with	many	 already	 being	 available	 clinically,	 it	was	
predicted	that	some,	if	not	all,	clinical	5-NFNs	would	be	active	against	ALDH	and	have	some	
degree	of	anti-cancer	activity,	 such	as	NFX.	As	shown	previously	 in	 this	chapter	and	work	
from	Dr	Saulnier	Sholler,112,126,131,132	NFX	is	an	effective	anti-cancer	agent,	however	there	is	
much	 room	 for	 improvement	when	 you	 compare	 experimental	 data	 of	NFX	 to	NFN1.	 To	
explore	 whether	 other	 clinical	 5-NFNs	 may	 show	 promising	 anti-cancer	 activity,	 a	 small	
screen	 of	 clinical	 5-NFNs	 was	 set	 up	 against	 the	 A375	 melanoma	 cell	 line	 and	 potency	
compared	 against	 NFN1	 and	 NFX.	 Cell	 viability	 assays	 were	 set	 up	 as	 before,	 with	 a	
logarithmic	dose	of	each	clinical	drug,	Nifurtimox	(NFX),	Nifuroxazide	(NAZ),	Nitrofurantoin	
(NFT)	 and	 Furazolidone	 (FURA)	 (Figure	 5.2A-D)	 in	 series	 with	 NFN1	 against	 a	 vehicle								
(0.1%	 DMSO)	 control.	NAZ	 is	 used	 in	 the	 treatment	 of	 diarrhoea	 and	 colitis	 in	 humans	
administered	 orally	 at	 400mg/day,175	 however	 NAZ	 is	 more	 commonly	 used	 as	 a	 feed	
additive	 in	 livestock,	 and	 the	 only	 5-NFNs	 still	 approved	 by	 the	 FDA	 to	 do	 so.	 However,	
there	 are	 growing	 concerns	 over	 the	 safety	 NAZ	 in	 the	 bulk	 treatment	 of	 livestock,	
considering	 that	NAZ,	and	 its	potentially	carcinogenic	metabolites,	have	been	detected	 in	
chicken	meat	 up	 to	 7days	post-treatment.176	NFT	 is	 a	WHO	essential	medicine	 as	 a	 basic	
health	 medicine	 for	 the	 treatment	 of	 UTIs.121	NFT	 is	 one	 of	 the	 most	 widely	 prescribed								
5-NFNs,	along	with	NFX,	typically	given	in	doses	at	5-7mg/kg/day,	however	is	also	plagued	
with	 several	 adverse	 and	 toxic	 side	 effects,	 with	 hospitalization	 and	 fatalities	 from	
treatment	also	reported.177	FURA	is	broad	spectrum	anti-biotic	and	anti-parasitical,	used	in	
both	 veterinary	 and	 human	medicine,	 however	 amid	 safety	 concerns	 that	 FURA	 may	 be	













Figure	 5.2:	 Screen	 of	 clinical	 5-NFNs	 for	 anti-cancer	 activity.	 A-D)	 Molecular	 structures	 of	
Furazolidone	 (FURA),	 Nitrofurantoin	 (NFT),	 Nifurtimox	 (NFX)	 and	 Nifuroxazide	 (NAZ)	 respectively.	
The	 5-nitrofuran	moiety	 is	 highlighted	 in	 red.	E,F)	 Cell	 viability	 assay	 of	 A375	melanoma	 cells	 and	
A2780	ovarian	cells	respectively	upon	NFX	 (yellow),	NFT	 (purple),	NAZ	(red)	or	FURA	(blue)	against	
NFN1	 (orange)	 treatment	 over	 96hours,	 EC50	 values	 determined	 by	 PrestoBlue™	 treatment	 and	
normalised	to	vehicle	(1%	DMSO)	control.	EC50	values	for	each	drug	in	both	A375	and	A2780	cells	are	
displayed	in	Table	G.	All	drugs	showed	some	degree	of	anti-cancer	activity,	however	NAZ	treatment	
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We	 tested	 all	 the	 stated	 clinical	 5-NFN	 compounds	 on	 A375	melanoma	 cell	 growth,	 and	
found	 that	 all	 clinical	 compounds	 had	 some	 degree	 of	 anti-cancer	 activity	 (Figure	 5.2E),	
however	 NAZ	 was	 the	 only	 compound	 to	 show	 substantial	 toxicity	 in	 A375	 cells																
(EC50	 =	 9.78µM),	 approximately	 10-fold	 less	 potent	 than	 NFN1.	 The	 other	 clinical	
compounds,	although	showing	toxicity	in	A375	cells	at	much	higher	doses,	did	not	show	any	
notable	 improvement	 in	comparison	 to	NFX	 (NFX	 EC50	=	82.9µM,	NFT	 EC50	=	78.2µM	and	
FURA	 EC50	 =	 Did	 not	 converge).	 Similar	 results	 were	 seen	 when	 the	 same	 cell	 viability	
screen	 was	 conducted	 on	 a	 second	 cell	 line,	 the	 A2780	 ovarian	 cell	 line	 (Figure	 5.2F),39	










A375	melanoma	cells	 compared	 to	NFX.	 It	 could	also	be	 likely	 that	NAZ	 can	more	 readily	
permeate	across	 the	melanoma	cell	membrane	 than	NFX,	 to	drive	 this	 increased	 toxicity.	
Similarly,	 it	 could	 also	 be	 the	 opposite	 effect,	where	NFX	 could	more	 readily	 be	 effluxed	
from	the	melanoma	cell	compared	to	NAZ,	 leading	to	why	NAZ	 is	more	potent	than	NFX.	





The	anti-cancer	 activity	of	NAZ	was	assessed	 in	 comparison	 to	NFN1	 on	 the	 same	3	 cells	
lines	 as	 previous:	 A375	melanoma	 cells,	 A2780	 ovarian	 cells	 and	HCT116	 colorectal	 cells.	










cells	 (EC50	 =	 9.55µM	NAZ	 vs	 EC50	 =	 1.04µM	NFN1)	 and	 3-fold	 less	 potent	 than	NFN1	 in	








treatment	 over	 96hours,	 EC50	 values	 determined	 by	 PrestoBlue™	 treatment	 and	 normalised	 to	
vehicle	 (1%	 DMSO)	 control	 A)	 A375	 melanoma	 cell	 viability.	 NAZ	 EC50	 =	 9.55µM	 vs	 NFN1																		















A375	 cells	 were	 subjected	 to	 the	 Aldefluor™	 assay	 24hrs	 after	 treatment	 with	NAZ.	 The	











As	 Aldefluor™	 activity	 is	 attenuated	 in	 A375	 melanoma	 cells	 by	 treatment	 with	 5-NFNs	
during	 flow	 cytometry	 analysis,	 it	 should	 be	 possible	 to	 see	 visually	 on	 adhered	 cells	
cultures	 the	 same	 reduction	 of	 Aldefluor™	 activity,	 including	NAZ.	 A375	melanoma	 cells	
treated	 with	NFN1,	NAZ	 or	 vehicle	 (1%	 DMSO)	 control,	 against	 negative	 control,	 DEAB,	
were	 assessed	 for	 Aldefluor™	 activity	 visually	 (Ex:	 488nm,	 Em:	 525nm).	 Vehicle	 treated	
A375	 cells	 had	 high	 Aldefluor™	 activity,	 compared	 to	 A375	 cells	 treated	with	 both	NFN1	
and	NAZ,	 where	 this	 expression	 was	 dramatically	 reduced	 (Figure	 5.4B).	 DEAB	 also	 had	
similar	 reduction	 in	 Aldefluor™	 activity	 as	 expected.	 This	 is	 visual	 confirmation	 that	 the							
5-NFNs,	NFN1	and	clinical	NAZ,	can	both	ablate	Aldefluor™	activity,	and	consequently	ALDH	
activity,	 in	A375	melanoma	cells.	Although	this	 is	 likely	due	 to	a	direct	 inhibition	of	ALDH	
enzymes	in	the	cells	themselves	leading	to	such	a	dramatic	reduction	in	Aldefluor™	activity,	
it	could	also	be	possible	that	 the	5-NFNs	specifically	 targeted	and	eradicated	the	ALDHhigh	
melanoma	 cells,	 leaving	 only	 the	 ALDHlow	 cells	 in	 the	 sample.	 Although	 both	 outcomes	
would	be	desirable,	further	work	to	explore	how	cells	with	different	ALDH	status	respond	to	










activity	 in	 A375	 cells	 after	 24hrs	 NAZ	 (red)	 treatment.	 DMSO	 (blue)	 positive	 and	 DEAB	 (green)	
negative	 control	 treated	 for	24hrs	 and	2hrs	 respectively.	NAZ	 reduced	Aldefluor™	activity	 in	A375	
cells	by	42.6%	after	24hrs	of	treatment.	DMSO	and	DEAB	treated	A375	cells	assumed	100%	and	0%	
Aldefluor™	activity	respectively	(n=2).	B)	Non-adhered	A375	melanoma	cells	treated	with	NAZ,	NFN1	
or	 vehicle	 (1%	 DMSO)	 for	 24hrs;	 DEAB	 treated	 for	 2hrs	 used	 as	 negative	 control,	 stained	 with	
Aldefluor™	imaged	10x	magnification	(Ex:	488nm,	Em:	525nm).	Treatment	with	NAZ,	NFN1	and	DEAB	




































NAZ	 can	 reduce	 Aldefluor™	 activity,	 and	 consequently	 ALDH	 activity,	 in	 A375	melanoma	
cells,	 so	 it	 expected	 this	 reduction	 of	 ALDH	 activity	 should	 be	mirrored	 in	 vitro.	 As	 with	
NFN1,	 His-tagged	 ALDH2	 was	 subjected	 to	 the	 in	 vitro	 activity	 assay	 as	 before,	 where	
ALDH2-His	 was	 pre-incubated	 with	 NAD+	 against	 a	 logarithmic	 dose	 of	 NAZ	 prior	 to	
acetaldehyde	 initiation.	 Present	 controls	 were	 vehicle	 (1%	 DMSO)	 and	 ALDH2	 inhibitor,	






As	 shown	before,	ALDH1A3	activity	 drives	Aldefluor™	activity	 in	A375	 cells.	 Because	NAZ	
was	able	to	attenuate	Aldefluor™	activity	 in	 these	cells,	 this	should	also	be	reflected	by	a	
reduction	 in	ALDH1A3	activity	 in	vitro	upon	NAZ	 treatment.	As	before,	ALDH1A3	was	pre-
incubated	 with	 NAD+	 and	 NAZ	 or	 NFN1,	 prior	 to	 acetaldehyde	 initiation.	 Activity	 was	
monitored	 against	 vehicle	 (1%	 DMSO)	 control.	 NAZ	 and	 NFN1	 treatment	 significantly	
reduced	 ALDH1A3	 activity	 (NAZ:	 P	 =	 0.017,	NFN1:	 P	 =	 0.016;	 Figure	 5.5B)	 where	 NADH	
turnover	was	reduced	by	73.9%	and	65.5%	respectively.	Considering	this	data	that	NAZ	 is	
not	a	competitive	substrate	for	ALDH2,	but	can	reduce	ALDH1A3	activity	in	vitro,	it	provides	
evidence	 that	 NAZ	 has	 some	 selectivity	 towards	 ALDH1	 over	 other	 ALDH	 isoforms.	 As	
ALDH1	 has	 been	 described	 as	 a	 desirable	 target	 in	 recent	 reports,35,45,118	 it	 would	 be	 a	
















inhibitor,	 daidzin	 (green).	 Enzymatic	 rate	 determined	 using	 initial	 linear	 rate	 of	 NAD+	 to	 NADH	




at	 λ	 =	 340nm	 (ε	 =	 6220M-1cm-1)	 after	 10mins.	 ALDH1A3	 activity	 represented	 at	 %DMSO	 activity.	
ALDH1A3	activity	was	significantly	reduced	after	NAZ	treatment	(P	=	0.017)	with	a	73.9%	reduction	






As	 shown	 previously,115	 5-NFN	mediated	melanocyte	 cell	 death	 in	 zebrafish	 is	 driven	 via				
bio-activation	by	Aldh2b.	 If	NAZ	 is	 indeed	not	being	bio-activated	by	ALDH2,	melanocytes	
should	be	unaffected	in	zebrafish	treated	with	NAZ.	AB	WT	zebrafish	embryos	were	treated	
with	NAZ,	NFN1	of	vehicle	(1%	DMSO)	control	at	48hpf.	Drug	was	washed	off	at	3dpf	and	
embryos	were	 allowed	 to	 grow	 until	 5dpf	 where	melanocyte	 numbers	were	 analysed.	 It	
was	immediately	visible	that	NAZ	treatment	had	no	effect	on	melanocytes	in	the	zebrafish,	







treatment	 resulted	 in	 a	 dramatic	 reduction	 in	 melanocytes,	 with	 numbers	 noticeably	
depleted	 and	 the	 melanocytes	 remaining	 on	 the	 NFN1	 zebrafish	 appearing	 smaller	 and	
more	 rounded.	 The	 lack	 of	 activity	 of	 NAZ	 on	 zebrafish	 melanocytes	 was	 confirmed	 by	
counting	 melanocyte	 cell	 numbers	 on	 the	 zebrafish.	 Melanocyte	 cell	 number	 of	 NAZ	
treated	 fish	was	 not	 significantly	 decreased	 compared	 to	 vehicle	 treated	 fish	 (P	 =	 0.650,	
Figure	5.6B)	however,	NFN1	treatment	had	a	significant	ablation	of	melanocyte	cell	number	
compared	 to	 vehicle	 treatment	 (P	 >	 0.0001).	 This	 is	 consistent	 that	NAZ	 has	 no	 activity	
towards	ALDH2	in	vivo,	confirming	the	results	seen	in	vitro.		
	
Figure	 5.6:	 NAZ	 does	 not	 mediate	 melanocyte	 cell	 death	 in	 zebrafish	 embryos	 (n=15).																												
A)	Photographs	of	zebrafish	embryos	(5dpf)	treated	with	NAZ,	NFN1	or	vehicle	(1%	DMSO)	for	48hrs.	
NAZ	treatment	led	to	no	change	in	zebrafish	melanocytes,	with	fish	looking	similar	to	that	of	DMSO	



















between	 ALDH1A3	 expression	 in	 melanoma	 cells	 and	 sensitivity	 to	 NAZ	 treatment.	 To	
assess	this,	cell	viability	assays	were	set	up	on	the	same	11	cell	lines	kindly	provided	by	Dr	
Marco	Ranzani	 and	Dr	David	Adams	 (Wellcome	Trust	 Sanger	 Institute,	Cambridge,	UK)	as	
before	 in	 accordance	 to	 Appendix	 I,	 where	 the	 expression	 of	 all	 19	 isoforms	 has	 been	
previously	 determined	 by	 RNAseq	 (Appendix	 II).	 Sensitivity	 to	 NAZ	 (EC50	 value)	 was	
correlated	 against	 the	 RNAseq	 expression	 for	 ALDH1A3	 in	 each	 individual	 cell	 line													
(Figure	 5.7).	 Although	 there	 was	 a	 trend	 that	 increasing	 ALDH1A3	 expression	 correlated	
with	sensitivity	to	NAZ,	this	was	particularly	weak	(R2	=	0.0944).	As	with	NFN1,	which	has	a	
far	weaker	correlation	(Figure	4.4,	R2	=	0.0246),	this	gives	an	indication	that	far	more	than	
just	 the	expression	of	ALDH1A3	plays	a	 role	 in	mediating	5-NFN	driven	 toxicity,	and	most	
likely	 the	 full	 ALDH	 environment	 within	 each	 cell	 line	 will	 play	 a	 role	 in	NAZ	 sensitivity.	
However,	 this	 is	 also	 indicative	 of	 anti-cancer	 effects	 being	 driven	 by	 other	 targets.	 For	
instance,	NAZ	has	been	previously	reported	as	a	STAT3	inhibitor,	in	turn	promoting	death	in	
myeloma	 and	 breast	 cancer	 cell	 lines.135,136	 The	 activity	 of	 NAZ	 against	 melanoma	 has	
recently	 been	 published,	 where	 inhibition	 of	 cell	 proliferation,	 promotion	 of	 apoptosis,	
accumulation	of	intercellular	ROS,	and	suppression	of	metastasis	in	melanoma	xenographs	
have	been	observed	post-NAZ	treatment.137	Although	the	study	suggests	these	effects	are	
attributable	to	STAT3	 inhibition,	 it	 is	 likely	that	bio-activation	by	ALDH	plays	an	 important	
factor	 in	 driving	 these	 phenotypes	 also.	 As	 such,	 it	 is	 important	 to	 characterise	 all	 the	
targets	 for	NAZ,	and	 indeed	all	 the	5-NFNs,	where	 it	 is	 likely	 that	some,	 if	not	all,	5-NFNs	
have	dual	target	effects	promoting	anti-cancer	activity.	However,	it	has	been	reported	that	
STAT3	 regulated	 CSC	 behaviour	 in	 melanoma	 cells	 also	 regulates	 the	 expression	 of	
ALDH1A3.85	 It	 is	 therefore	 possible	 that	NAZ	 treatment	 may	 affect	 this	 STAT3-ALDH1A3	
pathway	in	melanoma,	and	be	possible	to	target	a	more	specific	STAT3highALDH1A3high	CSC	
subpopulation.	Within	the	last	few	years,	novel	derivatives	of	NAZ	have	been	synthesised,	
showing	 marked	 improvement	 in	 anti-microbial	 activity	 compared	 with	 NAZ.181-183	






















EC50	 the	more	 sensitive	 the	 cell	 line	 is	 to	NAZ.	ALDH1A3	expression	 is	determined	 through	RNAseq	










the	 5-NFNs	 drugs,	 and	 creating	 novel	 5-NFN	 compounds	 with	 a	much	 higher	 affinity	 for	
ALDH	and	efficacy	in	cancer,	specifically	any	selectivity	for	ALDH1,	would	be	greatly	desired.		
	
NFN1	 is	 a	 previously	 published	 compound,115	 so	 although	 it	 possesses	 favourable	
characteristics	against	cancer	and	ALDH,	it	is	unable	to	be	patented	and	brought	forward	as	


















For	 the	 development	 of	 a	 bis-5-nitrofuran	 molecule	 I	 designed	 a	 strategy	 to	 bind	 two											
5-NFNs	 through	 an	 amide-bound	 benzene	 linker.	 This	 compound	 has	 some	 structural	
similarities	 to	NFN3	 (Figure	3.1C),	which	 showed	similar	 cancer	 cell	 toxicity	 to	NFN1,	 and	





The	 original	 pathway	 to	 synthesise	 the	 proposed	 bis-5-NFN	 involved	 the	 carbodiimide,				
N,N'-diisopropylcarbodiimide	 (DIC)	 to	 promote	 amide	 bond	 formation	 between	 a	
diaminobenzene	 and	 furoic	 acid.	 (Scheme	 2.1)	 However,	 an	 abundance	 of	 an	 expected,	
undesired	 bi-product,	 RC-NFN-WP1,	 was	 produced	 (Figure	 5.8A).	 The	 product	 was	
produced	in	a	substantial	yield	(43%)	and	could	be	readily	purified.	As	this	novel	compound	
was	 still	 a	 5-NFN,	 there	was	 potential	 for	 anti-cancer	 activity	 as	 seen	with	 other	 5-NFNs	
previously.	 To	 test	 for	 this,	 a	 simple	 cell	 viability	 assay	 was	 set	 up	 as	 before	 with	 A375	
melanoma	cells,	with	a	 logarithmic	dose	of	RC-NFN-WP1	and	NFN1.	RC-NFN-WP1	had	no	





To	 further	 confirm	 the	 lack	 of	 biological	 activity	 presented	 by	 RC-NFN-WP1,	 zebrafish	
embryos	were	 treated	with	RC-NFN-WP1	 and	NFN1	 and	vehicle	 (1%	DMSO)	 for	48hrs.	At	




























of	 the	RC-NFN-WP1.	The	5-nitrofuran	moiety	 is	highlighted	 in	 red.	B)	A375	melanoma	cell	viability	
upon	 RC-NFN-WP1	 or	 NFN1	 treatment.	 treatment	 over	 96hours,	 EC50	 values	 determined	 by	
PrestoBlue™	treatment	and	normalised	to	vehicle	(1%	DMSO)	control.	RC-NFN-WP1	had	no	activity	
in	 A375	 cells,	 with	 no	 change	 in	 cell	 viability	 across	 all	 concentrations.	 NFN1	 EC50	 =	 1.76µM																	
C)	Photographs	of	zebrafish	embryos	(5dpf)	treated	with	RC-NFN-WP1,	NFN1	or	vehicle	(1%	DMSO)	



























in	 all	 3	 cell	 lines	 (Figure	 5.9C)	 where	 EC50	 values	 were	 comparable	 to	 NFN1	 treatment	
(A375:	RC-NFN5	EC50	=	1.45µM	vs	NFN1	EC50	=	867nM;		HCT116:	RC-NFN5	EC50	=	3.08µM	vs	




















structure	 of	 bis-5-NFN,	 RC-NFN-WP1.	 The	 5-nitrofuran	 moiety	 is	 highlighted	 in	 red.	 B)	 Molecular	
structure	 of	 the	 no-nitro	bis-control,	RC-NFN5.1.	 The	 furan	moiety	 is	 highlighted	 red	 and	 the	 5-H	
replacing	 the	 NO2	 highlighted	 blue.	 C)	 A375	 melanoma	 (squares),	 A2780	 ovarian	 (triangles)	 and	
HCT116	colorectal	(diamond)	cell	viability	against	RC-NFN5	(blue)	and	RC-NFN5.1	(purple)	treatment	
over	 96hours,	 EC50	 values	 determined	 by	 PrestoBlue™	 treatment	 and	 normalised	 to	 vehicle										
(0.1%	 DMSO)	 control.	 For	 RC-NFN5,	 A2780:	 EC50	 =	 285nM,	 A375:	 EC50	 =	 1.45µM	 and																					
HCT116:	EC50	=	3.08µM.	RC-NFN5.1	treatment	had	no	effect	of	cell	viability	in	all	3	cell	lines.	







If	 the	 cellular	 toxicity	 of	 RC-NFN5	 is	 attributable	 to	 bio-activation	 by	 ALDH	 enzymes,	 a	
comparative	 reduction	 in	 ALDH	 activity	 should	 be	 observed	 through	 Aldefluor™	 analysis.	
A375	cells	treated	with	RC-NFN5	were	subjected	to	the	Aldefluor™	assay,	against	DEAB	and	
vehicle	 (1%	 DMSO),	 to	 analyse	 intercellular	 ALDH	 activity.	 After	 24hrs	 of	 treatment	with				
RC-NFN5,	A375	cells	had	a	dramatic	reduction	in	Aldefluor™	activity	(Figure	5.10A)	where	
approximately	100%	of	Aldefluor™	activity	was	ablated,	comparable	to	that	seen	with	24hrs	
of	NFN1	 treatment	 (Figure	 3.6).	 To	 reaffirm	 this	 finding,	 in	 vitro	 assays	 were	 set	 up	 to	
analyse	whether	RC-NFN5	was	a	substrate	for	both	ALDH2	and	ALDH1A3.	As	before,	ALDH	
enzymes	 were	 pre-incubated	 with	 NAD+	 and	 RC-NFN5,	 where	 enzymatic	 activity	 was	
determined	using	NADH	turnover	at	λ	=	340nm	(ε	=	6220M-1cm-1)	after	10mins.	For	ALDH2	
assay,	RC-NFN5	 treatment	was	 compared	 against	NFN1,	NFN1.1,	 known	 ALDH2	 inhibitor	
daidzin	 and	 vehicle	 (1%	DMSO).	RC-NFN5	 treatment	 resulted	 in	 a	 significant	 reduction	 in	
ALDH2	 activity	 (Figure	 5.10B,	 P	 =	 0.005)	 where	 76.2%	 reduction	 in	 ALDH1A3	 activity	 in	
observed.	 Treatment	 with	 NFN1	 and	 daidzin	 also	 resulted	 in	 a	 significant	 reduction	 in	
ALDH2	activity	 (P	=	0.005	&	P	=	0.014	 respectively)	 as	expected.	 For	 the	ALDH1A3	assay,				
RC-NFN5	 treatment	 was	 compared	 against	 NFN1	 and	 vehicle	 (1%	 DMSO)	 only.	 Both										





for	ALDH	enzymes	both	 in	vivo	 and	 in	vitro.	Although	RC-NFN5	does	not	have	 the	ALDH1	
selectivity	 as	 seen	with	NAZ,	 it	 still	 proves	 to	 be	 an	 effective	 novel	 5-NFN	 compound	 in	




potential	 both	 in	 increasing	 potency	 against	 cancer	 cells	 and	 ALDH1	 selectivity.	 Another	
factor	 in	 which	 RC-NFN5	 highlights	 the	 need	 for	 new	 5-NFN	 compounds	 is	 through	





























histogram	 counts	 of	 A375	melanoma	 cells	 treated	 with	RC-NFN5.	 DMSO	 (light	 blue)	 positive	 and	
DEAB	 (green)	 negative	 controls.	 DMSO	 and	 DEAB	 treated	 A375	 cells	 assumed	 100%	 and	 0%	
Aldefluor™	 activity	 respectively.	 Aldefluor™	 activity	 of	 A375	 cells	 after	 2hrs	 RC-NFN5	 (dark	 blue)	






























was	also	coupled	with	weak	Aldefluor™	activity	and	 in	vitro	 evidence	 that	NFX	 could	also	
potently	 inhibit	 ALDH	 enzymes	 in	 the	 same	 regard	 as	NFN1.	 Through	 a	 small	 screen	 of	
clinical	 5-NFNs,	NAZ	was	discovered	 to	have	 similar	 anti-cancer	 properties	 to	NFN1,	with	
evidence	through	Aldefluor™	that	ALDH	inhibition	upon	bio-activation	of	the	drug	 is	seen.	
Importantly,	NAZ	was	not	a	substrate	for	ALDH2,	and	as	such	exhibited	selectivity	 for	the	
ALDH	 isoform	 most	 associated	 with	 CSC-characteristic	 in	 melanoma,	 ALDH1.	 Finally,	 I	
synthesised	a	novel	bis-5-NFN	compound,	RC-NFN5,	displaying	potent	anti-cancer	activity	
and	can	strongly	 inhibit	ALDH,	by	Aldefluor™,	similarly	to	NFN1.	These	findings	describe	a	
clinical	 compound	 that	 has	 the	 potential	 to	 be	 repurposed	 for	 use	 as	 an	 anti-cancer	
therapeutic,	which	 is	not	only	 improved	 from	NFX,	 the	5-NFN	currently	 in	clinical	 trial	 for	






































occurs	 by	 addition	 of	 a	 hydrogen	 on	 the	 2-amido-pyridine	 ring	 terminus,	 at	 the																
para-position	 to	 the	 nitrogen	 (Figure	 6.1).	 This	 mechanism	 is	 somewhat	 similar	 to	 the	
chemistry	expected	in	the	bio-activation	of	5-NFNs	by	ALDH;	where	5-NO2	reduction	is	likely	
driven	 by	 hydrogen	 addition	 (or	 substitution)	 on	 the	 heterocyclic	 aromatic	 ring.	 I	
hypothesise	that	5-NFNs	will	be	bio-activated	by	the	catalytic	cysteine	present	in	the	ALDH	
active	 site,	 where	 bio-activation	 of	 5-NFNs	 by	 ALDH	 enzymes	 is	 driven	 by	 5-NFNs	





modelling,	 preliminary	 enzymatic	 trials	 and	mass	 spectrometry;	 working	 in	 collaboration	
with	 both	 the	 Institute	 of	 Structural	 and	Molecular	 Biology	 (University	 of	 Edinburgh,	UK)	
and	Center	 for	 Structural	Biology	 (University	of	 Indiana,	USA).	 I	 report	5-NFNs	 can	 tightly	
bind	in	the	ALDH	binding	pocket,	through	computational	simulations,	with	the	potential	for	
these	compounds	to	interact	with	the	active	cysteine	residue.	I	show	that	NAD+	is	vital	for	
5-NFN	 activity,	 mediating	 an	 oxidation	 on	 the	 catalytic	 cysteine,	 as	 determined	 by	mass	



































6.2	 Theoretical	 docking	 studies	 suggests	 ALDH	 enzymes	 potentially	 bind																		
5-nitrofurans	at	the	NAD+	binding	pocket.	
	






Houston	 (Institute	 of	 Structural	 &	 Molecular	 Biology,	 University	 of	 Edinburgh,	 UK).	
Modelling	was	performed	using	 the	 structure	of	ALDH1A1,	 solved	previously.145	ALDH1A3	
could	not	be	modelled,	as	its	structure	has	yet	to	be	determined	and	published.	ALDH1A1	




NFN1.1).	 Theoretical	 dissociation	 constants	 (Tkd)	 were	 determined	 and	 expressed	 in	
kcal/mol,	where	a	shift	of	1kcal/mol	translates	to	a	10-fold	reduction	in	Tkd.	It	appears	the	










of	 the	 5-NO2	moiety	 being	 able	 to	 couple	 to	 residues	 in	 the	 pockets.	 The	 docking	 of	 the						
5-NFNs	in	the	NAD+	binding	pocket	using	AutoDock	4.2.3	(Table	6.1B)	displayed	a	significant	
loss	 of	 affinity	 in	NFN1.1,	 in	 comparison	 to	 the	 other	 three	 5-NFNs.	 	 This	 supports	 data	
observed	experimentally,	where	NFN1.1	has	no	effect	of	ALDH	activity	(Chapter	3),	and	the	
slight	 loss	 of	 affinity	 displayed	 by	 NFX,	 also	 couples	 with	 the	 reduction	 in	 NFX	 activity	
reported	 in	 Chapter	 5.	 Although	 AutoDock	 quotes	 an	 approximate	 error	 margin	 of	
2.5kcal/mol	 (AutoDock4.2.3	 UserGuide),	 the	 loss	 of	 affinity	 observed	 theoretically	 upon	
removal	 of	 the	 5-NO2	 moiety	 (NFN1	 -8.19kcal/mol	 vs	 NFN1.1	 -6.37kcal/mol	 -																							
ΔTkd	 =	 1.89kcal/mol)	 is	 a	 large	 enough	 margin	 to	 confidently	 predict	 what	 is	 expected	
practically.	 Upon	 rendering	 how	 the	 5-NFNs	 interact	 with	 the	 structure	 of	 ALDH1A1	
(Figures	6.2A-D)	 it	 is	clear	that	interactions	between	asparagine	and	lysine	residues	in	the	
ALDH	binding	pocket,	and	the	NO2	moiety	is	crucial	for	the	high	affinity	of	5-NFNs	towards	
ALDH	 enzymes.	 Considering	 the	 structural	 similarities	 of	 NFN1.1	 to	 NFN1,	 it	 could	 be	
expected	that	NFN1.1	would	show	some	degree	of	reduction	in	ALDH	activity.	However,	as	
this	interaction	between	NO2	and	ALDH	is	lost	with	NFN1.1	and	offers	an	explanation	as	to	
why	 no	 reduction	 in	 ALDH	 activity	 is	 seen	 upon	 NFN1.1	 treatment.	 This	 highlights	 the	





pocket,	 where	 interactions	 between	 ALDH	 residues	 and	 NO2	 may	 contribute	 to	 the	































Table	 6.1:	 Theoretical	 dissociation	 constants	 (Tkd)	of	binding	between	5-NFNs	and	ALDH1A1.	Both	
AutoDock	4.2.3	ad	AutoDock	Vina	were	used	for	all	computational	simulations.	5-NFNs	(NFN1,	NAZ,	
NFX	 and	NFN1.1)	 were	 docked	 against	 both	 catalytic	 and	 co-factor	 binding	 pockets.	A)	 ‘Docking’	
studies	of	5-NFNs	in	the	substrate	binding	pocket	of	ALDH1A1.	AutoDock	Vina	presents	the	strongest	
theoretical	dissociation	constants	for	5-NFNs	binding	in	this	pocket.	B)	‘Docking’	studies	of	5-NFNs	in	
the	 co-factor	 binding	 pocket	 of	 ALDH1A1.	 AutoDock	 4.2.3	 presents	 the	 strongest	 theoretical	










Figure	 6.2:	 Theoretical	 molecular	 docking	 of	 5-NFNs	 in	 the	 NAD+	 binding	 pocket	 of	 ALDH1A1,	
rendered	 by	 PyMol.	 Docking	 studies	 highlight	 important	 interaction	 between	 5-NO2	 moiety	 and	
Asparagine	 and	 Lysine	ALDH	 residues	 in	 the	 co-factor	 pocket.	Molecules	 also	 sit	 close	 in	 space	 to	
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production	 can	 be	 monitored	 using	 absorbance	 (λ=340nm)	 to	 determine	 ALDH	 activity.	
Upon	pre-incubation	with	5-NFNs,	ALDH	activity	is	lost.	If	5-NFNs	are	binding	into	the	NAD+	
cofactor	binding	pocket,	and	5-NO2	reduction	is	being	driven	by	hydride-transfer	from	the	
aldehyde,	 this	 suggest	NAD+	will	 not	be	 required	 for	5-NFN	bio-activation.	 To	preliminary	
probe	the	mechanism	in	which	5-NFNs	interact	with	ALDH,	the	in	vitro	enzymatic	assay	with	
ALDH2-His	 was	 repeated,	 however,	 different	 combinations	 of	 acetaldehyde	 (substrate),	





























Catalytic	 activity	 was	 initiated	 after	 10mins	 upon	 addition	 of	 the	 remaining	 substrates.	
Enzymatic	 activity	 was	 monitored	 via	 NADH	 production	 (λ	 =	 340nm,	 ε	 =	 6220M-1cm-1)	 and	
enzymatic	 rate	 determined	 by	 initial	 linear	 turnover.	 ALDH2-His	 activity	 is	 significantly	
reduced	by	NFN1	treatment	in	the	majority	of	activity	conditions	(Figure	6.3:	P	<	0.0001	–	P	
=	0.08),	highlighting	5-NFNs	as	competitive	substrates	for	ALDH2-His	in	vitro.	However,	the	




NFN	 activity	 towards	 ALDH2-His	 (Δ	 =	 88.1%	 AcAld	 initiate	 vs	 Δ	 =	 41.3%	 -	 AcAld	 +	 NAD+	
initiate,	next	best).	NAD+	 is	needed	 to	bind	preliminarily	 to	ALDH	 in	 the	co-factor	binding	
pocket,	 in	 order	 to	 mitigate	 a	 conformational	 change	 and	 activate	 the	 catalytic	
cysteine.2,11,12	 As	 it	 is	 clear	 ALDH	 enzymes	 need	 pre-incubation	 with	 NAD+	 and	NFN1	 to	
mediate	 5-NFN	 bio-activation,	 it	 is	 likely	 that	 co-factor	 binding	 is	 required	 in	 order	 to	
activate	 the	 ALDH	 enzyme,	 for	 5-NFN	 bio-activation	 to	 occur,	 as	 during	 its	 natural	
functionality.	 Although	 this	 contradicts	 predictions	 drawn	 from	 the	 previous	 in	 silico	

























Pre-set	 NAD+	 AcAld	 AcAld	 NAD+	 AcAld	 Drug	 None	
(10mins)	 Drug	 Drug	 NAD+	 	 	 	 	
Initiator	 AcAld	 NAD+	 Drug	 AcAld	 NAD+	 AcAld	 All	3	
	 	 	 	 Drug	 Drug	 NAD+	 	
	





















ALDH2-His	 was	 not	 initiated	 by	 acetaldehyde	 addition.	 Instead,	 NADH	 production	 was	
monitored	(λ	=	340nm,	ε	=	6220M-1cm-1)	with	only	NAD+	and	NFN1	present,	to	assess	whether	
reduction	of	NAD+	by	ALDH2	is	required	for	5-NFN	activity.	Traces	of	NADH	production	over	
time	exhibited	no	production	of	NADH	after	 treatment	with	NFN1	 (Figure	 6.4).	 As	NADH	
production	 is	 driven	 by	 hydride	 transfer	 from	 acetaldehyde	 in	 ALDH2	 normal	
functionality,2,11,12	it	suggests	that	NAD+	is	required	only	for	ALDH	structural	conformational	









































6.4	 5-Nitrofuran	 bio-activation	 leads	 to	 covalent	 oxidation	 on	 catalytic	 ALDH	
cysteine	
	
Insights	 from	 the	 Aldefluor™	 assay	 suggest	 that	 5-NFNs	 have	 the	 potential	 to	 potently	
inhibit	 ALDH	 activity	 in	 A375	melanoma	 cells.	 Such	 potent	 inhibition,	 in	 comparison	 to	 a	
known	reversible	 inhibitor	DEAB	(Figure	3.6),	could	arise	 from	a	covalent	 interaction	with	
ALDH	enzymes,	denaturing	functional	activity.	This	hypothesis	is	supported	by	the	extent	in	
which	 ALDH	 activity	 is	 inhibited	 by	 5-NFNs,	where	 recovery	 of	 activity	was	 not	 observed	




6.4.1	 ALDH	 enzymes	 are	 oxidized	 by	 5-nitrofuran	 treatment,	 only	 when	 NAD+	 is	
present.	
	




enzymes,	 in	 vitro	 enzymatic	 assays	 were	 subjected	 to	 whole	 protein	 mass	 spectrometry	










mass	 increase	 of	 31amu	 and	 338.02amu.	 The	 increase	 of	 31amu	 is	 likely	 as	 a	 result	 of	 a	
double	oxidation	substituted	on	an	active	hydrogen	[ALDH2+O2-H],	likely	the	active	cysteine	









to	 act	 solely	 as	 a	 tightly	 bound	 inhibitor	 of	 ALDH2,	 it	 would	 not	 describe	 why	 a	 double	
oxidation	adduct	is	also	produced.	As	ESI	is	a	‘soft’	ionisation	technique,	which	is	employed	
due	to	the	reduction	in	fragmentation	to	study	whole	protein	mass	shifts,	it	can	also	detect	
masses	 of	 small	 molecules	 that	 are	 tightly	 bound	 to	 proteins	 through	 non-covalent	
interactions.184	 Considering	 the	 results	 from	 theoretical	 binding	 studies	 previously	 in	 this	
chapter,	 describing	 5-NFNs	 having	 the	 potential	 to	 tightly	 bind	 in	 both	 the	 catalytic	 and					
co-factor	binding	pockets	of	ALDH,	it	is	likely	this	mass	shift	is	associated	with	a	tight,	non-









marker,	 ALDH1A1,79	 is	 treated	with	 5-NFNs,	 the	 experiment	was	 repeated	with	ALDH1A1	




is	 double	 oxidized	 by	 treatment	 with	NFN1.	 In	 comparison	 to	 ALDH2,	 displaying	 far	 less	
efficiency	 in	 double	 oxidizing,	 this	 indicates	 that	NFN1	 is	much	more	 efficacious	 towards	
ALDH1A1.	 Interestingly,	NAZ	 and	NFX	 also	 appeared	 to	 exhibit	 a	 similar	 yet	 subtle	mass	
shift	 upon	 treatment	 on	 ALDH1A1.	 This	 gives	 an	 indication	 that	NAZ	 and	NFX	 can	 also	
interact	with	ALDH1A1,	and	facilitate	ALDH1A1	enzymes	to	undergo	double	oxidation.	The	
ability	for	NAZ	to	oxidise	ALDH1A1	over	ALDH2	is	supported	by	what	was	observed	in	vitro	
(Chapter	 5),	 where	NAZ	 appears	 to	 exhibit	 some	 specificity	 towards	 ALDh1	 enzymes.	 As	
NFX	could	also	oxidise	ALDH1A1,	it	also	suggests	that	NFX	has	a	greater	affinity	for	ALDH1	















































































































5-NFNs.	 As	 such,	 it	 would	 be	 appropriate	 to	 assume	 that	 modifications	 in	 protein	 mass	
associated	 with	 5-NFN	 treatment	 will	 also	 depend	 on	 NAD+	 being	 present.	 To	 confirm	
whether	 NAD+	 is	 important	 for	 these	 modifications,	 in	 concurrence	 with	 the	 in	 vitro	
reaction	 order	 analysis,	 the	 ESI	 Q-TOF	 MS	 assay	 was	 repeated	 with	 both	 ALDH2	 and	
ALDH1A1	in	the	absence	of	NAD+.	Neither	ALDH2	nor	ALDH1A1	(Figure	6.7)	resulted	in	any	
alteration	 in	 protein	 mass	 upon	 treatment	 with	 all	 5-NFNs	 compared	 to	 native	 enzyme					
(1%	 DMSO).	 This	 indicates	 that	 the	 double	 oxidation	 on	 ALDH2	 and	 ALDH1A1	 by	 5-NFN	
treatment	is	dependent	on	the	presence	of	NAD+,	where	the	whole	compound	interaction	
between	NFN1	and	ALDH2	was	also	not	observed	without	NAD+.	This	suggests	that	NAD+	is	







is	 also	 essential	 for	 5-NFN	 bio-activation.	 Comparatively,	 in	 silico	 data	 performed	 by												
Dr	 Douglas	 R.	 Houston,	 also	 suggested	 5-NFNs	 will	 ‘fit’	 close	 in	 space	 to	 this	 catalytic	
cysteine	 also.	 As	 such,	 I	 hypothesised	 that	 the	 observed	 oxidation	 of	 ALDH	 by	 5-NFNs,	
performed	 Professor	 Thomas	 D.	 Hurley,	 will	 likely	 be	 mediated	 by	 modification	 on	 this	
residue	 (Cys302).	 	 In	 order	 to	 determine	 the	 mechanism	 by	 which	 ALDH	 enzymes	 are	





Edinburgh,	 UK),	 purified	 ALDH2-His	 samples	were	 prepared	 upon	 treatment	with	 5-NFNs	
(NFN1,	NFN1.1,	 RC-NFN5,	 RC-NFN5.1	 and	NFX)	 and	 incubated	 in	 the	 presence	 of	 NAD+.	
Samples	 were	 then	 digested	 and	 subjected	 to	 quadrupole-orbitrap	 mass	 spectrometer	
analysis.	Probing	the	amino	acid	sequence	containing	the	catalytic	cysteine	(Cys302)	found	
a	 triple	 oxidisation	 on	 the	 Cys302	 (Figure	 6.8	 –	 y6		 y7:	 Δ	 =	 151amu	 (Cys+3O2-H2O)).	








increase	 in	 TripOx	 species	 upon	 treatment	with	no-nitro	 controls	 (NFN1.1	&	RC-NFN5.1),	
which	 were	 also	 significantly	 less	 than	 their	 nitro	 counterparts	 (P	 =	 0.004	 &	 P	 <	 0.0001	
respectively).	 It	was	 interesting	 to	observe	 the	 increase	 in	TripOx	species	upon	treatment	
with	NFN1,	without	NAD+	present,	in	contrast	to	both	the	5-NFN-ALDH	order	activity	assay	
and	mass	 spectrometry	 work	 by	 Professor	 Thomas	 D.	 Hurley,	 that	 conclude	 presence	 of	
NAD+	 is	 essential	 for	 both	 5-NFN	 activity	 and	 ALDH	 oxidation.	 However,	 the	 increase	 of	
TripOx	 species	upon	NFN1	 treatment,	without	NAD+	present,	 is	 still	 significantly	 less	 than	
when	 both	 NAD+	 and	NFN1	 were	 present	 (P	 =	 0.016).	 This	 suggests	 that,	 while	 NAD+	 is	
required	 for	 cysteine	 activation,	 there	 may	 be	 some	 residual	 ALDH	 activity	 that	 can	
potentially	bio-activate	5-NFNs,	 leading	 to	 this	 small	 increase	 in	TripOx	 species	observed.	
Although,	as	treatment	of	ALDH2-His	with	NAZ,	shown	in	Chapter	5	not	to	be	a	substrate	
for	ALDH2,	also	resulted	in	an	increase	of	TripOx	production,	this	suggests	that	treatment	of	
ALDH2-His	 with	 any	 5-NFN	 (or	 indeed	 any	 small	 molecule)	 could	 promote	 some	 minor	
TripOx	 species	 promotion.	 However,	 it	 is	 clear	 that,	 in	 the	 presence	 of	 NAD+,	 5-NFN	
treatment	significantly	increased	TripOx	species	formation	(with	nearly	all	ALDH2-His	triple	








Professor	 Thomas	 D.	 Hurley’s	 work	 previous.	 The	 discrepancy	 between	 the	 two	 mass	
spectroscopy	data	could	be	as	a	result	of	differing	methodologies	and	ionisations,	owing	to	
the	resultant	cysteine	oxidative	state.	However,	both	data	sets	suggest	a	covalent,	oxidative	
modification	 on	 the	 catalytic	 cysteine	 of	 ALDH2	 upon	 5-NFN	 treatment.	 Structural	













































Figure	 6.9:	 Ratio	 of	 triple	 oxidised	 (TripOx)	 ALDH2-His	 species	 comparable	 to	 total	 ALDH2-His	
isoforms	present	in	mass	spectrometry	spectral	analysis.	Control,	NAD+	only	(black),	has	little	TripOx	
species	present.	Addition	of	5-NFNs	significantly	 increased	TripOx	species	production	compared	 to	
control	 (P	 <	 0.0001	 by	 ANOVA,	 not	 shown),	 with	NFN1+NAD+	 (dark	 orange)	 showing	 the	 largest	
increase	of	average	78%	total	population.	NFN1	only	(light	orange)	also	showed	a	significant	increase	
in	 TrpOx	 species	 production,	 however	 this	 was	 significantly	 lower	 than	 NFN1+NAD+	 samples															










































Here	 I	 demonstrate	 that	 NAD	 is	 required	 for	 5-NFN-ALDH	 activity,	 where	 NAD	 is	 likely	
needed	as	a	structural	co-factor	in	order	to	drive	activity	of	ALDH	enzymes	towards	5-NFNs.	
Although	 this	 was	 surprising	 considering	 computational	 docking	 studies	 suggest	 that												
5-NFNs	 would	 bind	 tightly	 in	 the	 NAD	 co-factor	 binding	 pocket,	 where	 theoretical	
dissociation	 constants	 were	 in	 keeping	 with	 experimental	 data.	 Through	 utility	 of	 mass	
spectrometry,	 I	 show	 in	 collaboration	 that	 5-NFNs	 are	 substrates	 for	ALDH	enzymes,	 and	
upon	bio-activation,	can	covalently	modify	ALDH	enzymes	through	oxidation	at	the	catalytic	
cysteine	 (Figure	 6.11).	 Although	 the	 exact	 mechanism	 of	 the	 oxidation	 has	 yet	 to	 be	





Figure	6.11:	Schematic	of	 the	mechanism	of	5-NFN-ALDH	activity.	NAD+	 is	 required	as	a	structural			
co-factor,	 binding	 to	 ALDH	 prior	 to	 5-NFN	 bio-activation.	 5-NFN	 are	 bio-activated	 to	 drive	 cell	











































































































isoforms	 present	within	 cells,	 all	 of	which	 potentially	 contribute	 to	 5-NFN	 bio-activation.	
Assessing	the	ALDH	expression	of	all	19	isoforms	in	a	panel	of	cell	lines	and	conditions	can	
potentially	 provide	 an	 idea	 of	 the	 cellular	 ALDH	environment	 and	how	 this	 varies	 due	 to	







sorted	 high	 vs	 low	 Aldefluor™	 treated	 cells	 (A375,	 A2780	 and	 HCT116)	 against	 the	 non-
treated	 equivalents.	 GAPDH,	 18S	 and	 TBP	 were	 used	 for	 reference	 genes.	 Expressed	 as	
heatmaps,	Δct	 (difference	 in	 cycle	 threshold)	 values	were	 calculated	 through	exponential	
expression	comparable	to	reference	gene	expression.	Δct	values	were	determined	by:	
	
∆"# $%&% = "# ()*+,% − "#(/%0%/%&"%)	
	
Where	 a	 lower	 Δct	 value	 (red)	 indicates	 higher	 gene	 expression	 and	 a	 higher	 Δct	 value	
(blue)	indicates	lower	gene	expression.	
	
To	 explore	 whether	 expression	 of	 specific	 ALDH	 isoforms	 in	 the	 cancer	 cell	 lines	 used	
correlated	with	 their	 sensitivity	 to	 5-NFNs,	 as	well	 as	 to	 determine	which	ALDH	 isoforms	
played	a	major	role	 in	Aldefluor™	activity,	 the	ALDH	environment	 for	these	samples	were	
characterised.	As	expected,	ALDH1A3	was	one	of	the	dominant	ALDH	isoforms	in	the	A375	








other,	 more	 highly	 expressed	 ALDH	 isoforms	 in	 the	 cell	 environment	 that	 could	 be	
contributing	to	5-NFN	toxicity.	
	
It	was	surprising	 to	observe	 the	 low	 levels	of	ALDH1A1	expression	across	all	 cell	 samples,	
especially	 considering	 its	 supposed	 high	 expression	 in	 CSCs	 across	 nearly	 all	 tumour	
types.31,75	 A	 partial	 explanation	 lies	 in	 that	 because	 only	 a	 small	 subpopulation	will	 have	
high	ALDH1A1	expression,	i.e.	the	CSC	niche,	owing	to	such	low	total	expression.	However,	
it	could	also	be	indicative	that	not	all	cancer	cell	populations	follow	this	trait	of	ALDH1A1	as	
a	CSC	marker	as	 so	previously	universally	 coined,44	 reflecting	 the	more	 realistic	 view	 that	
cancer	 phenotypes	 vary	 between	 patients.	 This	 is	 also	 further	 supported	 by	 cross-
examination	with	the	Sanger	melanoma	cell	 line	panel,	where	ALDH1A1	expression	varies	
quite	widely	between	all	22	samples.	Moreover,	in	the	A375	melanoma	cell	line,	it	has	been	
reported	 that	 ALDH1A3,	 not	 ALDH1A1,	 is	 the	 predominant	 ALDH	 CSC	 marker.	 This	 also	
helps	to	explain	why	ALDH1A1	expression	was	not	detectable	by	western	blot	in	A375	cells.	
	
Considering	A2780	cells	especially,	which	were	highly	 sensitive	 to	5-NFNs,	 it	 is	difficult	 to	
extract	which	ALDH	 enzymes	 are	 contributing	more	 extensively	 to	 5-NFN	 sensitivity	 than	






and	 24hrs	 post	 treatment	 and	 submitted	 for	 RT-qPCR	 analysis.	 When	 A375	 cells	 were	
treated	with	5-NFNs,	known	ALDH	inhibitors,	the	natural	substrate	acetaldehyde	or	DMSO	
alone,	 there	 is	 no	 change	 in	 the	 ALDH	 expression	 pattern	 –	 both	 2hrs	 and	 24hrs	 post	
treatment	(Figure	7.1B).	After	2hrs	of	treatment	with	NFN1,	a	sharp	 increase	 in	ALDH5A1	
(succinate	 semialdehyde	 dehydrogenase)	 expression	 is	 seen,	 however	 is	 not	 prolonged	
after	 24hrs.	 This	 may	 be	 indicative	 of	 an	 initial	 cellular	 response	 to	 ROS-induced	 stress,	
however,	there	 is	no	evidence	that	ALDH5A1	plays	a	role	 in	cellular	response	to	oxidative	
stress.84	 It	was	 also	 noteworthy	 to	 see	 that	 expression	 levels	 of	 ALDH	 overall	 seemed	 to	
















a	 single	 point	 in	 time	 for	 each	 condition	 (n=1).	 Although	 replicate	 values	 were	 taken	 in	
triplicate	for	each	sample,	thus	improving	the	overall	accuracy	of	the	ALDH	expression	data,	
the	samples	themselves	still	only	represent	a	single	point	 in	time	and	as	such,	 it	could	be	
possible	 to	 be	 drawing	 a	 conclusion	 from	 an	 anomaly.	 The	 sharp	 but	 acute	 increase	 of	
ALDH5A1	 expression	 in	 A375	melanoma	 cells,	 2hrs	 after	NFN1	 treatment,	may	 not	 truly	
reflect	 the	normal	 response	of	A375	cells	 to	NFN1	 treatment,	 and	ALDH5A1	 is	 irregularly	
upregulated	in	this	sample.	Therefore,	although	this	data	does	gives	good	indication	of	the	
ALDH	expression	behaviour	for	these	samples	and	conditions,	 it	 is	 impossible	to	draw	any	
significant	conclusions	without	further	probing	whether	ALDH	expression	is	consistent	upon	
replication.	 Further	 analysis	 using	 replicate	 samples	would	be	 required	 to	 confirm	all	 the	
findings	 above,	 however,	 this	 data	 has	 already	 provided	 some	 indication	 about	 the	














This	data	 reflects	 the	ALDH	profile	of	 the	cancer	 cell	 line	population	whole.	While	 it	may	
prove	 a	 useful	 in	 determining	which	 ALDH	 enzymes	 are	 potentially	 contributing	 towards	
overall	5-NFN	cancer	 cell	 toxicity,	 it	provides	 little	evidence	 towards	whether	5-NFNs	can	
specially	target	the	ALDH+	subpopulation.	This	may	help	explain	why	it	is	difficult	to	extract	
which	 ALDH	 isoforms	 directly	 contribute	 to	 5-NFN	 sensitivity.	 As	 described	 in	Chapter	 4,					
5-NFN	 toxicity	 can	differ	within	 subpopulations	of	a	heterogeneous	 tumour,	 so	while	 this	
screen	 provides	 an	 insight	 into	 the	 whole	 cell	 population	 ALDH	 expression,	 it	 does	 not	
reflect	 how	 subpopulations	 of	 cancer	 cells	 will	 differ	 in	 both	 their	 ALDH	 expression	 and	
consequent	5-NFN	 sensitivity.	 It	will	 be	 thus	 incredibly	useful	 to	 characterise	 these	ALDH	
environments,	however,	experiments	whereby	the	ALDH+	is	 isolated,	analysed	for	CSC-like	
behaviour	 and	 assessed	 for	 5-NFN	 sensitivity,	 would	 prove	 more	 useful.	 As	 such,	 ALDH	
characterisation	between	these	ALDH+	and	ALDH-	counter	population	will	provide	a	much	








Zhuo	 et	 al.	 (2012)	 previously	 reported	 that	 Aldhb	 is	 the	 primary	 substrate	 for	 5-NFNs	 in	
zebrafish	melanocytes,	using	a	biotinylated-based	pulled	down	assay.	 In	melanoma	cells,	 I	
have	 already	 shown	 that	 5-NFNs	 are	 competitive	 substrates	 for	 ALDH1A3	 and	 ALDH2.	
However,	there	are	19	ALDH	isoforms	in	human	cells,	all	with	the	potential	to	bio-activate	




their	 HaloTag	 system,185	 where	 a	 chloroalkane	 PEG-linker	 is	 attached	 to	 the	 5-NFN	
compound	of	interest	and	validated	by	proteomic	MS,	the	full	target	spectrum	for	5-NFNs	
can	 be	 characterised.	 This	will	 not	 only	 provide	 full	 identification	 of	 all	 ALDH	 targets	 for							
5-NFNs,	 but	 also	 other	 side-targets	 potentially	 contributing	 to	 the	 anti-cancer	 activity	 of	







When	 considering	which	 ALDH	 enzymes	 can	 bio-activate	 5-NFN	 and	 contribute	 to	 5-NFN	
toxicity,	 it	 is	 possible	 to	detail	which	 cancers	may	also	benefit	 from	5-NFN	 treatment.	As	
previously	 reported,44	 cancers	 have	 differing	 expression	 of	 specific	 ALDH	 isoforms	 that	
contribute	 to	 CSC	 activity.	 Determining	 which	 ALDH	 enzymes	 may	 bio-activate	 5-NFNs	
would	give	some	indication	which	cancers	may	also	benefit	from	5-NFN	treatment.	 I	have	
already	 shown	 in	 previous	 chapters	 that	 5-NFN	 compounds,	 both	 clinical	 and	 synthetic,	
have	 potent	 anti-cancer	 activity	 in	 other	 tumour	 types.	 Considering	 ALDH	 activity	 is	
associated	with	a	wide	range	of	different	cancers,2,80	particularly	ALDH1A1;44	which	I	have	
already	described	as	a	target	for	NFN1,	it	is	likely	that	as	research	into	the	use	of	5-NFNs	as	
potential	 anti-cancer	 therapeutics	 continues,	 their	 application	of	numerous	 tumour	 types	
will	 develop,	 determined	 by	 ALDH	 status.	 If	 the	mode	 of	 binding	 can	 be	 determined	 for	
each	 5-NFN	 (either	 computationally	 or	 more	 favourably	 through	 crystallography)	 tagged					
5-NFNs	 can	 be	 designed	 that	 can	 potential	 lessen	 the	 interferences	 the	 tag	may	 have	 to	
normal	5-NFN	 functionality,	 and	give	a	 realistic	picture	of	 the	 target	profile	 for	 individual					






can	 drive	 cancer	 cell	 toxicity,	 and	 whether	 these	 side-targets	 can	 also	 be	 exploited	 to	
develop	 more	 potent	 5-NFN	 compounds.	 In	 the	 case	 of	 NAZ,	 tumours	 with	 both	 high	
ALDH1A	and	STAT3	status	should	be	much	more	sensitive	to	treatment.	As	such,	designing	




















Figure	 7.2:	 Resolution	 of	 ALDH2	 crystals	 diffracted	 too	 low	 for	 conclusive	 structure	 solution.													
A)	 Photograph	 of	 purified,	 untagged	 ALDH2	 crystal	 mounted	 prior	 to	 diffraction	 by	 synchrotron.	
Crystals	were	left	to	soak	in	5-NFNs	for	1hr	in	preparation,	where	it	was	noted	the	drug	concentrated	
within	the	crystal.	B)	Diffraction	pattern	from	diffracted	ALDH2	crystal.	Resolution	was	too	 low	for	





main	 driver	 of	 5-NFN	 toxicity	 in	 A375	 melanoma	 cells.	 We	 hypothesise	 that	 ALDH1A3	
should	 interact	 with	 5-NFNs	 in	 a	 similar	 mechanism	 that	 is	 expected	 with	 ALDH2.	 Mass	
spectrometry	 (ESI	 QTOF	MS)	 data	 from	 Professor	 Thomas	 D.	 Hurley	 highlighted	 a	 much	
stronger	double	oxidation	of	ALDH1A1	upon	5-NFN	bio-activation,	where	almost	no	native	
ALDH1A1	 was	 observed	 after	 treatment.	 Further,	 my	 work	 from	 Chapter	 4	 described	





this,	 it	 is	 likely	to	assume	that	5-NFN	bio-activation	can	cause	 inhibition	of	ALDH1A3	(and	
indeed	ALDH1A1	also)	 through	oxidation	of	a	catalytic	cysteine.	To	assess	 for	 this,	solving	
the	 structure	 of	 ALDH1A3	 upon	 treatment	 with	 5-NFNs	 will	 give	 the	 likely	 modification	
(covalent	or	otherwise)	that	renders	this	potent	inhibition	of	ALDH1A3	by	5-NFNs.	It	is	also	
hypothesised	 that	 the	 structural	 data	 will	 also	 give	 key	 indication	 to	 how	 ALDH1A3	 can				




5-NFNs,	 is	 that	 crystallisation	 conditions	 have	 yet	 to	 be	 published.	 Although	 it	 may	 be	
possible	 to	 use	 the	 crystal	 conditions	 for	 ALDH1A1	 as	 a	 template,	 considering	 their	
structural	similarities,11,152	it	will	still	present	a	lot	of	optimisation	and	there	is	no	guarantee	












CSC-like	 properties.	 To	 assess	 whether	 or	 not	 the	 cells	 being	 targeted	 by	 5-NFNs	 in	
melanoma	are	associated	with	CSC-like	behaviour,	it	is	possible	to	sort	melanoma	cells	into	








ALDH+	 subpopulation	 is	 more	 ‘stem-like’	 than	 its	 ALDH-	 counterpart,	 where	 the	 ALDH+	
subpopulation	 is	 expected	 to	 have	 significantly	 increased	 colony	 and	 sphere	 formation.	
From	 this,	 the	 sensitivity	 of	 the	 two	 populations	 to	 5-NFNs	 can	 be	 assessed,	 where	 it	 is	
likely	that	ALDH+	melanoma	cells	will	be	more	sensitivity	to	5-NFN	treatment.	This	will	thus	
represent	 whether	 or	 not	 ALDH+	 cells,	 sorted	 by	 Aldefluor™,	 are	 likely	 to	 contain	 the	
melanoma	CSC	subpopulation	and	if	these	cells	are	more	sensitive	to	5-NFNs.	This	can	then	




whether	sorted	CD271+	melanoma	also	correlated	with	ALDH	expression,	and	 if	so,	 I	 then	
hypothesise	 the	 CD271+	 subpopulation	 of	 melanoma	 cells	 should	 therefore	 be	 more	
sensitive	 to	 5-NFN	 treatment.	 This	 would	 help	 determine	 and	 characterise	 the	 CSC-nice	
more	 precisely	 within	 melanoma	 cells,	 while	 also	 serving	 to	 conclusively	 describe	 how									
5-NFNs	can	target	this	CSC	subpopulation.	
	
The	 gold	 standard	 assay	 for	 detection	 of	 CSCs	 is	 through	 transplantation	 into	
immunosuppressed	mice.27	 By	 transplanting	 both	 ALDH+	 and	 ALDH-	 melanoma	 cells	 into	
NOD/SCID	 mice,	 and	 monitoring	 tumour	 formation,	 it	 will	 be	 possible	 to	 determine	
whether	 the	 ALDH+	 cells	 are	 more	 tumorigenic,	 as	 thus,	 contain	 the	 melanoma	 CSC	
subpopulation.	This	can	be	determined	if	ALDH+	xenographs,	in	comparison	to	ALDH-,	have	
a	 higher	 frequency	 of	 tumour	 formation	 upon	 transplantation,	 faster	 and	 larger	 tumour	
growth,	 and	 tumour	 population	 could	 also	 be	 driven	 using	 fewer	 cells.	 It	 would	 then	 be	
interesting	 to	 explore	whether	 these	 ALDH+	 populated	 tumours	 are	more	 sensitive	 to	 5-
NFNs,	in	comparison	to	any	tumours	formed	by	ALDH-	transplantation.	Characterisation	of	
ALDH	expression	of	these	populated	tumours	prior	to	5-NFN	treatment	will	be	essential	to	








Unpublished	 preliminary	 work	 performed	 by	 a	 post-doctoral	 research	 fellow	 in	 our	 lab,						
Dr	 Sana	 Sarvi	 (University	of	 Edinburgh,	UK)	describes	how	clonogensisis	 of	ALDHhigh	A375	
melanoma	cells	 is	 inhibited	by	NFN1	 treatment,	where	ALDHlow	cells,	while	exhibiting	 low	
clonogenic	 efficiency,	 were	 not	 affected	 by	 NFN1	 treatment.	 This	 highlight	 both	 the	
importance	 of	 ALDH	 in	maintaining	 A375	 CSC	 behaviour,	 but	 importantly,	 the	 ability	 for							
5-NFNs	 to	disrupt,	 and	even	 target	 this	 niche.	 She	has	 also	described	how	ALDHhigh	A375	
melanoma	 cells	 develop	 much	 larger	 tumours	 transplanted	 cells	 in	 immunosuppressed	
mice,	comparable	to	ALDHlow	transplantation,	and	begins	now	to	investigate	the	effect	the	
clinical	 5-NFN,	 NAZ,	 has	 on	 these	 tumours.	 It	 is	 hypothesised	 that,	 when	 treated	 in	







Although	 most	 work	 in	 targeting	 ALDH	 enzymes	 focuses	 only	 on	 their	 inhibition,60,117,152	
here	I	describe	a	class	of	compounds,	5-NFNs,	which	target	ALDH1A3,	a	known	melanoma	
CSC	marker,79	with	dual	action	–	ALDH	enzymes	can	bio-activate	these	compounds	in	order	
to	drive	 cell	 death	and	ALDH1A3	activity	 is	 also	 consequently	 inhibited	as	 a	direct	 result.	
Bio-activation	of	5-NFNs	 is	essential	 in	mediating	cancer	cell	death,	where	ALDH	enzymes	
can	generate	ROS	through	reduction	of	5-NO2	moiety.115	In	turn,	this	is	likely	to	render	the	
ALDH	 enzyme	 non-functional,	 through	 a	 double	 or	 triple	 oxidation	 at	 the	 active	 cysteine	




that	 the	5-NO2	moiety	 is	 lost	 from	the	5-NFN	compound,	considering	zebrafish	capillaries	
are	 reported	 to	 vasodilate	 upon	 5-NFN	 treatment,	 attributable	 to	 NO	 formation												
(Patton	 2012,	 unpublished).	 Further	 metabolomic	 studies	 in	 determining	 the	 5-NFN	






Figure	 7.4:	 Proposed	mechanism	 of	 interaction	 between	 5-NFNs	 and	 ALDH	 enzymes.	 5-NFNs	 are				
bio-activated	by	ALDH	enzymes,	in	turn,	promoting	the	oxidation	of	the	catalytic	cysteine	on	ALDH,	




Inhibition	 of	 ALDH1	 in	 cancers	 has	 been	 reported	 to	 increase	 sensitivity	 to	




to	 increased	chemo-resistance,	metastasis	and	poor	clinical	outcome,79,106	where	 it	 is	now	
widely	 hypothesised	 that	 there	 exists	 an	 ALDHhigh	CSC	 subpopulation,	 that	 promotes	 this	
phenotype	 and	 can	 also	 drive	 relapse.26,43	 The	 ability	 for	 5-NFNs	 to	 target	 and	 kill	 the	
ALDHhigh	CSC	niche	through	ALDH-driven	bio-activation	offers	a	new	approach	 in	targeting	
melanoma.	Since	the	discovery	of	oncogenic	driver	BRAF-mutations,	present	in	the	majority	
of	 melanoma	 cases,	 in	 particular	 BRAFV600E,	 the	 introduction	 of	 targeted	 therapies												
(BRAF	inhibitors),	offered	a	new	and	effective	treatment	for	melanoma.186	Although	many	
patients	 saw	 remarkable	 improvement	 upon	 BRAF-inhibitor	 treatment,	 it	 still	 not	 a	 cure,	
with	relapse	and	resistance	seen	more	often	than	not.187	As	research	into	developing	new	
therapeutics	 targeting	 the	 MAPK	 pathway	 continues	 to	 show	 promise,188,189	 it	 is	 still	






















































ALDH1A	 enzymes.	 In	 neuroblastoma,	 ALDH1A2	 has	 been	 reported	 as	 a	 predominant	 CSC	
marker,42	and	overall	ALDH	expression	is	also	likely	to	be	higher	in	these	tumours,	due	the	
functionality	 of	 dopaminergic	 pathway	 in	 neuronal	 cells.	 Considering	 the	 results	 I	 report	
highlighting	 the	 ability	 for	 ALDH1A	 enzymes,	 but	 also	ALDH2,	 to	 bio-activate	 5-NFNs	 and	
drive	cancer	cell	death,	it	has	become	reasonable	to	assume	the	anti-cancer	activity	of	NFX	
against	neuroblastoma	is	likely	driven	by	bio-activation	by	ALDH	enzymes.	Bio-activation	by	
ALDH2	 would	 also	 help	 to	 explain	 why	 NFX	 has	 such	 toxic	 side	 effects,	 where	 alcohol	
intolerance,	gastrointestinal	problems	and	neuronal	stress,122	can	be	 implicated	to	ALDH2	
driven	bio-activation	as	a	side	target.	One	of	the	encouraging	results	from	this	project	was	
the	potential	 for	 the	clinical	5-NFN,	NAZ,	 to	kill	melanoma	cells,	where	 it	displayed	some	
specificity	 for	the	melanoma	stem	cell	marker,	ALDH1A3.	The	anti-cancer	capacity	of	NAZ	
has	also	been	reported	 in	myeloma,	melanoma	and	breast	cancer,	attributing	this	toxicity	
to	 STAT3	 inhibition.135-137	 Although	 these	 reports	 do	 not	 explore	 ALDH	 as	 a	 target,													
bio-activation	by	ALDH	enzymes	may	offer	an	explanation	to	the	reported	increase	in	ROS	







NAZ,	 a	 clinically	 available	 5-NFN,	 can	 target	 2	 separate	 oncogenic	 targets	 in	 melanoma,	
both	associated	with	CSC-potential.	The	specificity	NAZ	displays	towards	ALDH1	would	also	
help	to	explain	why	NAZ	is	much	better	tolerated	than	other	5-NFNs,	such	as	NFX,175	largely	
through	the	 lack	of	bio-activation	by	ALDH2,	which	 is	 likely	the	main	cause	of	side-effects	
seen	 in	 the	majority	of	5-NFNs.	However,	 importantly,	NAZ	 offers	a	pre-approved	clinical	
therapeutic	 with	 the	 potential	 to	 kill	 melanoma	 cells,	 via	 a	 similar	 mechanism	 to	 that	
described	 of	 NFN1,	 with	 specificity	 towards	 the	 ALDH	 isoforms	 most	 associated	 with								
CSC-potential	 and	 chemo-resistance	 in	 these	 cancers.	 Should	 the	 results	 with	 NAZ	 be	
further	 validated	 on	 the	 future	 experiments	 described	 above,	 especially	 in	 vivo,	 the	




RC-NFN5,	 presents	 a	 potent	 anti-cancer	 compound	with	 increased	 stability	 and	 potential	
for	 molecular	 editing	 in	 order	 to	 improve	 potency.	 Additional	 work,	 in	 both	 drug	
development	 and	mechanism	of	 action,	 is	 required	 to	 fully	 characterise	 the	 potential	 for	
RC-NFN5	 to	move	 forward	 a	 lead	 compound	 in	 5-NFN	 drug	 discovery	 efforts	 –	 where	 a						
bis-5-NFN	 compound,	 with	 selectivity	 similar	 to	 NAZ	 while	 keeping	 or	 improving	 on	
potency,	would	be	the	ideal	next	step	when	taking	this	work	forward.	
	
One	 drawback	 to	 this	 work	 is	 the	 sole	 reliance	 of	 using	 cancer	 cell	 lines	 to	 model	
behaviours	of	melanoma,	and	indeed	other	cancers,	in	their	ALDH	status	and	in	response	to	
5-NFNs	 treatment.	 Although	 cancer	 cell	 lines	 offer	 a	 useful	 tool	 is	 characterising	 drug	
responses	and	validating	mechanisms	of	action,	their	use	is	truncated	when	trying	to	model	
solid	tumour	behaviour,	for	 instance	the	lack	of	hypoxia	found	in	the	majority	of	tumours	
isn’t	well	defined	 in	cancer	cell	 lines,194	but	proves	an	 important	 factor	when	considering	
drug	 responses.195	 in	 vivo	 modelling	 and	 transplantation	 is	 always	 the	 gold	 standard	 for	
assess	 how	 solid	 tumours	will	 respond	 to	 drug	 treatments,	 and	 how	 this	 relates	 back	 to	
predictive	 patient	 responses.194	 Although	 the	 work	 reported	 here	 describes	 promising	
sensitivity	of	melanoma	to	5-NFN	compounds,	the	differences	between	the	characteristics	
of	solid	tumours	and	cancer	cell	 lines	may	actually	help	to	explain	why	NFX	 is	so	effect	 in	
treating	neuroblastomas	 in	patient,	but	 is	poorly	reflected	by	their	 toxicity	 in	both	cancer	
176	
	
cells	 lines	 reported	 here,	 and	 neuroblastoma	 cell	 lines	 reported	 previously.132,153	
Considering	this	increase	of	sensitivity	to	NFX	in	vivo	compared	to	 in	vitro,		it	is	with	great	
anticipation	that	we	begin	in	vivo	studies	with	melanoma	xenographed	immunosuppressed	
mice	 and	 the	 treatment	with	 5-NFNs,	where	we	hope	 to	discover	melanoma	 xenographs	
are	highly	sensitive	to	our	5-NFN	compounds,	especially	as	they	are	much	more	potent	than	





to	 5-NFN	 toxicity.	 	 Although	 the	 preliminary	 data	 above	 conducted	 through	OakLabs	 did	
provide	a	good	basis	 to	draw	some	preliminary	conclusions	 from,	 the	expense	needed	 to	
outsource	 this	 experiment	made	 it	 unviable	 to	 validate	 through	 repetition.	 Although	 the	
work	 with	 the	 panel	 of	 melanoma	 cell	 lines,	 kindly	 donated	 from	 the	 Sanger	 Institute	
(Cambridge,	UK),	did	offer	one	potential	solution	for	this,	 it	still	proved	difficult	to	extract	
any	 meaningful	 data;	 also	 considering	 the	 RNAseq	 of	 these	 samples	 were	 also	 not	
statistically	validated.	One	other	revealing	problem	with	ALDH	expression	also	appeared	to	




cell	 population	 as	 a	 response	 to	 both	 time	 and	 minor	 changes	 in	 the	 cellular	
microenvironment.	This	also	explains	why	the	5-NFN	EC50	values	drift	 from	experiment	to	
experiment,	where	 it	 is	 indeed	highly	possible	 that	 the	 fluctuations	 in	ALDH	expression	 is	
proportionally	represented	by	changes	in	5-NFN	sensitivity.	 In	an	ideal	setting,	monitoring	
the	 ALDH	 environment	 with	 each	 experiment	 would	 be	 highly	 desirable,	 and	 could	
potentially	 help	 to	 indicate	 other	 ALDH	 enzymes	 that	 are	 also	 primary	 drivers	 of	 5-NFN	
toxicity.	Through	designing	a	cheap,	high-throughput	and	rapid	assay	that	can	analyse	the	









high	 in	 cancers	 due	 to	 their	 prevalence	 as	 a	 CSC	 marker,	 5-NFN	 can	 both	 inhibit	 ALDH	
activity	 and	 drive	 cell	 death.	 I	 report	 5-NFN	 can	 be	 bio-activated	 by	 ALDH1A3,	 a	 key	
melanoma	stem	cell	marker,	in	turn	driving	toxicity	in	a	subpopulation	A375	melanoma	cell	
lines.	The	sensitivity	of	this	subpopulation	can	consequently	be	reqed	upon	knock-down	of	
ALDH1A3,	 while	 transient	 overexpression	 of	 ALDH1A3	 in	 turn	 promotes	 hypersneisivity,	
providing	 further	 evidence	 that	 5-NFN	 can	 target	 melanoma	 cells	 with	 high	 ALDH1A3	
expression.	 I	 describe,	 in	 collaboration,	 the	 ability	 for	 5-NFNs	 to	 potently	 inhibit	 ALDH	
activity,	 where	 inhibition	 is	 likely	 caused	 by	 a	 covalent	 medication	 on	 the	 enzyme	 itself	






cancer.	 Finally,	 I	 importantly	 describe	 how	 the	 clinically	 available	 5-NFN,	NAZ,	while	 also	
able	 to	 potently	 promote	 cancer	 cell	 death,	 also	 presents	 selectivity	 towards	 ALDH1	




































































































































































































































































































































































































































































































































Cell	line	 Flask	size	 Passage	 Date	frozen	 Relevant	lesions	 Media	 Split	rate	 Comments	on	growth	
A04	 T25	 P6	 15-08-14	 	-	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
C008	 T75	 P9	 17-08-15	 NF1	negative	 RPMI1640	 1:3	 slow	growth	rate	
C021	 T75	 P9	 06-02-15	 NF1	negative	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
C022	 T25	 P6	 22-07-14	 BRAF	translocation	 RPMI1640	 1:2	-	1:3	 very	slow,	attach	slowly,	tricky	to	seed	homogenously	in	MW96	(pipette	well)	
C025	 T75	 P13	 18-05-15	 NF1	negative	 RPMI1640	 1:3		 slow;	generally	resistant	to	most	of	the	drugs	
C037	 T75	 P12	 30-01-15	 BRAF	translocation	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
C052	 T75	 P9	 06-02-15	 		 RPMI1640	 1:3	 slow;	change	media	every	2-3	days		
C067	 T75	 P9	 31-07-15	 NF1	negative	 RPMI1640	 1:3	 medium-slow	growth,	quite	big	cells	
C077	 T75	 P13	 05-05-15	 BRAF	S467L;	NF1	neg	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
C084	 T75	 P14	 08-05-15	 		 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
C086	 T25	 P6	 21-05-14	 NF1	negative;	KIT	G826R	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
C089	 T75	 P12	 30-01-15	 BRAF	V600E	 RPMI1640	 1:4-1:6	 medium-fast	growth	rate,	small	
C092	 T25	 P6	 01-04-14	 	-	 RPMI1640	 1:3	-	1:4	 medium	growth	rate,	cell	line	with	the	lowest	number	of	lesions	(mut	and	CNV)	
CHL-1	 T25	 P8	 28-04-14	 KIT	E640K	 DMEM/F12	 1:5	-	1:10	 very	fast	growth	
Colo-792	 T75	 P11	 30-01-15	 NF1	negative	 DMEM/F12	 1:5	-	1:8	 fast	growth	rate	
D10	 T75	 P15	 18-05-15	 KIT	M541L	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
D22	 T25	 P6	 22-04-14	 	-	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
D24	 T75	 P17	 18-05-15	 NF1	negative	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
D35	 T75	 P9	 30-06-15	 	-	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	
D38	 T75	 P13	 16-04-15	 	-	 RPMI1640	 1:3	-	1:4	 medium	growth	rate	





Cell	line	 6day	assay	 72hr	assay	 siRNA	transfection	
MW96	 cell/well	 cell/well	 cell/well	
A04	 5000	 15000	 16500	
C008	 3000	 9000	 9900	
C021	 3500	 10500	 11550	
C022	 4000	 12000	 13200	
C025	 3500	 10500	 11550	
C052	 3000	 9000	 9900	
C067	 1000	 3000	 3300	
C077	 3000	 9000	 9900	
C084	 5000	 15000	 16500	
C086	 3500	 10500	 11550	
C089	 2500	 7500	 8250	
C092	 2500	 7500	 8250	
C037	 3000	 9000	 9900	
CHL-1	 500	 1500	 1650	
Colo-792	 2500	 7500	 8250	
D10	 5000	 15000	 16500	
D22	 2000	 6000	 6600	
D24	 3500	 10500	 11550	
D35	 3500	 10500	 11550	
D38	 2500	 7500	 8250	
M002	 3000	 9000	 9900	










A04 C008 C021 C025 C037 C052 C067 C077 C084 C086 C089 C092 CHL-1 COLO-792 D10 D22 D24 D38 M002 MEWO
ALDH1A1 334.3889 26.56243 9.581963 3.507376 114.2107 13.95971 0.29079 2.283137 3.363288 13.8035 7.586397 0.054671 0.077577 3.8070827 7.092818 0.093786 1.5599581 18.9118 160.619 4.842421
ALDH1A2 3.812738 23.12301 0.123749 16.16446 5.627982 10.21814 0.47233 0.385264 0.21353 9.845608 0.102203 0.019791 0.007423 0.7252329 0.587517 0.024513 24.552633 0.9208293 0.307968 1.629807
ALDH1A3 63.88532 0.339993 143.4239 0.384956 21.29148 5.147514 629.1024 312.634 0.3236 202.1175 61.7181 22.58277 0.40215 174.80283 21.72953 12.20283 1265.8197 47.27347 7.317165 4.885375
ALDH1B1 36.98992 9.822547 10.03827 33.25124 11.70621 16.1401 18.43911 5.976208 0.373012 8.414438 20.8363 8.554065 11.54573 33.622315 13.59367 11.85966 5.5084666 9.3911461 12.06943 13.50829
ALDH1L1 0.231684 0.008203 0 0 35.07555 0.004314 0 0.021551 0.043516 0.09434 0.175148 0.073268 0.004428 0.0223309 0.195848 0.02681 0.0346281 0.0512962 0.144973 0.018759
ALDH1L2 14.51429 0.122748 0.168012 30.19767 3.828581 39.17514 0.094183 0.424219 0.029138 0.032595 0.225638 3.704774 18.78739 0.0962185 72.83752 0.45272 5.7678777 15.142141 0.107918 0.312372
ALDH2 0.307307 0.218045 0.339716 7.468295 18.53243 0.807075 0.353793 1.7152 0.07128 0.303755 0.874582 3.996286 27.40965 0.0517552 43.66951 0.129491 0.0683501 5.1937979 0.131046 0.033111
ALDH3A1 0.065158 0.126599 0.014031 0.251379 0.089872 0.006004 0.00857 0.054246 0 0 0.255546 0.059039 0.497683 0.7123002 0.0937 0 0.8079353 0.0150068 0.032281 0.00821
ALDH3A2 30.74007 27.97154 26.56697 18.68896 15.42117 10.49295 32.36554 54.6453 23.69337 0.952893 54.36657 19.70016 31.93639 39.992979 17.53233 20.13902 97.384585 25.079128 8.924886 35.4449
ALDH3B1 3.80625 5.972396 12.42268 23.07749 0.278026 9.096022 35.14028 14.07838 15.51818 8.081205 12.98594 16.02599 5.894044 16.071152 10.21353 19.40413 28.312896 4.2982987 3.082425 25.07162
ALDH3B2 1.133068 0.085323 86.32294 4.774931 0.056936 0.353845 0.01261 0.49196 0.600421 0.370251 0.048592 0.002444 0 2.1633269 0.156703 0.00687 0 0.0071097 19.17246 0.039968
ALDH4A1 10.59333 5.233102 7.768549 17.17236 3.38862 11.38132 3.854832 11.06419 12.54001 10.50709 4.897874 5.846582 7.490439 14.956618 10.18472 7.941782 6.2463469 5.3722725 37.26175 8.417984
ALDH5A1 11.85201 0.551076 3.984271 8.043175 8.789863 6.356714 0.403175 0.525989 0.024147 4.985864 14.72562 3.683074 9.889199 18.198813 12.90234 7.585425 2.8245954 3.9329018 3.848972 1.724769
ALDH6A1 5.882529 6.959225 7.273771 15.31742 11.9926 17.32032 23.38827 18.45164 7.673927 20.49994 21.66782 12.77455 11.52897 4.9862398 21.7427 4.348227 14.757503 4.6678878 5.318022 10.40178
ALDH7A1 61.87025 35.74744 63.42438 33.75924 61.89622 48.78037 85.26293 102.0255 46.36889 61.75107 76.4987 78.58636 26.92053 52.398989 31.89971 41.99787 54.779774 104.31369 60.08238 56.74447
ALDH9A1 92.11546 131.3017 86.33794 58.43186 146.7694 92.31622 51.7616 67.74004 105.7785 96.43331 29.9512 60.03402 74.43012 134.86874 50.63851 63.95581 39.66163 32.91405 40.07535 87.91001
ALDH8A1 0.675895 0.227795 0.095049 0.108938 1.082511 0.204235 0.261852 0.114876 0.686982 0.84913 0.128431 0.796763 0.428442 0.1523744 0.031276 0.033337 0.2853351 0.1270171 0.250245 0.128807
ALDH16A1 14.43383 12.00804 14.05996 13.37542 9.643836 26.82486 5.145173 19.94117 13.51909 12.86327 17.45192 8.028629 14.7634 8.8068131 6.738047 9.08198 4.0916353 17.637988 27.74042 13.14779



































































ALDH16A1 Hs01035457_m1 NM_153329.3;NM_001145396.1 AK297101.1;AY007096.1;BC035641.1;BC014895.2;BC042142.1;AK298587.1 81
ALDH18A1 Hs00913261_m1 NM_001017423.1;NM_002860.3
BC117242.1;BC143930.1;BC106054.1;X94453.1;BC117240.1;AK295487.1;U68758.1;U7654
2.1;AK299557.1;AK312271.1
71
GAPDH Hs03929097_g1 58
18S Hs99999901_s1 187
TBP Hs00427621_m1 65
